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9General introduction
1
Obesity is both a significant and an increasing health care problem, the 
prevalence of which has nearly tripled since 1975. Level of obesity is graded 
using the body mass index (BMI), which is the ratio of body weight and squared 
body length. Normal weight is defined as a BMI between 18.5–25 kg/m2.  
Once BMI exceeds 25 kg/m2, a person is considered overweight. Obesity is 
defined as a BMI of 30 kg/m2 or more, while morbid obesity is defined as a BMI 
exceeding 40 kg/m2. In 2016, approximately 650 million people suffered from 
obesity worldwide, and this prevalence is still rising.1
Until very recently, obesity was not recognized as a disease, and within the 
general population, the deteriorating effects of obesity are still underestimated. 
Obesity’s official recognition as a disease by the American Medical Association in 
2013 raised awareness among physicians, increased access to treatment and spurred 
clinics worldwide to investigate the etiology, pathophysiology and treatment 
options for obesity.2
Interest in obesity as a disease is fueled by its association with myriad 
diseases, such as hypertension (HT), dyslipidemia, coronary artery disease, type 2 
diabetes mellitus (T2DM), non-alcoholic fatty liver disease, asthma, sleep apnea, 
musculoskeletal diseases, various forms of cancer and psychiatric diseases, all of 
which can result in reduced life expectancy.2 The exact pathophysiology of obesity 
is poorly understood; many factors are proposed to exert an impact, such as the 
environment, genetics, the microbiome, hormones, peptides, central nervous 
system regulation, inflammation and adipose tissue (AT) biology.3
Due to the long list of obesity-associated diseases and their effects on life 
expectancy, scientists have been searching for the best treatment for obesity for 
decades. Unfortunately, lifestyle changes and medical treatment have not proven 
to be successful interventions in subjects suffering from morbid obesity. As early as 
the 1950s, interest in surgical procedures to accomplish weight loss existed; today, 
bariatric surgery is thought to be the only effective intervention to achieve both 
substantial and long-term weight loss and improvements in obesity-associated 
comorbidities.3
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The first part of this thesis focuses on the effects of obesity on cardiovascular 
risk (CVR) factors, cardiovascular outcome measures and the role of AT and 
inflammation, while the second part focuses on bariatric surgery and the safety of 
such procedures.
Part I: 
Cardiovascular consequences of obesity
Cardiovascular disease and cardiovascular risk factors
Cardiovascular disease (CVD) is the leading cause of death in most countries,4,5 
although improved prevention strategies and treatment options have led to 
decreased CVD mortality over the past two decades. CVD comprises coronary heart 
disease, cerebrovascular disease, peripheral artery disease and both atherosclerotic 
and aneurysmatic aorta disease, in which coronary heart disease is the primary 
contributor to the number of cases with CVD.6
Smoking, dyslipidemia, HT, T2DM and obesity are the five leading modifiable 
risk factors responsible for more than half of CVD deaths.7 Over 90% of CVD events 
occur in subjects with at least one major CVR factor.8 The risk of a cardiovascular 
event increases with the presence of multiple risk factors. Additional modifiable risk 
factors, as described in the INTERHEART study in 2004, are psychosocial factors, 
consumption of fruits and vegetables, alcohol consumption and physical activity.9
Obesity and cardiovascular disease
Not only is obesity considered a major modifiable risk factor for CVD, it has 
also been associated with a higher prevalence of comorbidities, such as insulin 
resistance, T2DM, HT and dyslipidemia.10,11 The prevalence of these so-called 
obesity-related diseases rises with increasing BMI,10 and in addition, increases in 
BMI lead to higher all-cause mortality and cardiovascular mortality.11,12 In fact,  
all-cause mortality rises by 30% when BMI increases by 5 kg/m2.11
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Ongoing debate exists regarding whether obesity is actually an independent 
risk factor for CVD. Different studies primarily attribute this effect of obesity to 
differences in classic CVR factors between non-obese and obese subjects rather 
than to obesity itself.13,14 Even though these risk factors are known to be increased in 
obese subjects, the relationships of these risk factors with BMI in different levels of 
obesity are unclear; Chapter 2 describes the relationships of these risk factors with 
BMI in both obese and non-obese subjects.
In non-obese subjects, women are relatively protected from CVD, particularly 
before menopause.15 The prevalence of CVD in women approaches the prevalence in 
men in the seventh decade of life.15,16 The mechanism behind this gender difference 
in CVD is still not fully understood;17 Chapter 3 investigates cardiovascular gender 
differences in morbidly obese subjects.
T2DM is known to cause micro- and macrovascular complications with 
significant morbidity and mortality rates.18 It is also associated with atherosclerosis19 
and, as previously described, is a major modifiable risk factor for CVD; Chapter 4 
focuses on the effects of T2DM on CVD in morbidly obese subjects.
Atherosclerosis and inflammation in obesity
Atherosclerosis is the most common cause of CVD.20 The process of atherosclerosis 
begins with the accumulation of foam cells in the intima, which leads to the 
formation of fatty streaks21 and eventually atherosclerotic plaques.22 Atherosclerosis 
is a multifactorial disease; endothelial dysfunction, inflammation, dyslipidemia and 
immunologic factors are contributors to its pathogenesis.
In recent decades, it has become evident that inflammation is critical in 
the development of atherosclerosis, which is therefore considered a low-grade 
chronic inflammatory disease.23 Several inflammatory markers, such as C-reactive 
protein (CRP), leukocyte count and complement component 3 (C3), are associated 
with CVD.24 Both the innate and adaptive immune systems are active in the 
various stages of atherogenesis,20 from early binding of leukocytes to the vascular 
endothelium, increased transmigration of monocytes and foam cells into the intima 
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and degradation of collagen, making the plaque more vulnerable.25,26 A crucial 
step in atherosclerosis is the activation of leukocytes in the circulatory system. 
After activation, different integrins are expressed on the leukocyte’s cell surface. 
Expression of such integrins causes the enhanced adherence of leukocytes on the 
endothelium, after which they migrate into the arterial wall and form foam cells.24
Subjects with morbid obesity are also known to have increased levels of 
CRP27,28 and C3,29,30 and morbid obesity is therefore also considered a form of 
chronic low-grade systemic inflammation.31 It is well established that AT secretes 
a great number of pro-inflammatory agents, which have been called adipokines.32 
In particular, AT secretes tumor necrosis factor a and interleukin 6, which are 
well known stimulators of CRP production in the liver.33,34 The mechanism 
through which this cytokine production is initiated remains unclear;35 however, 
cytokine-driven inflammation is thought to be critical in the pathophysiology of 
obesity-related diseases such as metabolic syndrome, CVD and T2DM.32,35,36 The 
increased inflammation is thought to be the link between obesity and the increased 
risk of CVD in obese subjects; Chapter 5 focuses on the differences in systemic 
inflammation in subjects with and without T2DM.
Part II: 
Treatment strategies for obesity
Weight loss strategies
Cardiovascular prevention strategies, as applied in the general population, are 
beneficial for subjects suffering from morbid obesity; however, weight loss itself 
is also known to prevent and improve many obesity-related diseases.37 A loss of 
5–10% of initial body weight can decrease blood pressure,38,39 insulin resistance40 
and incidence of T2DM;41,42 improve lipid profiles; reduce CRP levels;43 and improve 
endothelial function.44 Therefore, weight loss is considered one of the most 
important treatment modalities in subjects suffering from overweight and obesity.
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Initial treatment of overweight and obesity comprises a comprehensive 
lifestyle intervention that includes dietary therapy, exercise and behavioral 
modification. However, the overall effects of these lifestyle interventions are small 
and often result in weight losses of only 5–7% of initial body weight and substantial 
weight regain over time.45
In subjects with BMI >30 kg/m2 or BMI > 27 kg/m2 and comorbidities who 
have not met weight loss goals with lifestyle interventions, drug therapy can 
be considered. Various agents are available, including orlistat, liraglutide and 
lorcaserin, that can induce weight reductions of 4–8%; 46 however, the role of drug 
therapy in obesity has been widely questioned due to concerns about efficacy, 
potential for abuse, side effects and cost. The effects of drug therapy on body weight 
slow and plateau over time, and most patients regain weight after discontinuation.
For many obese individuals, these behavioral and medical approaches to 
weight loss may be insufficient. Bariatric surgery is known to be the only effective 
intervention to achieve substantial and long-term weight loss with improvements 
of comorbidities.47,48 According to international guidelines, subjects are eligible 
for bariatric surgery once their BMI surpasses 40 kg/m2, or 35 kg/m2 with one or 
more obesity-associated comorbidities.49 More recently, international guideline 
committees suggested to offer bariatric surgery to subjects with BMI between  
30.0–34.9 kg/m2 and uncontrollable type 2 diabetes.50 
Many procedures for accomplishing weight loss have been proposed, the most 
extensively investigated of which are the laparoscopic adjustable gastric banding, 
laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy 
(LSG). However, the laparoscopic adjustable gastric banding has been gradually 
replaced by other bariatric procedures due to its modest amount of expected weight 
loss, high rate of revisional surgery and weight regain after removal of the band.51 
The LRYGB is considered the gold standard procedure in adults, although the LSG 
has gained widespread popularity due to its good results in terms of weight loss, the 
resolution of comorbidities, quality of life and low complication rates.52–54 In recent 
years, the LSG has become the most commonly performed bariatric procedure.55
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Obesity and bariatric surgery in children and adolescents
The prevalence and severity of obesity continues to rise. Unfortunately, this is true 
not only for adults but for children and adolescents as well.52,56 In the United States, 
approximately 17% of all children suffer from obesity, and both the prevalence and 
severity increase with advancing age.57 Childhood obesity is associated with health 
hazards during childhood as well as later in life, independent of adult BMI.52,58,59 
Early treatment is thought to be crucial; therefore, morbidly obese adolescents are 
increasingly being considered for bariatric surgery. Controversy exists regarding 
the ethics of bariatric surgery in adolescents; questions remain regarding the 
long-term safety and effectiveness of these procedures in adolescents. The LSG 
may be a safer alternative to the LRYGB in adolescents, because the procedure 
keeps the gastrointestinal tract intact, which results in the absence of dumping, 
less malnutrition and fewer vitamin disturbances.60,61 This may be critical, since 
adolescents are known to have a low compliance to follow-up.62 In the search for 
the best surgical options for morbidly obese adolescents, Chapter 6 describes the 
results of both the LSG and LRYGB in young adults.
Efficacy and safety in bariatric surgery
With the increasing prevalence of obesity and obesity-related diseases, 
obesity-related healthcare costs have become a considerable economic burden.63 
Not only is bariatric surgery the best treatment in terms of weight loss, with 
substantial long-term results, it is also thought to be more cost-effective than the 
lifelong treatment of obesity-related diseases.64 The number of bariatric procedures 
performed has therefore been rising in recent years, with over 600,000 bariatric 
procedures performed worldwide in 2014.65 To improve the success rates and  
cost-effectiveness of these procedures, it is important to be aware of the adverse 
effects and complications associated with bariatric surgery and to continue 
to search for methods to improve its safety, efficiency and cost-effectiveness. 
For example, one requirement for both the bariatric surgeon and the bariatric 
clinic is to perform a minimum number of procedures annually (over 100 per 
clinic) to reduce morbidity and mortality.66,67 Furthermore, medical industries 
are continuously searching for improvements in existing medical devices and 
developing new products to improve safety and efficiency.
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In search of efficient and cost-effective healthcare, enhanced recovery 
after surgery (ERAS) protocols (or fast-track protocols) have been developed 
for different types of abdominal procedures.68–70 Such protocols focus on the 
standardization of specific perioperative care based on the implementation of 
evidence-based interventions; Chapter 7 describes an enhanced recovery after 
bariatric surgery (ERABS) protocol, including the results of the implementation 
of such a protocol on procedural times, length of stay in hospital, and number of 
complications and reoperations.
Furthermore, pre- and intraoperative checklists, to estimate perioperative 
risks, are regularly used as a safety tool in standardized surgical treatment 
programs. It is known that the proper use of these checklists results in lower rates 
of postoperative complications.71 While the use of these checklists is thought to be 
best practice, the use of postoperative checklists to structurally monitor signs of 
possible complications and subsequent early interventions is not standard care, and 
literature on this subjects is scarce. An in-house-developed postoperative checklist 
for bariatric surgery and its effects on complication management in bariatric 
surgery is described in Chapter 8.
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Abstract 
Background
Obesity is related to increased cardiovascular risk. It is unknown whether increasing 
levels of obesity also increase levels of cardiovascular risk factors and systemic 
inflammation. This study describes the relationship between classic cardiovascular 
risk factors and inflammatory markers with BMI in a group of obese and non-obese 
subjects.
Materials and methods
Obese subjects (BMI ≥ 30 kg/m2; n = 576; mean BMI = 43.8 [±7.58] kg/m2) scheduled 
for bariatric surgery were included. The reference population consisted of non-
obese volunteers (BMI < 30 kg/m2; n = 377, mean BMI = 25.0 [±2.81] kg/m2). The 
relationship between BMI quintiles and the levels of cardiovascular risk factors 
was analyzed. Adipose tissue volumetry was performed in 42 obese subjects using 
abdominal CT-scans.
Results
The obese group included more women and subjects with type 2 diabetes mellitus, 
hypertension and current smokers. In obese subjects, HDL-C and triglycerides 
decreased with increasing BMI. Systolic and diastolic blood pressure, total 
cholesterol, LDL-C and apo-B were not related to BMI in the obese group, in 
contrast to the non-obese group. Inflammatory markers CRP, leukocyte count and 
serum complement C3 increased with increasing BMI in the obese group, while 
these relations were less clear in the non-obese group. The subcutaneous adipose 
tissue surface was positively correlated to BMI, while no correlation was observed 
between BMI and visceral adipose tissue.
Conclusions
Markers of inflammation are strongest related to BMI in obese subjects, most likely 
due to increased adipose tissue mass, while cardiovascular risk factors do not seem 
to deteriorate above a certain BMI level. Limited expansion capacity of visceral 
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Introduction 
Obesity has been associated to a higher prevalence of comorbidities, such as 
insulin resistance, type 2 diabetes mellitus (T2DM), hypertension (HT) and 
dyslipidemia.1-2 The risk for these obesity-related comorbidities is elevated 
with increasing body mass index (BMI), at least up to a BMI of 40 kg/m2.1 
Additionally, the excess body weight in obesity is known to increase all-cause 
mortality as well as cardiovascular mortality,2-3 with the lowest mortality rates 
in subjects with a BMI between 20–25 kg/m2.2-4 An increase in BMI of 5 kg/m2 
can increase all-cause mortality with 30%, as well as mortality as a result of 
ischemic heart disease, stroke and T2DM.2
Although obesity may be an independent risk factor for cardiovascular disease 
(CVD), different studies attribute this effect of obesity mainly to differences in 
classic cardiovascular risk (CVR) factors between non-obese and obese subjects 
instead to obesity itself.5-6 Classic CVR factors are widely used to estimate the risk 
of CVD or mortality and include systolic and diastolic blood pressure, glycated 
hemoglobin (HbA1c) and dyslipidemia7 and the values of these classic CVR factors 
increase with increasing BMI. More recently, interest has increased in inflammation 
as a risk factor for CVD,8 using C-reactive protein (CRP) and complement 
component 3 (C3) as markers of inflammation. Both CRP and C3 are associated with 
an increased risk of CVD9-11 and increase with increasing BMI.12-13
In these studies, there has been an underrepresentation of morbidly obese 
subjects. Only a few studies investigated the relationships of BMI and markers of 
dyslipidemia in morbid obesity, and these studies suggest an “obesity paradox” 
in which LDL-C levels are actually lower in subjects with the highest BMI, when 
compared to moderately obese subjects,14-15 but these studies only focused on 
markers of dyslipidemia and not on other CVR factors.
The purpose of this study was to investigate the relationship of BMI with 
classic CVR factors and markers of inflammation in obese and non-obese subjects 
covering a wide range of BMI.
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Materials and methods 
Design and study population
This was a cross-sectional study of obese and non-obese patients. This single 
center case-control study included all morbidly obese patients who underwent 
preoperative screening for bariatric surgery from September 2009 to April 2011 in 
our bariatric clinic. All patients visiting the clinic for preoperative screening were 
asked to participate without any restrictions. Approximately 90% of all evaluated 
patients underwent surgery, the other 10% did not continue in the program due 
to several reasons. Inclusion criteria for bariatric surgery were age between 18–60 
years old, BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with obesity-associated disease. 
The reference population consisted of non-obese subjects with a BMI < 30 kg/m2 
participating in observational studies in our outpatient clinic16-17 from July 2009 to 
February 2013 and non-obese subjects referred to our clinic for CVR management. 
These observational studies aimed to evaluate novel CVR factors.
The cohort was divided in two groups according to BMI. The first group 
consisted of non-obese subjects (i.e. BMI < 30 kg/m2), hereafter referred to as  
“non-obese subjects.” The second group consisted of obese and morbidly obese 
subjects (i.e. BMI ≥ 30 kg/m2), hereafter referred to as “obese subjects.” Both 
subgroups were further divided into quintiles according to BMI.
Written informed consent was obtained from each individual and the study 
protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. For 
this type of study, no approval of the institution’s ethics committee was required.
Baseline characteristics
Baseline characteristics were collected according to a standard protocol in our 
clinic. Anthropometric measurements included weight, height, waist circumference 
and blood pressure. BMI (kg/m2) was calculated using both weight and height.
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Laboratory tests
Standard non-fasting screening laboratory tests were performed. Total cholesterol, 
HDL-C and triglycerides (TG), as well as glucose and inflammatory marker CRP 
were analyzed using the LX20 or DxC analyzers (Beckman Coulter, Miami FL, USA). 
LDL-C values were calculated using the Friedewald formula. C3 and Apolipoprotein 
B (apo-B) were determined by rate nephelometry using IMAGE by commercially 
available kits (Beckman Coulter).
Adipose tissue depot analyses using abdominal CT-scans
Volumetry measurements, using abdominal CT-scans, were performed in order to 
analyze the relation between CVR factors and the volume of visceral adipose tissue 
(VAT) and subcutaneous adipose tissue (SAT). Within this cohort, 42 obese subjects 
underwent abdominal CT-scans within a period of two weeks after bariatric surgery 
for clinical reasons. An abdominal CT-scan is not part of the standard postoperative 
care in our department. The indication for these 42 abdominal CT-scans was a 
(suspected) complication.
Two investigators independently measured volumes of SAT and VAT in these 
scans. The CT-scans were exported as Digital Imaging and Communications in 
Medicine (DICOM) data and analyzed using an open source image analysis software 
package, OsiriX® (version 7.0, 32-bit). The methods of CT volumetric analyses using 
OsiriX® have been described previously.18 Adipose tissue was identified by Hounsfield 
units (HU) with a range between –190 and –30 HU19 and measured on a single slice 
at level L4–L5, since the amount of VAT at this level correlates best with total VAT 
volume.19 The total amount of VAT was measured by selecting the abdominal cavity 
as “Region Of Interest.” The total amount of SAT was calculated by subtracting the 
amount of VAT from the total amount of adipose tissue. The mean adipose tissue 
surface of both investigators was used in the analysis. Interobserver reliability was 
analyzed by computing the two-way mixed absolute agreement single-measures 
intraclass correlation coefficient (ICC). The interobserver reliability was 0.961 for 
VAT (p < 0.001) and 0.980 for SAT (p < 0.001).
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Statistical analysis
All analyses were performed using SPSS (PASW) 18.0 software (SPSS Inc., Chicago, 
Illinois, USA). Continuous variables were presented as mean ± standard deviation 
(SD). Due to non-Gaussian distribution, both TG and CRP are described as median 
and minimum–maximum. Categorical data were described as an absolute number  
as well as a percentage of the total cohort. Differences between obese and  
non-obese subjects were analyzed using independent T-tests, chi-squared tests  
and Kruskall-Wallis tests. The relationship between BMI quintiles and metabolic 
and inflammatory parameters was analyzed using one-way ANOVA or the  
Kruskall-Wallis test in the case of non-Gaussian distribution.
Patients on statins were excluded from the analyses on the relation between 
BMI and total cholesterol, HDL-C, LDL-C, TG, C3, CRP and apo-B. Subjects on 
antihypertensive drugs were excluded from analyses on the relation between BMI 
and systolic and diastolic blood pressure. Subjects on glucose-lowering drugs were 
excluded from the analysis on the relation between BMI and glucose. Pearson’s 
correlation coefficients were calculated in order to analyze the relationship of 
BMI with the different adipose tissue surfaces. Results were evaluated at a 95% 
confidence interval at a significance threshold of p < 0.05 (two-sided).
Results
The obese group consisted of 576 subjects (418 women and 158 men), with a mean 
age of 44.2 (±13.0) years and a mean BMI of 43.8 (±7.6) kg/m2. The non-obese group 
consisted of 377 subjects (173 women and 204 men). The mean age was 58.7 (±13.0) 
years, and the mean BMI was 25.0 (±2.81) kg/m2. Additional baseline characteristics 
of both groups are displayed in Table 1. The obese group included significantly more 
women than the non-obese group and was significantly younger. T2DM, HT and 
current smoking behavior were more prevalent in the obese group. The obese group 
had a significantly higher BMI and waist circumference, when compared to the 
non-obese subjects. Focusing on classic CVR factors, the mean systolic and diastolic 
blood pressure, LDL-C and glucose levels were significantly higher in the obese 
subjects then in non-obese subjects, while HDL-C was lower in the obese group. 
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Apo-B, C3 and CRP, which are thought to be related to CVR, were also elevated in 
the obese subjects. Only total cholesterol levels and triglyceride levels were not 
different between the groups (Table 1).
Table 1
Non-obese (n=377) Obese (n=576) p -value
Sex (%)°
   female 173 (45.9%) 418 (72.6%) p  < 0.001
Age*
   (years) 58.7 (±13.0) 44.2 (±13.0) p  < 0.001
BMI*
   (kg/m2) 25.0 (±2.81) 43.8 (±7.58) p  < 0.001
Waist circumference*
   (cm) 93.5 (±10.6) 128.6 (±16.3) p  < 0.001
Medical history
    Type 2 diabetes° 41 (10.9%) 132 (22.9%) p  < 0.001
    Hypertension° 107 (28.4%) 199 (34.5%) p  = 0.019
    Dyslipidemia° 73 (19.4%) 96 (16.7%) p  = 0.436
Current smoking p  = 0.031
    Yes° 70 (18.6%) 286 (24.3%)
    No° 306 (81.2%) 284 (74.7%)
Systolic blood pressure*
    (mmHg) 125 (±14.3) 138 (±16.0) p <0.001
Diastolic blood pressure*
    (mmHg) 76 (±9.6) 84 (±10.2) p <0.001
Total cholesterol*
    (mmol/l)
5.26 (±1.28) 5.23 (±0.99) p =0.745
HDL-cholesterol*
    (mmol/l)
1.49 (±0.45) 1.20 (±0.30) p <0.001
LDL-cholesterol*
    (mmol/l)
3.18 (±1.11) 3.41 (±0.96) p =0.008
Triglycerides†
    (mmol/l)
1.16 (0.3-9.7) 1.18 (0.3-9.5) p =0.296
ApoB*
    (g/l)
0.97 (±0.305) 1.08 (±0.264) p <0.001
CRP†
    (nmol/l)
19 (9.5-1542) 67 (9.5-486) p <0.001
Complement C3*
    (mg/l)
1.07 (±0.226) 1.65 (±0.275) p <0.001
Leukocytes*
    (10^9/l)
6.6 (±1.78) 8.5 (±2.32) p <0.001
Glucose*
    (mmol/l)
5.7 (±1.59) 6.5 (±1.69) p <0.001
* group differences were tested using independent T-tests
Baseline characteristics of both obese and non-obese subjects in absolute numbers or mean 
value, with its percentage or SD, respectively, presented within brackets
° group differences were tested using χ2
† described as median (minimum-maximum) and analyzed using the Kruskal-Wallis test
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In both the obese and non-obese group, no clear relation was observed 
between the level of BMI and the level of systolic blood pressure. In contrast, 
diastolic blood pressure increased with increasing BMI in the non-obese group,  
but no relation was observed between the level of diastolic blood pressure and  
BMI in the obese group. 
A similar trend was observed in the level of LDL-C and apo-B in relation 
to BMI in both groups. HDL-C decreased with increasing BMI in both groups, 
although the decrease in the obese group stabilizes from the second quintile and up. 
The significant decrease can be solely explained by a relatively high HDL-C level in 
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* group differences were tested using one way ANOVA
† described as mean (minimum-maximum) and analyzed using the Kruskal-Wallis test
Mean value (±SD) of cardiovascular risk factors and inflammatory markers 
in the different quintiles based on BMI of the obese group
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the triglyceride level showed a gradual increase with increasing BMI in the  
non-obese group, but a gradual decrease in the obese group (Tables 2 and 3).
Inflammatory markers, which are also related to CVR, followed a different 
pattern with BMI in both groups. Both CRP and leukocyte count were not related to 
BMI in the non-obese group. However, both parameters showed a clear relationship 
with BMI in the obese group. Complement C3 was the only parameter with a positive 
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* group differences were tested using one way ANOVA
† described as mean (minimum-maximum) and analyzed using the Kruskal-Wallis test
Mean value (±SD) of cardiovascular risk factors and inflammatory markers 
in the different quintiles based on BMI of the non-obese group
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Adipose tissue in subcutaneous and visceral depots by CT-scans
Forty-two abdominal CT-scans of obese patients were performed in the 
perioperative period for bariatric surgery. No significant differences in baseline 
characteristics were seen between obese subjects who did or did not undergo an 
abdominal CT-scan. A positive correlation of BMI with SAT surface was found  
(r = 0.633, p < 0.001), while no significant correlation of BMI with VAT surface was 
observed (r = -0.068, p = 0.670; Figure 1). There were no significant correlations 
between the surface areas of VAT and SAT on the one hand, and the classic CVR 
factors or inflammatory markers on the other.
Figure 1
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Discussion
Although diastolic and systolic blood pressure and the levels of LDL-C, glucose 
and apo-B were significantly increased in our obese subjects, the level of BMI 
in this group did not seem to influence the level of CVR factors. Therefore, 
derangement of CVR factors overall appears to reach a plateau at a certain 
level of obesity. A clear explanation for these observations is lacking.
One explanation for this finding may be the different metabolic effects of 
VAT and SAT. Central adiposity is strongly associated with metabolic disturbances, 
such as insulin resistance, dyslipidemia and systemic inflammation, which play 
essential roles in the pathogenesis of CVD.20,21 Furthermore, it is also associated 
with both cardiovascular mortality, cancer mortality and overall mortality.20 More 
specifically, fat distribution may play an important role in the risk of metabolic 
disease and CVD,22 in which VAT is most strongly related to measures of metabolic 
disease.21 The present study suggests that VAT appears to have limited potential for 
expansion. Therefore, it can be hypothesized that after saturation of the VAT depot, 
further increases in obesity (i.e. BMI) result in fat storage in other depots, such as 
SAT. As a result, the detrimental effects of VAT will not increase with increasing 
BMI in morbid and superobese subjects, as suggested by the present data. 
Expansion of SAT at the expense of VAT may protect obese subjects from 
further deterioration of their CVR factors. The adipose tissue expandability model 
states that adipose tissue in general has a maximum potential for expansion in a 
given individual.23 Once this degree of maximal expansion is reached the adipose 
tissue is no longer able to safely store excess energy and the lipid flux to non-adipose 
organs will increase, resulting in ectopic fat accumulation. Storage of lipids in 
ectopic sites, such as hepatocytes or beta cells, can eventually result in metabolic 
disturbances as seen in obese patients.24,25 However, none of these studies evaluated 
the expansion capacity of VAT and SAT in the course of increasing obesity in 
humans. It should be noted that a limitation of the present study is the small 
number of abdominal CT-scans in the obese group. Furthermore, due to the lack 
of abdominal CT-scans in the non-obese group, our data concerning the different 
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adipose tissue depots only apply to obese subjects. Future studies investigating this 
issue should include measurements of adipose tissue depots.
In contrast to the previously mentioned CVR factors, inflammatory markers 
showed a clear relationship with the level of obesity in the obese group, while 
CRP and leukocyte count did not show an association with BMI in the non-obese 
group. Adipose tissue is known to secrete several adipokines that in part may cause 
increases in CRP as suggested by the relationship found in obese subjects between 
BMI and CRP. We did not use a highly sensitive CRP assay, which may in part explain 
the lack of association in the non-obese subjects. However, the inflammatory marker 
C3 did increase with increasing BMI in both the non-obese and obese group, and 
C3 levels have been shown to be associated with CRP levels.26 Although systemic 
inflammation is positively related to BMI, classical CVR factors seem to reach a 
maximal level at BMI 35–40 kg/m2. Increased CVR in subjects with BMI > 40 kg/m2 
may depend more on systemic inflammation and less so on classic CVR factors.
One unexpected finding of this study was the paradoxical decrease in TG with 
increasing BMI in our obese subjects, causing a peak level of TG within the group 
of subjects with a BMI between 26–35 kg/m2. A limitation in our measurement of 
TG is that fasting venipuncture was not a requirement within our cohort; we were 
unable to distinguish between fasting and non-fasting subjects. However, the latest 
guidelines on lipid measurements questions the need for fasting measurements 
since normal food intake does not largely affect lipids levels and the intra-individual 
variability in TG remains comparable throughout the day.27,28 Additionally, it is 
unlikely that non-fasting TG levels were mainly measured in subjects with a BMI 
between 26–35 kg/m2. Therefore, we assume that the combination of fasting and 
non-fasting TG levels cannot explain the paradoxical trend in TG levels in the obese 
group. Porter et al.29 previously noticed an increase of TG levels with increasing 
visceral fat volume. However, in the group with the highest visceral fat volumes, TG 
levels decreased with increasing subcutaneous fat volumes,29 which is in line with 
our findings. They suggested that SAT may have beneficial effects on triglyceride 
metabolism in those subjects with large VAT volumes. Unfortunately, the molecular 
mechanism behind these findings has not been determined yet.
37
2
BMI and cardiovascular risk factors
Even though excess body weight is known to increase all-cause mortality 
and cardiovascular mortality, previous studies only included subjects with a BMI 
up to 35 kg/m2.5,20,22 However, 1.5–6% of all adults in developed countries are known 
to be morbidly obese,30 with a BMI > 40 kg/m2 and this prevalence is still rising. 
Much interest exists on the treatment of these morbidly obese subjects, in order to 
achieve significant weight loss and resolution of obesity-related comorbidity and 
thereby, prevention of preterm mortality. The Prospective Studies Collaboration 
has demonstrated that overall mortality, as well as cardiovascular mortality, 
increases with increasing BMI, at least up to a BMI of 50 kg/m2.2 Furthermore, 
overweight and obesity are associated with an early onset of CVD, not only 
resulting in higher mortality, but also in a greater portion of life lived with CVD 
morbidity.31 These findings should urge clinicians to intensify CVR management 
in obese subjects. The current CVR management should not be simply assumed to 
be suitable for morbidly obese patients. Previous studies reveal that HT in obese 
patients is of a different phenotype than HT in the lean population. In addition, 
not all antihypertensive drugs appear to be equally effective in obesity-related HT 
as in HT in lean patients.32,33 Furthermore, current guidelines for the treatment of 
dyslipidemia may not be suitable in obesity. Obese subjects are thought to require 
more intensive treatment for dyslipidemia with higher doses of lipid-lowering 
drugs.34 Nevertheless, our data suggest that classic CVR factors do not further 
deteriorate with increasing BMI, from a BMI of approximately 35 kg/m2 and higher. 
This suggests that the increased cardiovascular mortality in obesity is not caused 
by deterioration of classic CVR factors, but that obesity is an independent CVR 
factor itself. The increased cardiovascular mortality in obese patients2,35 may be 
influenced by other factors, such as systemic inflammation or non-atherosclerotic 
heart disease. Future studies should distinguish between different cardiovascular 
mortality causes in morbidly obese subjects, such as atherosclerotic heart disease, 
hypertensive heart disease, cardiomyopathies or heart failure.36
The distinct difference in baseline characteristics between the non-obese 
and obese groups in this study is a major limitation, even though the results were 
adjusted for comorbidity. When interpreting our results, we should keep in mind 
that patients on antihypertensive or lipid-lowering drugs were excluded from the 
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analysis when the drug would interfere with the CVR factor under investigation. 
Therefore, the relationships may not be applicable in subjects who already receive 
treatment for CVR reduction. These excluded subjects could elevate the level of the 
specific risk factor if they were added to the analysis after cessation of their therapy. 
However, we do not have these data and felt that the use of antihypertensive and 
lipid-lowering drugs would disturb the natural relationship between BMI and 
the risk factors. Therefore, these confounding factors were excluded with the 
realization that the data may be biased. Regardless of this limitation, the results 
of this study provide new insights in CVR in a population of high interest, since 
obesity and morbid obesity is reaching epidemic proportions37 with substantial 
economic burden, not only in terms of medical costs, but also in terms of non-
medical costs (e.g. absenteeism and personal costs).38 Our future perspective is to 
analyze CVR factors in relation to BMI in a larger population in which we are able to 
match on age and gender and correct for confounding factors. The level of obesity 
should become a part of the currently available CVR calculators.
In conclusion, obesity is related to an increased risk on metabolic disease 
and CVD and mortality, but this increased risk may not be solely explained by 
deterioration of classic CVR factors. The lack of correlation of CVR factors and BMI 
in obese subjects may be explained by the expansion of SAT with increasing BMI 
after saturation of the VAT compartment. In order to reduce the risk of CVD and 
mortality in obese subjects, treatment may need to focus on reduction of systemic 
inflammation and on non-atherosclerotic heart diseases.
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Abstract 
Background
Women are relatively protected from cardiovascular disease compared to men. 
Whether this is also the case in high-risk patients like the morbidly obese is not 
known. The current study investigated whether the association between sex and 
cardiovascular risk factors and outcomes can be demonstrated in subjects suffering 
from morbid obesity.
Materials and methods
Two hundred subjects enrolled in a study evaluating cardiovascular risk factors 
in morbid obesity underwent extensive laboratory screening. Structural vascular 
changes were determined by carotid intima media thickness (cIMT) and pulse wave 
velocity (PWV) measurements reflected functional changes. Gender differences 
were analyzed using univariate and multivariable linear regression models. Results 
of these models were reported as B coefficients with 95% confidence intervals.
Results
The group consisted of 52 men and 148 women, with a mean age of 41 (±11.8) years 
and a mean body mass index (BMI) of 42.7 (±5.2) kg/m2. Both cIMT and PWV were 
significantly higher in men than in women. The most important determinants 
for cIMT differences were waist circumference, age, high-density lipoprotein 
cholesterol and mean arterial pressure. The gender differences for PWV remained 
after adjustments for these covariables.
Conclusions
Morbid obesity is associated to sex-specific differences in vascular function. 
However, differences in structural vascular changes seem to depend on classic 
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Introduction
Even though cardiovascular disease (CVD) is one of the major causes of death 
in both men and women at all ages, the prevalence in women is relatively low 
before menopause.1 This prevalence approaches similar rates for men and 
women in their seventh decade of life. Women are relatively protected against 
CVD and require a heavier risk factor load before developing CVD.2 The exact 
mechanism behind this remarkable sex differences in CVD is still not fully 
understood.3
Focusing on classic cardiovascular risk (CVR) factors, hypertension and 
smoking are more prevalent in men than in women.1 Women have lower total 
cholesterol levels4 and higher high-density lipoprotein cholesterol (HDL-C) values1 
than men. These sex differences in cardiovascular risk factors diminish after 
menopause.1,2,4
When studying outcome measures for subclinical atherosclerosis, such as 
common carotid intima media thickness (cIMT) measurements or pulse wave 
velocity (PWV), previous studies showed that both cIMT5–8 and PWV9,10 are higher 
in men than in women. These sex differences also decrease after menopause.3,5
Obese subjects have increased levels of classic CVR factors11–13 and higher 
cIMT and PWV values14–16 and both overall and cardiovascular mortality is higher 
in obese subjects.17,18 Sex differences in cardiovascular mortality persist in different 
levels of overweight and obesity, although the differences may attenuate in obese 
individuals.19 It is unclear whether these sex differences persist in morbidly obese 
subjects. The purpose of this study was to investigate sex differences in CVR factors 
in morbid obese subjects and to investigate differences in structural and functional 
outcome measures in terms of cIMT and PWV.
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Materials and methods
Study population
This is a report from the ASSISI study. This prospective cohort study aims to 
investigate the effects of bariatric surgery on CVR factors in morbid obesity and 
comprises 200 patients, included in the study between April 2015 and April 2016. 
All subjects met the international criteria for bariatric surgery20 (i.e. BMI ≥ 40 kg/
m2 or BMI ≥ 35 kg/m2 and obesity-related comorbidity, aged 18–65 years). This 
obesity-related comorbidity includes hypertension, type 2 diabetes, dyslipidemia, 
respiratory disease, severe joint disease and severe obesity-related psychological 
problems. Subjects with a previous cholecystectomy, a previous bariatric procedure, 
an acute inflammatory disease within 6 weeks prior to inclusion or immune-
modulating medication were excluded. All data presented here are baseline data, 
which were collected at study entry.
The study was approved by the independent Regional Medical Ethical 
Committee Rotterdam (Maasstad Hospital, Rotterdam, the Netherlands, ABR no. 
NL47891.101.14) and all subjects gave written informed consent. The ASSISI study is 
registered in the Dutch Trial Register (NTR5172). Reporting of the study conforms 
to STROBE statement.21
Definition of menopause, type 2 diabetes, hypertension and 
hypercholesterolemia
Female subjects were considered postmenopausal based on a history of secondary 
amenorrhea of ≥ 1 year.22 Women who had previously undergone hysterectomy were 
excluded from the analysis in pre- and postmenopausal women.
Type 2 diabetes mellitus (T2DM) was defined as a glycated hemoglobin 
(HbA1c) level ≥ 48 mmol/mol (6.5%)23 and/or the use of glucose-lowering 
medication. Hypertension was defined by a systolic blood pressure > 140 mmHg, 
a diastolic blood pressure > 90 mmHg and/or the use of antihypertensive 
medication.24 Hypercholesterolemia was defined as low-density lipoprotein 
cholesterol (LDL-C) levels > 2.5 mmol/l and/or the use of lipid-lowering drugs.24
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Baseline characteristics
Baseline characteristics were obtained during standard preoperative screening 
by the endocrinologist prior to bariatric surgery and included medical history 
and current medication profile. Smoking within 6 months prior to inclusion was 
considered “active smoking.” Smoking before these 6 months was considered 
“previous smoking.” Anthropometric characteristics included height, weight,  
waist circumference and blood pressure. The body mass index (in kg/m2) and  
mean arterial pressure (MAP) were calculated.
Laboratory measurements
Extensive preoperative laboratory testing was carried out in all participants. Freshly 
drawn blood was used for all clinical and hematological chemistry measurements. 
C-reactive protein (CRP), glucose, total cholesterol, HDL-C and triglycerides (TG) 
were determined using the DxC analyzer (Beckman Coulter). LDL-C values were 
calculated using the Friedewald formula. Apolipoprotein B (Apo-B) was determined 
by rate nephelometry using IMAGE analyzer (Beckman Coulter). HbA1c was 
measured using an HPLC G8 analyzer (Tosoh Bioscience).
Carotid intima media thickness
cIMT measurements were performed by one observer, according to the consensus 
guidelines for carotid ultrasound for CVD risk assessment as described previously.25 
The measurements were carried out using the ART-LAB (Esaote, Italy) by a trained 
and experienced sonographer, who was unaware of the patient’s medical history. 
Ultrasound scans were performed with the patients lying in a supine position with 
the head resting comfortably and the neck slightly hyperextended and rotated in 
the opposite direction of the probe. The ultrasound images were obtained from 
the distal 1 cm of the far wall of each common carotid artery (CCA) using B-mode 
ultrasound producing two echogenic lines. These lines represent the combined 
thickness of the intimal and medial layers of the arterial wall. Each CCA has been 
imaged in three different projections: CCA right side 90–120–150, and CCA left side 
210–240–270 degrees. The segments were measured semi-automated in triplicate.
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Pulse wave velocity
PWV measurements were carried out using the Mobil-O-Graph (I.E.M., Germany) 
as previously described.26 The Mobil-O-Graph uses an inflatable cuff to measure 
the PWV. The cuff was placed on the patient’s bare left upper arm. Cuff size 
was selected based on the patient’s upper arm circumference. Triplicate manual 
measurements were performed. PWV has been calculated by the provided software 
and was expressed in m/s.
Statistical analysis
All analyses were performed using SPSS (PASW) 18.0 software (SPSS Inc., Chicago, 
Illinois, USA). Data are given as mean ± standard deviations. Skewed variables are 
given in median and interquartile range (IQR). Categorical data were described in 
an absolute number as well as a percentage of the total group. Differences between 
males and females were analyzed using independent T-tests for continuous data 
with normal distribution, chi-squared tests for categorical data and independent 
samples Mann–Whitney U tests for continuous data with non-normal distribution. 
For statistical analysis cIMT was defined as the mean of the six individual 
measurements, as described above, and PWV was defined as the mean of three 
individual measurements. Systolic and diastolic blood pressure were integrated in 
the mean arterial pressure (MAP), which is the sum of 1/3 systolic blood pressure 
and 2/3 diastolic blood pressure.27-29
The associations between cIMT and PWV with sex were evaluated with 
univariate linear regression analysis. Since cIMT is a skewed variable logarithmic 
transformation was performed on this variable. Within the models this transformed 
variables is named “log cIMT”. The log cIMT showed a normal distribution 
with skewedness of 0.414 and a kurtosis of –0.329 and is thereby an appropriate 
dependent variable for the models. Covariables in further analyses included age, 
BMI, waist circumference, smoking habit, TG, HDL-C, LDL-C, CRP, HbA1c and 
MAP. Correlations between covariables (multicollinearity) were checked for 
confounding and interaction effects were checked using stratified analysis. Within 
the regression model for log cIMT, a significant interaction effect was observed 
between HDL-C and TG, while waist circumference was a significant confounder. In 
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the PWV model, sex and waist circumference interacted. Other confounding factors 
were ignored in the analyses for having a low correlation or small effect on the 
outcome measures. After stratification for the confounder “waist circumference”, 
the association between log cIMT and sex was evaluated with multivariable linear 
regression analysis (model: backward stepwise). The following variables were 
entered into the model: sex, age, BMI, waist circumference, smoking habit, TG, 
HDL-C, LDL-C, CRP, HbA1c, MAP and the interaction effect “HDL-C x TG”. The 
association between PWV and sex was assessed in a multivariable linear regression 
analysis (model: backward stepwise), including sex, age, BMI, waist circumference, 
smoking habit, TG, HDL-C, LDL-C, CRP, HbA1c, MAP and the interaction effect 
“sex x waist circumference”.
In addition, the effect of menopausal status in women on cIMT as well as 
PWV was assessed using ANOVA tests and univariate and multivariable linear 
regression analysis (model: backward stepwise). The relationships of cIMT and 
PWV with age in both premenopausal and postmenopausal women as well as 
men were observed using scatterplots with LOESS smooth lines (α = 0.50). Due 
to high correlation with menopausal state, we eventually removed age from the 
models (spearman’s rho = 0.770, p < 0.001). No significant confounding factors or 
interaction effects were observed. The following variables were entered in both the 
log cIMT and PWV model: menopausal status, smoking habit, waist circumference, 
TG, HDL-C, LDL-C, CRP, HbA1c and MAP. Results of these models were reported as 
B coefficients with 95% confidence intervals.
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Results
The total cohort included 200 subjects, 52 men and 148 women, with a mean age of 
41 (±11.8) years and a mean BMI of 42.7 (±5.2) kg/m2. Men had a significantly higher 
waist circumference and were more likely to suffer from T2DM and myocardial 
infarction. Systolic and diastolic blood pressure, HbA1c and triglyceride levels were 
increased in men, while HDL-C, LDL-C and CRP were significantly higher in female 
subjects. Details are displayed in Table 1.
The median cIMT was measured in 152 study subjects and was significantly 
higher in men than in women (0.638 mm [IQR 0.549–0.735] and 0.529 mm [IQR 
0.478–0.600], respectively, p < 0.001). Furthermore, median PWV was measured in 
146 subjects and was also significantly higher in men in comparison with women (7.3 
m/s [IQR 6.6–8.0] and 6.8 m/s [IQR 5.9–8.0], respectively, p = 0.029; Figure 1).
Male Female p -value Premenopausal Postmenopausal p- value
Number 52 148 98 45
Age (years) 43.7 (±11.0) 40.6 (±12.0) p =0.098# 34.1 (±9.4) 53.4 (±4.2) p <0.001#
Medical history (n,%)
    Diabetes mellitus type 2 18 (34.6%) 22 (14.9%) p =0.002* 10 (10.2%) 11 (24.4%) p =0.025*
    Hypertension 22 (42.3%) 47 (31.8%) p =0.169* 21 (21.4%) 25 (55.6%) p <0.001*
    Hypercholesterolemia 15 (28.8%) 43 (29.1%) p =0.977* 18 (18.4%) 25 (55.6%) p <0.001*
    Active smoker 14 (26.9%) 37 (25.0%) p =0.273* 25 (25.5%) 10 (22.2%) p =0.872*
BMI (kg/m2) 43.9 (±6.5) 42.3 (±4.6) p =0.100# 42.3 (±4.1) 42.4 (±5.5) p =0.904#
Waist circumference (cm) 139 (±12.4) 126 (±11.5) p <0.001# 127 (±10) 125 (±14) p =0.342#
Systolic blood pressure (mmHg) 145 (±17) 137 (±19) p =0.009# 132 (±14) 149 (±20) p <0.001#
Diastolic blood pressure (mmHg) 86 (±10) 80 (±9) p <0.001# 78 (±9) 83 (±10) p =0.002#
HbA1c (mmol/mol) 47 (±18) 42 (±10) p =0.035# 40 (±7.2) 45 (±12.5) p =0.005#
Triglycerides (mmol/l) 2.69 (1.60 - 3.72) 1.63 (1.10 - 2.17) p <0.001§ 1.54 (1.02 - 2.08) 1.71 (1.27 - 2.27) p =0.112§
LDL-cholesterol (mmol/l) 2.8  (±0.9) 3.2 (±1.0) p =0.027# 3.08 (±0.90) 3.41 (±1.09) p =0.072#
HDL-cholesterol (mmol/l) 1.0 (±0.2) 1.3 (±0.3) p <0.001# 1.27 (±0.29) 1.40 (±0.27) p =0.010#
Apo B (g/l) 1.12 (±0.31) 1.13 (±0.30) p =0.875# 1.10 (±0.28) 1.20 (±0.34) p =0.090#
Lipoprotein (a) (mg/l) 143 (45 - 314) 211 (85 - 575) p =0.036§ 220 (78 - 568) 187 (99 - 584) p =0.773§
CRP (mg/l) 4 (2 - 8) 7 (4 - 11) p <0.001§ 8 (4 - 13) 6 (3 - 10) p =0.164§




§ Independent samples Mann-Whitney U test
Differences in baseline characteristics in male and female subjects and pre- and postmenopausal subjects
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Using univariate linear regression, female sex was associated with a decrease 
in log cIMT (beta: −0.362, adjusted R2: 0.125, p < 0.001). In the multiple regression 
analysis, after stratification for the confounder waist circumference, age, HDL-C 
and MAP were significant contributors to log cIMT. After adjustment for age, 
HDL-C and MAP, female sex was no longer significantly associated with a lower log 
cIMT in subjects with a relatively low waist circumference. Within the subgroup of 
subjects with a waist circumference of 129 cm or higher, it appears that female sex 
gives a decrease of 4.7% in cIMT after adjustment for covariables. Additional data 
are displayed in Table 2.
In a univariate analysis, female sex was negatively associated with PWV  
(beta: −0.165, adjusted R2: 0.020, p = 0.047). In the multivariable analysis, age, 
BMI, MAP, CRP and HbA1c were significant contributors to PWV. Female sex was 
associated with a lower PWV, when adjusted for these variables. Based on the 
Figure 1
Differences in median cIMT and PWV in women versus men (a + b) 
and in pre- and postmenopausal women versus men (c + d)
(a) Median carotid intima media thickness (b) Median pulse wave velocity
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appearance of the interaction effect “sex x waist circumference,” the effect size of 
female sex on PWV depended on the waist circumference. To be more precise, the 
advantage of women over men, in terms of PWV, diminishes with increasing waist 
circumference. Additional data are displayed in Table 3.
Among women, there was a non-linear relation between age and both cIMT 
and PWV, with an increased inclination of the LOESS smooth line from an age 
of approximately 45 years, while this relation in men appeared to be more or 
less linear (Figure 2). The female group consisted of 98 premenopausal and 45 
postmenopausal women. Five women were excluded from further analyses, due to 
a history of hysterectomy. Postmenopausal women were significantly more likely to 
suffer from comorbidities such as T2DM, hypertension and hypercholesterolemia. 
Systolic and diastolic blood pressure, HbA1c and HDL-C were significantly higher in 
postmenopausal women, than in premenopausal women (Table 1).
Parameter log cIMT in subjects with waist < 129 cm log cIMT in subjects with waist ≥ 129 cm
B coefficient (95% CI) p -value B coefficient (95% CI) p -value
Constant -0.340 (-0.427; -0.252) p  < 0.001 -0.517 (-0.660; -0.374) p  < 0.001
Female gendera --- --- -0.047 (-0.080; -0.014) p  = 0.006
Age 0.004 (0.002; 0.005) p  < 0.001 0.003 (0.002; 0.004) p  < 0.001
HDL cholesterol -0.057 (-0.112; -0.001) p  = 0.044 --- ---
Mean Arterial Pressure --- --- 0.002 (0.000; 0.003) p  = 0.016
Table 2
Impact of sex on subclinical atherosclerosis (log cIMT). The impact of sex on log cIMT was evaluated with 
multiple linear regression analysis (backward stepwise analysis).
a Male subjects were scored by 0, female subjects were scored by 1
Parameter PWV
B coefficient (95% CI) p -value
Constant -0.005 (-1.094; 1.084) p  = 0.993
Female sexa -1.242 (-2.495; 0.011) p  = 0.052
Age 0.083 (0.074; 0.091) p  < 0.001
BMI 0.015 (-0.003; 0,034) p = 0.100
Mean Arterial Pressure 0.026 (0.017; 0.034) p  < 0.001
CRP -0.013 (-0.027; 0.000) p  = 0.051
HbA1c 0.009 (0.001; 0.016) p  = 0.021
Waist x sex 0.012 (0.002; 0.021) p  = 0.021
Table 3
Impact of sex on arterial stiffness (PWV). The impact of sex on PWV was 
evaluated with multiple linear regression analysis (backward stepwise analysis).
a Male subjects were scored by 0, female subjects were scored by 1
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Figure 2
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Median cIMT was significantly higher in postmenopausal women, when 
compared with premenopausal women (0.591 mm [IQR 0.517–0.684] and 0.512 mm 
[IQR 0.465–0.563], respectively, p < 0.001). Additionally, PWV was also significantly 
higher in postmenopausal women than in premenopausal women (8.5 m/s [IQR 8.0–
8.8] and 6.2 m/s [IQR 5.6–6.9], respectively, p < 0.001). Even though no significant 
differences were observed in cIMT between men and postmenopausal women, PWV 
was significantly higher in the postmenopausal women than in men (Figure 1).
Postmenopausal state was associated with a higher log cIMT in univariate 
analysis (beta: 0.363, adjusted R2: 0.124, p < 0.001) as well as after adjustment for 
covariables (Table 4). Menopausal status was also positively associated with PWV 
in both univariate linear regression model (beta: 2.067, adjusted R2: 0.542, p < 0.001) 
and a multivariable regression analysis (Table 4).
Parameter log cIMT Parameter PWV
B coefficient (95% CI) p -value B coefficient (95% CI) p -value
Constant -0.550 (-0.683; -0.418) p  < 0.001 Constant 0.983 (-0.364; 2.330) p  = 0.151
Menopausea 0.037 (0.006; 0.067) p  = 0.020 Menopausea 1.452 (1.132; 1.771) p  < 0.001
HbA1c 0.002 (0.000; 0.003) p  = 0.035 HbA1c 0.035 (0.018; 0.052) p  < 0.001
MAP 0.002 (0.001; 0.003) p  = 0.002 CRP -0.019 (-0.038; -0.001) p  = 0.041
HDL --- --- MAP 0.044 (0.030; 0.057) p  < 0.001
a Premenopausal women were scored by 0, postmenopausal women were scored by 1
Table 4
Impact of menopausal state on subclinical atherosclerosis (log cIMT and PWV). The impact of 
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Discussion
Sex differences in CVR factors and outcome measures for subclinical 
atherosclerosis do not only exist in lean and overweight subjects but persist in 
subjects with obesity and morbid obesity. Even though obesity is associated 
with an increased risk of cardiovascular disease and mortality, morbidly 
obese women are still relatively protected in comparison to men. However, as 
previously seen in lean and obese women, this advantage appears to diminish 
in postmenopausal morbidly obese women.
The sex differences in classic CVR factors within this study are comparable 
to previously described differences;1,2,4 men had higher systolic and diastolic blood 
pressure and increased triglyceride levels, while women had higher HDL-C levels 
and higher CRP levels. In contrast to previous reports,4 women within this cohort 
had higher LDL-C levels in comparison with men. However, men were more likely 
to suffer from T2DM and the prescription of lipid-lowering drugs is part of the 
protocolled treatment of diabetic patients. This could explain the lower LDL-C 
levels in men.
Within this study, cIMT and PWV were used as outcome measures for 
atherosclerosis. Both measures were significantly lower in morbidly obese women in 
comparison with morbidly obese men, suggesting an advantage for women in terms 
of CVD and cardiovascular mortality. However, after adjustment for covariables, it 
appeared that cIMT was not so much influenced by sex, but by differences in waist 
circumference, age, HDL-C and MAP. Age is the main contributor to an increase in 
cIMT. Overall, cIMT is known to be lower in lean and overweight women, compared 
with men,5-8 but this difference appears to diminish with increasing weight.30 
Unfortunately, our study only included morbidly obese subjects and no non-obese 
controls. No firm statements can be made on the differential effect of increasing 
weight on cIMT in men and women. However, obesity has been shown to affect 
cIMT5,6 negatively and within lean subjects cIMT is correlated with BMI.6 It was 
thought that this effect of weight on cIMT may be more profound in women than in 
men,7 but our data do not support this hypothesis.
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In contrast to cIMT, PWV was still associated with sex after adjustments for 
covariables in morbidly obese patients. As previously described,31,32 age and blood 
pressure were the main contributors to PWV. In addition, female sex was associated 
with lower PWV, although this effect also depended on waist circumference. It 
has been suggested that sex is a major contributor to PWV in lean and overweight 
subjects33 and our data now show that this relationship persists in subjects with 
obesity and morbid obesity.
Women are relatively protected against CVD, but this advantage diminishes 
in postmenopausal women.2,34 Hormonal imbalances may play an important role 
in the development of CVD, although some hormone replacement studies do not 
support this hypothesis.34 In general, premenopausal women have lower cholesterol, 
LDL-C, TG and apo-B levels than men and higher HDL-C levels.19 After menopause 
both LDL-C and total cholesterol increase,19 where HDL-C shows a small decline.1 
In our morbidly obese population, the differences in CVR profile between pre- and 
postmenopausal women were small. Postmenopausal women had a significantly 
increased blood pressure, in agreement with the current literature,2 but no 
disadvantages were seen in the lipid-associated markers. In contrast, HDL-C was 
actually higher in postmenopausal women in comparison with premenopausal 
women. Our data suggest that the difference in CVR factors between pre- and 
postmenopausal women attenuates in morbidly obese subjects.
Within the current study, both cIMT and PWV were significantly increased in 
postmenopausal women compared with premenopausal women. These relationships 
persisted after adjustment for covariables. In addition to menopausal status, cIMT 
was mainly determined by HbA1c and MAP, whereas PWV was mainly determined 
by HbA1c, MAP and CRP. Age and blood pressure are two of the major determinants 
of these cardiovascular outcome measures.31,32 We decided to remove age from the 
multivariable analyses, due to the high correlation of age and menopausal status. 
It can be suggested that the differences in cIMT between pre- and postmenopausal 
women are solely explained by age differences. However, Figure 1 reveals that 
the effect of age on cIMT or PWV increases after an age of approximately 45 
years, suggesting an effect of menopausal status on top of the effect of age. Since 
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menopausal status was the factor of interest and since the high correlation suggests 
that the majority of information on age was included in the menopausal state, it 
seemed justified to remove age from this analysis. However, within this study, we 
cannot differentiate the absolute effect of age and the absolute effect of menopause, 
which is a limitation of this study. The effect of menopausal state on PWV may be 
clinically relevant. However, when not considering age as a significant contributor 
to cIMT, being postmenopausal only increases the cIMT value with 3.7%, making 
the effect on cIMT rather irrelevant. Furthermore, it is important to realize that the 
hormonal effects of menopause may also appear in subjects suffering from hormonal 
disbalance due to obesity itself, such as polycystic ovary syndrome. None of the 
postmenopausal women were formerly diagnosed with polycystic ovary syndrome, 
and all of these women were aged 45 years or older. However, we are not informed  
on the effects of hormonal disbalance on cardiovascular risk factors, cIMT and PWV 
in the premenopausal women.
As previously mentioned, the lack of non-obese control patients is one of the 
limitations of this study. It was previously suggested that differences in cIMT and 
PWV diminish with increasing weight. With the addition of a non-obese cohort, 
the relation of weight with cIMT and PWV in different weight groups could have 
been investigated. Another limitation of this study is the difference in baseline 
characteristics between men and women. Multivariable linear regression analysis was 
used to adjust for differences in the baseline, in order to be able to make statements 
on the effect of sex on cIMT and PWV. We decided to use MAP as a marker for 
hypertension. Since we were not informed on the duration of hypertension and the 
effect of treatment within the group of subjects suffering from hypertension, the 
current MAP was the most objective parameter on blood pressure effects on cIMT and 
PWV. Due to a small number of subjects within this cohort and no available follow-up 
data, conclusions were drawn on surrogate outcome measures for CVD and not on 
real clinical outcomes such as cardiovascular events. Unfortunately, not all subjects 
within this study underwent cIMT or PWV measurements due to technical problems. 
Baseline characteristics were presented on the entire study group and not on the 
subgroups that underwent cIMT and PWV measurement since the entire study group 
was representative for the groups that underwent cIMT and PWV measurements.
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In conclusion, commonly described sex differences in cardiovascular 
outcome measures, such as cIMT and PWV, persist in morbidly obese subjects. 
Differences in cIMT cannot be explained by sex alone and are mainly related to 
waist circumference, age, HDL-C and MAP. The advantage of women over men 
appears to diminish in morbidly obese women after menopause. The advantage in 
CVR translates into both lower cIMT and PWV values for premenopausal women. 
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Abstract 
Background
Type 2 diabetes mellitus (T2DM) and obesity are both related to increased risk 
of cardiovascular disease and mortality. Early atherosclerotic vascular changes 
can be detected by non-invasive tests like carotid intima media thickness (cIMT) 
and pulse wave velocity (PWV). Both cIMT and PWV are significantly impaired in 
T2DM and in obese patients, but the additional effect of T2DM on these vascular 
measurements in obese subjects has not been evaluated.
Materials and methods
200 morbidly obese patients with or without T2DM were enrolled in a prospective 
cohort study and underwent extensive laboratory testing, including cIMT and PWV 
measurements. The cohort was divided into a group with and a group without 
T2DM.
Results
Within this cohort, 43 patients (21.5%) were diagnosed with T2DM. These  
patients were older and had more often (a history of) hypertension as compared  
to patients without T2DM. HbA1c levels were significantly increased, while  
LDL-cholesterol was significantly lower and the use of statins higher than in  
non-diabetic participants. cIMT and PWV were significantly increased in subjects 
suffering from T2DM. The variability in cIMT and PWV was related to differences  
in age and systolic blood pressure, but not to the presence of T2DM.
Conclusions
While T2DM negatively affects the vasculature in morbid obesity, hypertension and 
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Introduction
Type 2 diabetes mellitus (T2DM) is a growing chronic health problem 
worldwide, and its micro- and macrovascular complications cause significant 
morbidity and mortality.1 T2DM is associated with atherosclerosis2 and is a 
major risk factor for cardiovascular disease (CVD).3-4 Atherogenic dyslipidemia 
is a key factor linking T2DM to CVD and includes reduced levels of high-
density lipoprotein cholesterol (HDL-C) and increased levels of triglycerides 
(TG) and small dense low-density lipoprotein cholesterol (LDL-C).3 LDL-C 
lowering therapy can modify the cardiovascular risk in adults suffering from 
T2DM, although the risk of CVD remains higher than in non-diabetic adults.3 
Both the onset and the progression of atherosclerosis are more rapid in 
T2DM patients.1 In addition, the disease may cause premature aging of the 
cardiovascular system.5
Vascular health can be easily monitored by measuring carotid intima media 
thickness (cIMT) using carotid ultrasound. cIMT is an easy and non-invasive 
method for the detection of structural signs of carotid atherosclerosis, which is 
a significant indicator of subclinical atherosclerosis and of future CVD.1,3,6-8 Close 
associations have been seen between cIMT and conventional cardiovascular 
risk factors, such as smoking status, hypertension and dyslipidemia.8-9 Patients 
suffering from T2DM are also known to have an increased cIMT in comparison to 
non-diabetic controls,8 and the presence of T2DM increases the likelihood of early 
carotid atherosclerosis.9 Both hyperglycemia and hyperinsulinemia are associated 
with an increased risk of atherosclerotic CVD, and changes in cIMT are correlated 
with changes in fasting plasma glucose, HbA1c and insulin levels.1,9
Another measure for vascular health is arterial stiffness, which is an 
independent risk factor for CVD and mortality.3,4,10,11 The “gold standard” 
measurement for arterial stiffness is the measurement of the pulse wave velocity 
(PWV).4,5 Subjects suffering from T2DM are known to have a higher PWV than  
non-diabetic subjects.4
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Both cIMT and PWV are also known to be increased in patients suffering 
from obesity4,9,12 and obesity is also strongly associated with cardiovascular risk and 
the occurrence of coronary heart disease.4 Furthermore, obese subjects are more 
likely to develop T2DM. It is unknown whether suffering from T2DM worsens 
vascular conditions in morbidly obese subjects. As cIMT and PWV may be used as 
prospective markers for vascular disease, we selected these markers to establish the 
effect of T2DM on the vascular status in morbidly obese subjects.
Materials and methods
Study population
The data for this study are derived from the ASSISI study, a prospective cohort 
study established between April 2015 and April 2016 and including 200 patients 
scheduled for bariatric surgery within out bariatric clinic. All met the international 
IFSO criteria for bariatric surgery13 (i.e. patients with a BMI ≥ 40 kg/m2 or  
patients with a BMI ≥ 35 kg/m2 and obesity-related comorbidity, aged 18–65 years). 
Patients with a previous cholecystectomy, a previous bariatric procedure, an  
acute inflammatory disease within 6 weeks prior to inclusion or using  
immune-modulating medication were excluded from this study. All data  
presented here were collected at study entry, before bariatric surgery.
The study was approved by the independent Regional Medical Research 
Ethics Committee Rotterdam (Maasstad Hospital, Rotterdam, the Netherlands, 
ABR no. NL47891.101.14) and all patients gave written informed consent. The 
ASSISI study is registered in the Dutch Trial Register (NTR5172).
Definitions 
T2DM was defined as a glycated hemoglobin (HbA1c) level ≥ 48 mmol/mol 
(6.5%)14 and/or previously diagnosed T2DM using glucose-lowering medication. 
Hypertension was defined by a systolic blood pressure > 140 mmHg and/or  
the use of antihypertensive medication.15 Hypercholesterolemia was defined  
as LDL-C > 2.5 mmol/l and/or the use of lipid-lowering drugs.15
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Baseline characteristics
Baseline characteristics were obtained during standard preoperative screening  
by the internist prior to bariatric surgery and included the medical history and  
current medication.16 Anthropometric characteristics included height, weight,  
waist circumference and blood pressure.
Laboratory measurements
Preoperative laboratory testing was carried out in all participants using non-fasting 
samples. C-reactive protein (CRP), glucose, total cholesterol, HDL-C and TG were 
determined using the DxC analyzer (Beckman Coulter, Crea, CA, USA). LDL-C values 
were calculated using the Friedewald formula. HbA1c was measured using an HPLC 
G8 analyzer (Tosoh Bioscience, King of Prussia, PA, USA). Apo-B was determined by 
rate nephelometry using IMAGE analyzer (Beckman Coulter).
Carotid intima media thickness
cIMT measurements were performed according to the consensus guidelines for carotid 
ultrasound for CVD risk assessment, as described previously.17 The measurement was 
carried out using the ART-LAB (Esaote, Italy) by a trained and experienced sonographer, 
who was unaware of the patient’s medical history. Ultrasound scans were performed with 
the patients lying in a supine position with the head resting comfortably and the neck 
slightly hyperextended and rotated in the opposite direction of the probe. The ultrasound 
images were obtained from the distal 1 cm of the far wall of each common carotid artery 
(CCA) using B-mode ultrasound producing two echogenic lines. These lines represent 
the combined thickness of the intimal and medial layers of the arterial wall. Each CCA 
was imaged in three different projections: CCA right side, 90–120–150, and CCA left side, 
210–240–270 degrees. The segments were measured semi-automated in triplicate.
Pulse wave velocity
PWV measurements were carried out using the Mobil-O-Graph (I.E.M., Germany), 
as previously described.18 The Mobil-O-Graph uses an inflatable cuff to measure the 
PWV. The cuff was placed on the patient’s bare left upper arm. Triplicate manual 
measurements were performed. PWV was calculated by the provided software and 
was expressed in m/s.
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Statistical analysis
All analyses were performed using SPSS (PASW) 18.0 software (SPSS Inc., Chicago, 
Illinois, USA). Data are given as mean ± standard deviations. Skewed variables are 
given in median and interquartile range (IQR). Categorical data were described 
in an absolute numbers and percentages. Differences between subjects with and 
without T2DM were analyzed using independent T-tests, chi-squared tests, Fisher’s 
exact tests and independent samples Mann–Whitney U tests. For statistical analysis, 
cIMT was defined as the mean of the six individual measurements, as described 
above, and PWV was defined as the mean of three individual measurements. Systolic 
and diastolic blood pressure were integrated in the mean arterial pressure (MAP), 
which is the sum of 1/3 systolic blood pressure and 2/3 diastolic blood pressure.
The association between cIMT and PWV, both intermediate measures 
of subclinical atherosclerosis, with T2DM was evaluated with univariate linear 
regression analysis. To evaluate the effects of both the occurrence of T2DM as well 
as the severity of dysregulation of glucose homeostasis, linear regression analyses 
were performed using both the previously described definition of T2DM and the 
HbA1c level. In further analyses, covariables included gender, age, smoking status, 
BMI, waist circumference, TG, HDL-C, LDL-C, CRP and MAP. Correlations between 
covariables (multicollinearity) were checked for confounding and interaction 
effects using stratified analysis. Within the regression models of T2DM and HbA1c 
on both cIMT and PWV, a significant interaction effect was observed between 
HDL-C and TG, while gender was a significant confounder. Other confounding 
factors were ignored in the analyses for having a low correlation (< 0.30) or small 
impact on the outcome measures. After stratification for gender, the associations of 
both T2DM and HbA1c level on cIMT and PWV were evaluated with multivariable 
linear regression analysis (model: backward stepwise). The following variables were 
entered into the models: gender, age, smoking status, waist circumference, TG, 
HDL-C, LDL-C, CRP, HDL-C x TG and MAP. Results of these models were reported 
as B coefficients with 95% confidence intervals. Goodness of fit was evaluated 
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Results
The total cohort included 200 patients, 52 men and 148 women, with a mean age of 
41 (±11.8) years and a mean BMI of 42.7 (±5.2) kg/m2. Within this cohort, 43 patients 
(21.5%) were diagnosed with T2DM. T2DM patients were older and suffered more 
frequently from hypertension. In addition, these patients had more frequently 
a history of myocardial infarction. While mean HbA1c values were significantly 
increased in diabetes patients, their LDL-C levels were significantly lower than in 
non-diabetics. Diabetic patients were more frequently treated with lipid-lowering 
drugs and antihypertensive drugs. Of all diabetic patients, 35 patients (81.4%) 
were treated with glucose-lowering drugs; 13 patients received monotherapy with 
metformin, eight received a combination of insulin and metformin, 10 received 
a combination of metformin with another oral glucose-lowering drug, and four 
received another treatment. Additional characteristics are displayed in Table 1.
The median cIMT was significantly increased in patients suffering from 
T2DM, when compared to non-diabetics (0.576 mm [IQR 0.531–0.726] and 
0.540 mm [IQR 0.481–0.634], respectively, p = 0.016). The median PWV was also 
significantly higher in diabetic patients compared to non-diabetics(7.6 m/s [IQR 
6.9–8.4] and 6.8 m/s [IQR 5.9–8.0], respectively, p = 0.005; Figure 1).
Figure 1
Median carotid intima media thickness (a) and pulse wave velocity (b) 
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Univariate linear regression showed that the presence of T2DM was 
associated with an increased cIMT (crude beta: 0.048, adjusted R2: 0.021, p = 0.033). 
Additionally, higher HbA1c levels were associated with an increased cIMT (crude 
beta: 0.001, adjusted R2: 0.019, p = 0.041). In a multiple regression analysis, both 
T2DM and HbA1c did not contribute to the cIMT after stratification for gender and 
adjusted for age, LDL-C, HDL-C and MAP. The other parameters included in the 
analysis did not have any significant effect on the cIMT.
Baseline characteristics
Non-diabetes Diabetes p -value
Number 157 43
Age (years) 39.8 (±12.1) 47.4 (±8.3) p <0.001a
Female gender 123 (78.3%) 25 (58.1%) p =0.007b
Medical history (n,%)
    Hypertension 77 (49.0%) 31 (72.1%) p =0.007b
    Hypercholesterolemia 124 (79.0%) 34 (79.1%) p =0.990b
    Stroke 3 (1.9%) 2 (4.7%) p =0.293c
    Myocardial infarction 2 (1.3%) 4 (9.3%) p =0.020c
Medication use (n,%)
    Lipid lowering agents 10 (6.4%) 21 (48.8%) p <0.001b
    Antihypertensive agents 38 (24.2%) 27 (62.8%) p <0.001b
Smoking habbit (n,%) p =0.861b
    No 68 (43.3%) 19 (44.2%)
    Former smoker 50 (31.8%) 12 (27.9%)
    Yes 39 (24.8%) 12 (27.9%)
BMI (kg/m2) 42.7 (±5.2) 42.7 (±5.2) p =0.990a
Waist circumference (cm) 129 (±12.9) 132 (±13.5) p =0.102a
Systolic bloodpressure (mmHg) 138 (±19) 143 (±19) p =0.143a
Diastolic bloodpressure (mmHg) 81 (±10) 82 (±11) p =0.671a
cIMT (mm) 0.540 (0.481 - 0.634) 0.576 (0.531 - 0.726) p =0.016d
PWV (m/s) 6.8 (5.9 - 8.0) 7.6 (6.9 - 8.4) p =0.005d
HbA1c (mmol/mol) 38 (±4) 61 (±17) p <0.001a
Triglycerides (mmol/l) 1.70 (1.13 - 2.44) 1.96 (1.26 - 2.93) p =0.073d
LDL-cholesterol (mmol/l) 3.3  (±0.9) 2.5 (±0.9) p <0.001a
HDL-cholesterol (mmol/l) 1.2 (±0.3) 1.2 (±0.3) p =0.699a
Apo B (g/l) 1.16 (±0.30) 1.00 (±0.25) p =0.002a
Lipoprotein a (mg/l) 196 (80 - 568) 126 (43 - 361) p =0.201d
CRP (mg/l) 5 (3 - 10) 6 (3 - 12) p =0.577d
Leukocytes (10^9/l) 8.5 (±2.3) 9.3 (±3.0) p =0.082a




d Independent samples Mann-Whitney U test
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Non-diabetes Diabetes p -value
Number 157 43
Age (years) 39.8 (±12.1) 47.4 (±8.3) p <0.001a
Female gender 123 (78.3%) 25 (58.1%) p =0.007b
Medical history (n,%)
    Hypertension 77 (49.0%) 31 (72.1%) p =0.007b
    Hypercholesterolemia 124 (79.0%) 34 (79.1%) p =0.990b
    Stroke 3 (1.9%) 2 (4.7%) p =0.293c
    Myocardial infarction 2 (1.3%) 4 (9.3%) p =0.020c
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    Lipid lowering agents 10 (6.4%) 21 (48.8%) p <0.001b
    Antihypertensive agents 38 (24.2%) 27 (62.8%) p <0.001b
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Using univariate analysis, T2DM was associated with increased PWV (crude 
beta: 0.685, adjusted R2: 0.039, p = 0.007). Furthermore, HbA1c levels were also 
associated with an increased PWV (crude beta: 0.023, adjusted R2: 0.043, p = 0.005). 
In the multivariable analysis, stratified for gender and after adjustment for age, 
waist circumference and MAP, T2DM was not associated with increased PWV. 
HbA1c tended to show a small contribution to PWV in men only (Table 2).
Parameter PWV in male PWV in female
adj. B coefficient (95% CI) p -value adj. B coefficient (95% CI) p -value
Constant 0.714 (-0.567; 1.996) p  = 0.265 -1.086 (-2.628; 0.457) p  = 0.166
HbA1c 0.007 (0.000; 0.014) p  = 0.060 --- ---
Age 0.082 (0.070; 0.095) p  < 0.001 0.085 (0.075; 0.096) p  < 0.001
Waist circumference --- --- 0.016 (0.007; 0.025) p  = 0.001
Mean Arterial Pressure 0.026 (0.014; 0.038) p  < 0.001 0.027 (0.016; 0.037) p  < 0.001
Table 2
Impact of HbA1c levels on pulse wave velocity (PWV). The impact of HbA1c level on PWV was evaluated with 
multiple linear regression analysis (backward stepwise analysis).
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Discussion
Vascular disease as measured by cIMT and PWV is significantly worse  
in morbidly obese subjects suffering from T2DM, in comparison to their  
non-diabetic counterparts. This is in line with previously described differences 
in non-obese subjects.4,8 Our data suggest that the presence of T2DM is not 
a significant contributor to the levels of cIMT and PWV within the morbidly 
obese subjects after adjustment for age, blood pressure and lipid profile.  
PWV was mainly determined by differences in gender, age, waist 
circumference and blood pressure.
cIMT and PWV values are increased in both T2DM8 and obesity.4,9,12 
However, the impact of having T2DM in a morbidly obese population on subclinical 
atherosclerosis has not been described before. Our study suggests that, patients 
with T2DM and morbid obesity have a significantly impaired vascular function, 
compared to their non-diabetic obese counterparts. However, it should be noted 
that other cardiovascular risk factors, linked to T2DM, may have a greater impact 
on vascular function, than T2DM itself. The consequence of our study is that in 
subjects with morbid obesity and T2DM one should consider more strict targets  
of conventional cardiovascular risk factors.
In general, it is well known that cIMT is mainly influenced by age and gender 
in which men and elderly people have an increased cIMT when compared to women 
and young subjects.19-23 In terms of classic cardiovascular risk factors, blood pressure 
is the main contributor to increased cIMT. Blood pressure influences cIMT in for 
example young healthy subjects,20,23,24 in lean subjects suffering from T2DM25 and 
in elderly patients with cardiovascular risk factors.21 Additionally, a decrease in 
blood pressure, for example by administering antihypertensive drugs, can provide 
a decrease in measured cIMT.26 The second important cardiovascular risk factor 
to influence cIMT is dyslipidemia20-22 and intensive lipid-lowering therapy can also 
positively influence cIMT,26-28 although this effect was not observed in diabetic 
subjects.29 The results in these non-obese study populations are in agreement 
with the results in our study. Smoking habit is also thought to influence cIMT in 
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different populations,20-23 but this association was not observed in our morbidly 
obese subjects.
The determinants of arterial stiffness, measured as the PWV, have been less 
well studied compared to cIMT. In healthy middle-aged and elderly subjects, not 
suffering from T2DM or CVD, PWV is mainly determined by age, blood pressure 
and waist circumference,30 which is in accordance with the results in our morbidly 
obese population. Fasting glucose levels are thought to have a modest impact on 
PWV and only when diabetic and cardiovascular patients are included in the study 
group.30 Additionally, both HbA1c25 and TG24 levels are thought to play a role in 
the development of arterial stiffness, although that effect is only seen in selected 
subjects and cannot be confirmed in all studies or patient groups. Both parameters 
were no major determinant of PWV within our morbidly obese study population.
Obesity is both a major and modifiable risk factor for the development of 
metabolic and CVD.12 Weight loss can be an important pillar in the prevention 
strategy for cardiovascular events. For example, bariatric surgery can significantly 
reduce cardiovascular morbidity and mortality. One study showed that cIMT values 
were significantly decreased 1 year after bariatric surgery.31 An interesting finding 
in the current study is the fact that the degree of obesity, in terms of both BMI 
and waist circumference, did not influence the value of cIMT or PWV. It can be 
suggested, that being morbidly obese indeed increases the values of PWV and cIMT, 
but that the level of obesity does not really matter once a certain BMI threshold 
is surpassed (ceiling effect). A certain ceiling effect was previously described for 
markers of dyslipidemia32,33 and may be true for other cardiovascular risk factors 
or vascular outcome measures, such as cIMT and PWV. Consequently, once 
morbid obesity is a fact, further increment of body weight may not cause further 
deterioration of subclinical atherosclerosis.
When analyzing the impact of diabetes on cIMT or vascular function, 
differences in cardiovascular risk management between diabetics and non-diabetics 
can affect the results. For example, one important pillar of the treatment for type 
2 diabetes is the reduction of diabetic dyslipidemia with prescription of statins. 
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Within our morbidly obese population, diabetic patients were more likely to use 
statins and therefore their mean LDL-C level was significantly lower than in the 
non-diabetic group. The differences in cIMT and PWV between diabetics and  
non-diabetics may be limited due to the extensive use of statins in diabetics.  
However, a previous study showed that statin use does not influence cIMT in 
diabetic patients without previous CVD29 and only aggressive treatment goals,  
such as LDL-C ≤ 70 mg/dl, can influence the progression of cIMT.34 Another 
important target in the treatment of diabetic patients is the prevention of  
micro- and macrovascular complications by administration of antihypertensive 
drugs. Within our cohort, the diabetic patients were more likely to be diagnosed 
with hypertension and to be treated with antihypertensive drugs. Diabetic patients 
with hypertension are known to have increased cIMT values and increased cIMT 
progression over time.35,36 Even though the actual value of systolic and diastolic 
blood pressure was not significantly different between the diabetic and non-diabetic 
subject in our cohort, it was previously shown that treatment with antihypertensive 
drugs had a positive influence on cIMT and progression of cIMT, independent of  
the level of blood pressure.35 Therefore, the effect of type 2 diabetes on cIMT in  
this study may be limited due to the excessive use of antihypertensive agents  
within this group.
In conclusion, although T2DM negatively affects the vasculature in morbid 
obesity, age and hypertension seem to be the main risk factors independent from 
the presence of T2DM.
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Abstract 
Background
Obesity is associated with type 2 diabetes mellitus (T2DM), and both are considered 
forms of low-grade systemic inflammation. In lean subjects, T2DM is associated 
with increased systemic inflammation and leukocyte activation, which results 
in micro- and macrovascular complications. This study investigates systemic 
inflammation and leukocyte activation in morbidly obese subjects with and  
without T2DM.
Materials and methods
Systemic inflammation, leukocyte activation markers, intima media thickness and 
pulse wave velocity were assessed in morbidly obese subjects scheduled for bariatric 
surgery. Differences between diabetic and non-diabetic subjects were assessed using 
independent T-tests and nonparametric tests. Multiple regression analyses were 
used to adjust for group differences.
Results
The total cohort consisted of 200 subjects (148 women, mean age 41.4 [±11.8] years, 
mean BMI 42.7 [±5.2] kg/m2). 43 subjects (21.5%) suffered from T2DM. Leukocyte 
count was significantly increased in T2DM (p = 0.041); no other markers of 
inflammation differed between diabetics and non-diabetics. After correction for 
group differences, CRP was also associated with T2DM (p = 0.011). cIMT and PWV 
were significantly higher in T2DM (p = 0.033 and p = 0.007, respectively).
Conclusions
Systemic inflammation and leukocyte activation in morbid obesity are not 
increased in subjects suffering from T2DM. The micro- and macrovascular changes 
seen in these patients are likely influenced by other factors, such as traditional 
cardiovascular risk factors. Treatment of this specific patient group should likely 
focus not on the reduction of inflammation but on weight loss and the improvement 
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Introduction
Obesity is a major risk factor for the development of type 2 diabetes 
mellitus (T2DM). The continuing rise of the obesity prevalence results 
in a continuously increasing prevalence of T2DM, with its micro- and 
macrovascular complications causing a major disease burden worldwide.1
Obesity is considered a form of low-grade systemic inflammation,2 and 
such inflammation is thought to be a significant factor in the development of the 
micro- and macrovascular complications seen in T2DM.3 Markers of systemic 
inflammation, such as C-reactive protein (CRP), are associated with insulin 
sensitivity and β-cell dysfunction.1,4 Insulin signaling can be further impaired by 
expansion of adipose tissue, since this is associated with an increased production 
and release of pro-inflammatory cytokines, such as tumor necrosis factor α.4
Different mechanisms are responsible for inflammation through 
hyperglycemia, one of which is the activation of leukocytes.5 Activated leukocytes 
express an increased number of cell surface integrins, such as CD11b and 
CD66b, and can thereby adhere to the intact endothelium and migrate into the 
subendothelial space, which is the first step in the generation of atherosclerosis6 
and microvascular changes, as seen in T2DM.7,8 Previous studies showed increased 
leukocyte activation in non-obese subjects suffering from T2DM.9,10 The current 
study investigates differences in systemic inflammation and leukocyte activation 
between subjects with and without T2DM in a morbidly obese population.
Materials and methods
Study population
This prospective cohort study included 200 patients scheduled for bariatric surgery 
in the Franciscus Gasthuis, Rotterdam, the Netherlands. All subjects met the 
international IFSO criteria for bariatric surgery11 (i.e. patients with BMI ≥ 40 kg/m2,  
or BMI ≥ 35 kg/m2 and obesity-related comorbidity). Subjects with previous 
cholecystectomy, previous bariatric procedure, acute inflammatory disease within 
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6 weeks prior to inclusion or immune-modulating medication were excluded from 
this study. The study was approved by the independent Regional Medical Ethical 
Committee Rotterdam (Maasstad Hospital, Rotterdam, the Netherlands, ABR 
no. NL47891.101.14) and all subjects gave written informed consent. This study is 
registered in the Dutch Trial Register (NTR5172).
Definitions 
T2DM was defined as glycated hemoglobin (HbA1c) level ≥ 48 mmol/mol 
(6.5%)12 and/or previously diagnosed T2DM using glucose-lowering medication. 
Hypertension was defined by systolic blood pressure > 140 mmHg and/or the use  
of antihypertensive medication.13 Hypercholesterolemia was defined as  
LDL-cholesterol > 2.5 mmol/l and/or the use of lipid-lowering drugs.13
Baseline characteristics
Baseline characteristics were obtained during standard preoperative screening by 
the endocrinologist prior to bariatric surgery and included medical history and 
current medication profile. Anthropometric characteristics included height, weight, 
waist circumference and blood pressure. Body mass index (BMI; in kg/m2) was 
calculated using weight and height.
Laboratory measurements
Systemic inflammation was investigated using the laboratory measures CRP, 
leukocyte count and markers of leukocyte activation. The leukocyte activation 
markers of interest were CD11b (ITGAM, leukocyte adhesion and migration 
marker), CD66b (CEACAM8, neutrophil degranulation marker) and CD35  
(CR1, complement receptor type 1).
Freshly drawn blood was used for all clinical and hematological chemistry 
measurements, which were analyzed in the Department of Clinical Chemistry, 
Franciscus Gasthuis. CRP was determined using the DxC analyzer (Beckman 
Coulter), and white blood cell counts were determined automatically using a 
DxH800 analyzer (Beckman Coulter). The degree of leukocyte activation was 
measured by flow cytometry on fresh blood samples collected in EDTA tubes;  
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this method has been previously described in detail.14 In summary, the cell surface 
expression of two pairs of leukocyte activation markers was detected using 
fluorescent labeled monoclonal antibodies (MoAbs, Beckman Coulter). Antibodies 
for CD45 were used to differentiate leukocytes from erythrocytes and platelets.  
Two separate tubes were prepared in triplicate: 1) a combination of 2.5 μL each of 
CD11b, CD66b and CD45 and 2) a combination of 2.5 μL each of CD35 and CD45.  
20 μL of blood from an EDTA-anti-coagulated blood sample was added to all  
tubes. Cells were incubated for 15 minutes in the dark at room temperature.  
After incubation, erythrocytes were lysed by adding 500 μL of lysing solution  
(1.5 M ammonium chloride, 100 mM potassium hydrogen carbonate, 0.82 mM 
EDTA, pH 7.4) for 15 minutes. 
Samples were measured until at least 1,000 monocytes were acquired or 
for a maximum of 5 minutes per sample using a flow cytometer (FC500, Beckman 
Coulter) with a 488 nm Argon ion laser and CXP software. The fluorescence 
intensity of each cell type was expressed as the mean fluorescence intensity, 
given in arbitrary units (au). Before each use, the optics and settings of the flow 
cytometer were checked with Flow-Check and Flow-Set beads (Beckman Coulter).
Carotid intima media thickness
cIMT measurements were performed according to the consensus guidelines 
for carotid ultrasound for CVD risk assessment as described previously.15 The 
measurement was conducted using the ART-LAB (Esaote, Italy) by trained and 
experienced sonographers, who were unaware of patients’ medical histories. 
Ultrasound scans were performed with the patients lying in a supine position, with 
the head resting comfortably and the neck slightly hyperextended and rotated in 
the opposite direction of the probe. The ultrasound images were obtained from 
the distal 1 cm of the far wall of each common carotid artery (CCA) using B-mode 
ultrasound producing two echogenic lines. These lines represent the combined 
thickness of the intimal and medial layers of the arterial wall. Each CCA has been 
imaged in three different projections: CCA right side 90–120–150 and CCA left side 
210–240–270 degrees. The segments were measured semi-automated in triplicate.
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Pulse wave velocity
PWV measurements were conducted using the Mobil-O-Graph (I.E.M., Germany) 
as previously described.16 The Mobil-O-Graph uses an inflatable cuff to measure the 
PWV. The cuff was placed on the patient’s bare left upper arm. Triplicate manual 
measurements were performed. PWV was calculated by the provided software and 
was expressed in m/s.
Statistical analysis
All analyses were performed using SPSS (PASW) 25.0 software (SPSS Inc., Chicago, 
Illinois, USA). Data are given as mean ± standard deviations. Skewed variables are 
given in median and interquartile range (IQR). Categorical data were described in 
an absolute number as well as a percentage of the total group. Outliers in leukocyte 
activation markers were identified in the dataset and removed when appropriate.
Differences between subjects with and without T2DM were analyzed using 
independent T-tests, chi-squared tests, Fisher’s exact tests and independent 
samples Mann–Whitney U tests. For statistical analysis, cIMT was defined as the 
mean of the six individual measurements, as described above, and PWV was defined 
as the mean of three individual measurements.
Differences in systemic inflammation and leukocyte activation between 
subjects with and without T2DM were analyzed using a multiple regression analysis, 
with adjustment for baseline group differences, and were reported as β-coefficients 
and their p-values with a significance threshold of p = 0.05 (two-sided).
Results
The total cohort consisted of 200 morbidly obese subjects, of whom 43 (21.5%) 
suffered from T2DM. The group consisted of 148 women and 52 men, with a mean 
age of 41.4 (±11.8) years and a mean BMI of 42.7 (±5.2) kg/m2. Subjects with T2DM 
were older, suffered more frequently from hypertension and were more likely to 
use lipid-lowering medication. Furthermore, the proportion of men was higher 
in the group suffering from T2DM. Both markers for subclinical atherosclerosis 
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were increased in subjects with T2DM when compared to non-diabetics; the 
median cIMT was 0.576 [IQR 0.531–0.726] mm and 0.540 [IQR 0.481–0.633] mm, 
respectively (p = 0.033), and the median PWV was 7.6 [IQR 6.9–8.4] m/s and  
6.8 [IQR 5.9–8.0] m/s, respectively (p = 0.007; Table 1).
Regarding inflammation in particular, only the leukocyte count was 
significantly increased in T2DM. No significant differences were observed in  
CRP or the different markers for leukocyte activation.
Baseline characteristics
Non-diabetic subjects Diabetic subjects p -value
Number 157 43
Gender (female) 123 (78.3%) 25 (58.1%) p  = 0.007
Age (years) 39.8 (±12.1) 47.4 (±8.3) p  < 0.001
Medical history
    Hypertension 77 (49.0%) 31 (72.1%) p  = 0.007
    Hypercholesterolemia 124 (79.0%) 34 (79.1%) p  = 0.990
    Stroke 3 (1.9%) 2 (4.7%) p  = 0.293
    Myocardial infarction 2 (1.3%) 4 (9.3%) p  = 0.020
Medication use
    Lipid lowering drugs 10 (6.4%) 21 (48.8%) p  < 0.001
    Beta blokking agents 9 (5.7%) 12 (27.9%) p  = 0.117
Smoking habbit p  = 0.861
    No 68 (43.3%) 19 (44.2%)
    Quited smoker 50 (31.8%) 12 (27.9%)
    Yes 39 (24.8%) 12 (27.9%)
BMI (kg/m2) 42.7 (±5.2) 42.7 (±5.2) p  = 0.990
Waist circumference (cm) 129 (±12.9) 132 (±13.5) p  = 0.102
Systolic bloodpressure (mmHg) 138 (±18.5) 143 (±18.6) p  = 0.143
Diastolic bloodpressure (mmHg) 81 (±9.7) 82 (±11.3) p  = 0.671
cIMT (mm) 0.540 (0.481 - 0.633) 0.576 (0.531 - 0.726) p  = 0.033
PWV (m/s) 6.8 (5.9 - 8.0) 7.6 (6.9 - 8.4) p  = 0.007
Laboratory values
    HbA1c 38 (±3.8) 61 (±17.3) p  < 0.001
    CRP (mg/L) 5 (3 - 10) 6 (3 - 12) p  = 0.430
    Leukocyte count (x10^9/L) 8.5 (±2.3) 9.3 (±3.0) p  = 0.041
    CD35 on monocytes (au) 7.22 (±3.02) 6.74 (±2.43) p  = 0.340
    CD35 on granulocytes (au) 10.65 (±5.57) 10.46 (±4.68) p  = 0.831
    CD11b on monocytes (au) 33.82 (±7.99) 32.67 (±8.61) p  = 0.413
    CD11b on granulocytes (au) 46.90  (±15.27) 46.85 (±15.40) p  = 0.985
    CD66b on granulocytes (au) 5.98 (±1.91) 6.06 (±1.66) p  = 0.793
Table 1
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In a multiple regression analysis, both leukocyte count (beta: 1.643, p = 0.001) 
and CRP (beta: 3.496, p = 0.011) appeared to be increased in T2DM, when adjusted 
for age, gender, hypertension and statin use. No significant differences were seen in 
the other markers for leukocyte activation (Table 2). When the model focused on 
HbA1c levels instead of the presence of T2DM, similar results were found (Table 3).
Dependent variable 𝛽𝛽-coefficients p -value
    CRP (mg/L) 3.496 p  = 0.011
    Leukocyte count (x10^9/L) 1.643 p  = 0.001
    CD35 on monocytes (au) -0.306 p  = 0.596
    CD35 on granulocytes (au) 0.274 p  = 0.797
    CD11b on monocytes (au) -1.257 p  = 0.441
    CD11b on granulocytes (au) -0.913 p  = 0.759
    CD66b on granulocytes (au) -0.268 p  = 0.462
Table 2
* adjusted for age, gender, history of hypertension and statin-use
The effect of type 2 diabetes mellitus on inflammatory markers after adjustment for 
group differences*
Dependent variable 𝛽𝛽-coefficients p -value
    CRP (mg/L) 0.139 p  = 0.001
    Leukocyte count (x10^9/L) 0.036 p  = 0.013
    CD35 on monocytes (au) 0.010 p  = 0.570
    CD35 on granulocytes (au) 0.019 p  = 0.555
    CD11b on monocytes (au) -0.048 p  = 0.320
    CD11b on granulocytes (au) -0.131 p  = 0.139
    CD66b on granulocytes (au) -0.012 p  = 0.262
Table 3
* adjusted for age, gender, history of hypertension and statin-use




Type 2 diabetes mellitus and systemic inflammation
Discussion
Although previous studies suggest increased leukocyte activation and 
systemic inflammation in non-obese diabetic patients when compared to 
non-diabetics, within our cohort of morbidly obese subjects, no differences 
were observed in leukocyte activation between diabetics and non-diabetics. 
Diabetics in our cohort did demonstrate higher CRP and leukocyte levels, 
which suggests a higher degree of systemic inflammation.
The leukocyte activation markers CD11b and CD66b reflect the early 
adhesion of leukocytes to the endothelium,9 which is essential for the development 
of atherosclerosis and microvascular diabetic complications.3 Since both obesity 
and T2DM are considered low-grade inflammatory diseases that affect micro- and 
macrovascular health, it was expected that the combination of obesity and T2DM 
would have an exaggerated effect on vascular health. Previous studies showed 
increased mortality rates in subjects with T2DM when BMI was increased, and 
within the different BMI groups, subjects with T2DM had higher mortality rates 
than non-diabetic subjects.17-18 In the present study, cIMT and PWV were used as 
surrogate markers for atherosclerosis. In non-obese subjects, both cIMT and PWV 
are known to be increased in T2DM,19-21 which is confirmed here in obese subjects. 
Inflammation is thought to significantly contribute to these changes. In our study, 
both CRP and leukocyte counts were associated with the presence of diabetes but 
not with vascular changes. Therefore, the differences in cIMT and PWV between 
morbidly obese diabetics and non-diabetics cannot be explained by differences in 
systemic inflammation and leukocyte activation.
It should be noted that the current study only investigates a small portion 
of all known inflammatory markers, with special interest in leukocyte activation. 
However, multiple mechanisms have been suggested to influence this low-grade 
systemic inflammation, such as the increased production of pro-inflammatory 
cytokines by adipose tissue2 and the increased formation of reactive oxygen species 
and oxidative stress.3 Dalmas et al.2 investigated multiple and different markers 
of inflammation, such as hsCRP, interleukin 6, ICAM-1 and VCAM-1, in a group of 
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morbidly obese subjects. They did not differentiate between diabetic and  
non-diabetic subjects, but they did report a lack of correlation between 
inflammatory markers and cIMT in these obese subjects. cIMT was determined 
by changes in classic cardiovascular risk factors, such as hypertension and 
dyslipidemia. Values of cIMT and PWV are known to be determined primarily  
by age, gender, blood pressure and lipid profile.22-25 The differences in cIMT and 
PWV found here could be explained by differences in these variables. Another 
limitation of our study is the lack of a lean control group to verify whether or  
not the markers of inflammation, as measured in the current study, are indeed 
increased in subjects suffering from morbid obesity.
Recent studies focus on the development of new therapeutics for T2DM and 
cardiovascular disease with special interest in lowering systemic inflammation.26-27 
In light of the results of the current study, these new therapeutics may not be the 
most appropriate therapy for T2DM in morbid obesity.
In conclusion, systemic inflammation and leukocyte activation in morbid 
obesity are not increased in subjects suffering from T2DM. The micro- and 
macrovascular changes seen in these patients are probably influenced by other 
factors, such as classic cardiovascular risk factors. Treatment of this specific patient 
group should likely focus not on the reduction of inflammation but on weight loss 
and the improvement of classic cardiovascular risk factors.
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Bariatric surgery in adolescents
Abstract 
Background
Interest in bariatric surgery in adolescents is increasing, since adolescent obesity 
equals increased health risks in adult life. To define the preferred procedure for a 
randomized controlled trial in adolescents, this study compares outcomes of LSG 
and LRYGB in late adolescence in our center.
Materials and methods
Data on baseline characteristics, operative details and follow-up were collected 
retrospectively in all patients (age 18–20 years) who underwent LSG or LRYGB in 
our clinic. Outcomes were analyzed using nonparametric tests.
Results
65 adolescents (54 female; median age 19 years) were included; 45 subjects 
underwent LSG; 20 patients underwent LRYGB.
Significant differences in percentage of excess weight loss (%EWL) were observed 
at 2-year follow-up; 69.4% in LRYGB (n = 6) versus 96.8% in LSG (n = 23), p = 0.01. 
No differences were observed in postoperative mortality, complication rate or 
resolution of comorbidities between both procedures.
Conclusions
LSG showed significantly better results than LRYGB in terms of %EWL after 2 
years in this selected group of older adolescents. Considering these results in LSG 
patients and the theoretical advantages of LSG (normal diet options, preservation 
of an intact GI-tract, less vitamin disturbances and better quality of life), LSG may 




Bariatric surgery in adolescents
Introduction
Bariatric surgery is the only effective intervention to achieve substantial 
long-term weight loss and improvement of comorbidities1,2 in adults. With the 
increasing prevalence of childhood and adolescent obesity3–5 and their related 
health risks both at current age6–8 as well as later in life,4,9 early treatment is 
of major importance and morbidly obese adolescents are increasingly being 
considered for bariatric surgery. However, there is controversy regarding the 
ethics of bariatric surgery in adolescents, with questions on long-term safety 
and effectiveness of bariatric surgery in adolescents remaining unanswered.
The laparoscopic Roux-en-Y gastric bypass (LRYGB) is considered the gold 
standard procedure in adults, although the laparoscopic sleeve gastrectomy (LSG) 
has gained widespread popularity due to its good results in terms of weight loss, 
resolution of comorbidities,4,10 quality of life1 and a low complication rate.4,11 LSG 
may be a safe alternative for LRYGB in adolescents, since the procedure keeps the 
gastrointestinal tract intact, resulting in no dumping, less malnutrition5 and fewer 
vitamin disturbances.12 Additionally, LSG allows secondary bariatric options in case 
of failure more easily than LRYGB. Early treatment of morbid obesity is thought to 
prevent many health risks, but what is the best surgical option for adolescents with 
morbid obesity?
In the Netherlands, legislation only allows surgeons to perform bariatric 
surgery in adolescents under the age of 18 years in study models. Our institute 
considers bariatric surgery for morbidly obese adolescents aged 15–18 years, 
comparing the effects of lifestyle intervention with bariatric surgery. The aim 
of the current study was to analyze the results of both LSG and LRYGB in older 
adolescents (18–20 years), and to extrapolate these results to the group 15–18 years 
old in order to determine the preferred bariatric technique in this specific patient 
group.
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Materials and methods
Study population
This retrospective cohort study included all consecutive patients (aged 18–20 
years) who underwent LSG or LRYGB in the bariatric clinic of the Sint Franciscus 
Gasthuis in Rotterdam, the Netherlands, between October 2006 and June 2014.  
In general, inclusion criteria for bariatric surgery are body mass index  
(BMI) ≥ 40 kg/m2, or BMI ≥ 35 kg/m2 with obesity-associated comorbidities, 
according to the multidisciplinary protocol.13
Surgical technique
Both LSG and LRYGB are performed with a five-trocar approach. LSG is, as 
previously described,11 calibrated over a 34-Fr bougie, starting 2–4 cm proximal to 
the pylorus. LRYGB is created with a small pouch (15 cc), which is anastomized  
over 3 cm with a linear stapler to a 150 cm alimentary limb followed by an  
entero-enterostomy created with a 60 cm biliopancreatic limb, and clip or  
suture closure14 of both mesenterial defects.
Allocation to a certain type of bariatric procedure occurred according to both 
patient’s and doctor’s preferences; extreme sweet eaters and patients suffering from 
gastro-esophageal reflux disease (GERD) were allocated to the LRYGB, since better 
results in terms of weight loss and postoperative complaints were expected in these 
patients.
Baseline characteristics
Baseline characteristics were collected at set time intervals according to our 
standard protocol: at the outpatient’s preoperative screening, postoperative period 
(clinical phase), and follow-up at 3–6 months postoperatively and then annually. 
Weight (in kg) and BMI (in kg/m2) were the main measurements for anthropometry. 
Additionally, weight loss was described as the percentage of excess weight loss 
(%EWL), using the following formula:  
%EWL = (preoperative BMI – current BMI) / (preoperative BMI – 25) x 100%. 
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Data on present comorbidity and medication use were collected during all visits to 
the outpatient clinic during follow-up.
Statistical analysis
All analyses were performed using SPSS (PASW) 18.0 software (SPSS Inc., Chicago, 
Illinois, USA). The results of LSG were compared to the results of LRYGB. 
Baseline characteristics sex, smoking habit, alcohol use and ASA classification, as 
well as medical history, were described as a percentage of the total cohort. Other 
baseline characteristics were presented as median value. Differences between both 
procedures, LSG and LRYGB, were analyzed using nonparametric tests. Results 
were evaluated at a significance threshold of p < 0.05.
Results
The patient cohort consisted of 65 adolescents, of whom 45 underwent LSG and 
20 LRYGB. In 10.3% of these patients, allocation to a certain procedure was based 
on patient characteristics, such as super obesity, GERD and extreme sweet eating 
behavior; in the rest of the patients, the type of procedure performed was based 
on the patient’s preference. There were 11 men and 54 women, with a median age 
of 19 years [interquartile range (IQR) 19–20] and median BMI 44.8 kg/m2 [IQR 
41.8–49.4]). There was no difference in preoperative BMI in both groups (Table 1). 
Significant differences were observed in sex, with 100% female in LRYGB and 75.6% 
female in LSG (p = 0.014), and in surgical operation time: median surgical operation 
time was 71 minutes [IQR 51–86] in LRYGB and 47 minutes [IQR 37–57] in LSG  
(p < 0.001). Additional baseline characteristics are displayed in Table 1.
Reintervention, due to complications, was necessary in two patients: one in 
each group. The patient with LSG developed anastomotic leakage and was treated 
with laparoscopic drainage, stenting and eventually a reoperation in which a 
revision to LRYGB was performed. The patient with LRYGB developed a subphrenic 
hematoma, which required coiling of the splenic artery and laparoscopic drainage 
of an infected hematoma. None of the patients in this cohort died during the early 
postoperative phase or follow-up. 
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In the overall adolescent study group, five patients (including three LRYGB 
patients) did not attend any follow-up visit. Median follow-up was 22 months  
[IQR 8–47] in the remaining 43 LSG patients and 18 months [IQR 11.5–28.5] 
in LRYGB patients. There was no significant difference between the length of 
follow-up between both groups (p = 0.506). Additional information on follow-up 
attendance is displayed in Table 2.
Table 1
Total (n=65) LSG (n=45) LRYGB (n=20) p -value*
Sex (%)
   female 54 (83.1%) 34 (75.6%) 20 (100%) p  = 0.014
Age
   (years) 19 (19-20) 19 (19-20) 19 (18.3-20) p  = 0.187
BMI
   (kg/m2) 44.8 (41.8-49.4) 44.8 (40.8-48.8) 45.0 (42.8-49.7) p  = 0.363
Waist circumference
   (cm)
136 (123-144) 134 (117-144) 137 (127-144) p  = 0.339
Medical history
    Type 2 diabetes 3 (4.6%) 2 (4.4%) 1 (5.0%) p  = 1.000
    Hypertension 2 (3.1%) 2 (4.4%) 0 (0%) p  = 1.000
    Dyslipidemia 3 (4.6%) 2 (4.4%) 1 (5.0%) p  = 1.000
    GERD 6 (9.2%) 3 (6.7%) 3 (15.0%) p  = 0.361
Smoking p  = 0.135
    Yes 25 (38.5%) 17 (37.8%) 8 (40.0%)
    No 36 (55.4%) 26 (57.8%) 10 (50.0%)
Alcohol p  = 0.255
    Occasionally 24 (36.9%) 15 (33.3%) 11 (55.0%)
    No 36 (55.4%) 25 (55.6%) 9 (45.0%)
ASA classification p  = 0.420
    ASA1 1 (1.5%) 1 (2.2%) 0 (0%)
    ASA2 30 (46.2%) 23 (51.1%) 7 (35.0%)
    ASA3 33 (50.8%) 20 (44.4%) 13 (65.0%)
    ASA4 1 (1.5%) 1 (2.2%) 0 (0%)
* group differences were tested using nonparametric tests
Baseline characteristics in absolute numbers or median value, with its percentage or 
interquartile range, respectively, presented within brackets
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The parameter %EWL showed a significant difference between both groups  
after 2 years of follow-up. Median %EWL was 81.0% [IQR 36.3–85.0] in the LRYGB 
group (n = 11) and 96.8% [IQR 85.2–111.2] in the LSG patients (n = 23), p = 0.007. 
Furthermore, a significant difference in BMI was observed after 2 years of follow-up, 
with a BMI of 29.7 kg/m2 [IQR 27.0–33.6] after LRYGB and 25.7 kg/m2 [IQR 23.3–27.9] 
after LSG (p = 0.012). Additional follow-up results are displayed in Figure 1 and Table 3.
Fourteen patients presented preoperatively with obesity-related comorbidities, 
such as hypertension, type 2 diabetes and dyslipidemia; none of them had more than 








Follow up 1 yr 45 (69.2%) 30 (66.7%) 15 (75.0%)
Follow up 2 yrs 34 (52.3%) 23 (51.1%) 11 (55.0%)
Follow up 3 yrs 18 (27.7%) 11 (24.4%) 7 (35.0%)
Number of subjects attending follow up in absolute numbers with its percentage 
presented within brackets
Figure 1
Comparison of percentage excess weight loss in 18- to 20-year-old late adolescents after laparoscopic 
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Approximately 86% of all subjects did not report any postoperative 
complaints. The most commonly reported complaints were fatigue (n = 4) and 
reflux (n = 4). Of all subjects reporting reflux postoperatively, one LRYGB patient 
already experienced reflux preoperatively. The other three patients underwent LSG 
and developed reflux afterwards.
Failure of bariatric surgery, defined as %EWL < 50% or BMI > 35 kg/m2, 
occurred in one patient in each group; the LRYGB patient underwent distalization 
of the bypass 35 months after the primary procedure, the LSG patient underwent 
revision into a LRYGB 36 months after the first procedure.
Table 3
Total (n=65) LSG (n=45) LRYGB (n=20) p -value*
Duration of surgery 
   (min) 51 (40-67) 47 (37-57) 71 (51-86) p  < 0.001
Hospital stay 
   (days) 3 (2-4) 3 (2-4) 2 (2-3) p  = 0.013
BMI (kg/m2)
    Baseline 44.8 (41.8-49.4) 44.8 (40.8-48.8) 45.0 (42.8-49.7) p  = 0.363
    1 yr follow-up 28.7 (26.8-31.4) 28.3 (25.2-30.8) 29.7 (27.1-35.1) p  = 0.125
    2 yr follow-up 26.9 (24.1-30.8) 25.7 (23.3-27.9) 29.7 (27.0-33.6) p  = 0.012
    3 yr follow-up 30.6 (27.5-37.7) 29.4 (24.7-35.9) 33.2 (28.0-45.6) p  = 0.247
EWL (%)
    1 yr follow-up 81.6 (70.2-90.9) 84.4 (71.6-99.4) 80.9 (55.9-88.2) p  = 0.165
    2 yr follow-up 89.8 (75.7-105.7) 96.8 (85.2-111.2) 81.0 (51.5-88.1) p  = 0.007
    3 yr follow-up 75.1 (52.2-90.0) 78.7 (64.6-103.2) 57.4 (36.3-85.0) p  = 0.165
Complications
    Early re-admission 8 (12.3%) 5 (11.1%)  3 (15.0%) p  = 0.693
    Early re-intervention 2 (3.1%) 1 (2.2%) 1 (5.0%) p  = 1.000
    Late re-admission 11 (16.9%) 8 (17.8%) 3 (15.0%) p  = 1.000
    Late re-interventions 9 (13.8%) 7 (15.6%) 2 (10.0%) p  = 0.491
        Revisional procedure 3 (4.6%) 2 (4.4%) 1 (5.0%) p  = 1.000
        Cholecystectomy 7 (10.8%) 5 (11.1%) 2 (10.0%) p  = 0.693
* group differences were tested using nonparametric tests
Follow-up in absolute numbers or median value, with its percentage or interquartile range, 
respectively, presented within brackets
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Discussion 
Bariatric surgery in adolescents is thought to be the cornerstone of obesity 
treatment,1,2,15 but data on adolescents bariatric surgery is scarce.16 This 
study investigated the results of the gold standard LRYGB,1,9,10 which is most 
commonly described in adolescents, with the relatively newer LSG.17 Only 
few studies evaluated the effects of LSG in adolescents, but these results 
are promising, not only in terms of weight loss, safety and comorbidity 
resolution,18 but also in terms of self-esteem improvement.19 However,  
most studies describing LSG in adolescents have small study samples,19,20  
short follow-up,10,19–22 or did not compare results of LSG with results  
of the gold standard LRYGB.10,19,20 An overview of all studies is given in  
Table 4. Furthermore, a recent review and meta-analysis on different  
bariatric procedures in adolescents,3 showed good results for LSG in  
terms of weight loss, complication rate and resolution of comorbidities.
In this patient cohort, LSG showed significant better results than LRYGB 
in terms of %EWL 2 years after the procedure; weight loss is approximating 100% 
%EWL 2 years after LSG. Unfortunately, long-term results in the LRYGB group 
are lacking in this study, due to small numbers and a short follow-up. However, 
our results on %EWL and BMI changes in LRYGB are comparable with other 
studies 23 (Table 4).The results of LSG in terms of %EWL appear to be better in 
this cohort than most of the other studies and are similar to the results of Raziel 
et al.19 However, conclusions on superiority cannot be drawn on results in %EWL 
alone, since this is influenced by the preoperative weight and the definition of ideal 
weight.24 Concerning the studies with lower %EWL, in our hospital relatively small 
gastric bypass pouches and narrow gastric sleeves are created. Although data on 
exact pouch and sleeve volume are not available, it can be hypothesized that there 
is reluctance to create a small pouch or sleeve in this young population, in order to 
prevent complications,25 such as leakage, stenosis and deficiencies. As a result, the 
procedure may become less successful in terms of weight loss.
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The number of comorbidities at baseline was very small, and therefore no 
statement can be made on the difference between LSG and LRYGB in terms of 
resolution of comorbidities. However, other studies have described good results 
of LSG on comorbidity resolution in adolescents,19 as well as in LRYGB.26 It is 
generally accepted that weight loss in itself can provide metabolic improvements 
and various theories are suggested to cause these changes.27,28
Our study results complement other studies on the conclusion that LSG is 
a safe procedure with a similar10,20,23 or even reduced9 complication rate compared 
to LRYGB. Additional advantages of LSG, compared to LRYGB, may be the easier 
application of single port techniques, with cosmetically better results and possible 
positive effects on feelings of shame towards peers, as well as the opportunity to 











BMI %EWL No. of subject BMI
Al-Sabah[32], 2015 135 135 none 19 (12-21)‡ 48.5 32.0 75.2% 54 (40%) 30.8
Aldaqal [22], 2013 64 32 healthy subjects 15.2 (13-17) 49.6 29.3 78.8% 32 (100%) ---
Alqahtani [4], 2012 108 108 none 13.9 (5-21) 49.6 32.4 61.3% 41 (38.0%) 31.8
Boza [33], 2012 51 51 none <19 38.5 25.2 96.2% 40 (78.4%) 26.3
Cozacov [34], 2014 18 LRYGB
    LRYGB 8 18.1 48.5 28.9 87.9% †* 6 (75%) ---
    LSG 10 17.1 46.2 32.5 64.9% †* 9 (90%) ---
Lennerz [23], 2014 365
    LRYGB 116 19.6 (16-21) 49.7 33.3 69.8% * 50 (43.1%) ---
    LSG 78 18.5 (8-21) 50.8 35.4 61.8% * 37 (47.4%) ---
Nadler [20], 2012 23 23 none 17.3 (14-19) 52.0 39.0 40% 9 (39.1%) ---
Nocca [35], 2014 61 61 none 19.5 (18-20) 46.7 unknown 66.7% 50 (81.9%) unknown
Raziel [19], 2014 32 32 none 16.7 (14-18) 43.2 unknown 81.7% 15 (46.8%) unknown
van Mil, 2014 65 LRYGB
    LRYGB 20 19 (18-20) 45.0 29.7 80.9% 14 (70.0%) 29.7
    LSG 45 19 (18-20) 44.8 28.3 84.5% 30 (66.7%) 25.7
‡ median and range
† no data available on 1 year follow-up. Data shown for median follow-up of 4 years
* calculated using the 85th percentile on the CDC growth charts
LSG; laparoscopic sleeve gastrectomy. LRYGB; laparoscopic Roux en Y gastric bypass. LAGB; laparoscopic adjustable gastric banding. 
GB; gastric balloon. GP; gastric pacemaker. BPD; biliopancreatic diversion.
LRYGB, LAGB, 
GB, GP and 
BPD
Table 4
BMI and excess weight loss changes in adolescents LSG in different studies
Baseline characteristics 1 year follow-up 2 year follow-up
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Within this cohort, only a small fraction of subjects reported postoperative 
complaints, such as fatigue and reflux. Gastro-esophageal reflux de novo only 
occurred in subjects who underwent LSG (n = 3). However, due to small numbers, 
especially in the LRYGB group, no significant differences between both groups were 
found. Current literature29 expresses concerns on the development or aggravation 
of reflux, although data in different studies are contradictory. Concerning both 
reflux as well as other postoperative complaints, data may be missing in this cohort, 
since this is a retrospective cohort study. Ideally, data on subjective outcomes 
should be objectified by the use of standardized questionnaires, such as the GerdQ 
for gastro-esophageal reflux, in order to make statements on the extend of the 
complaints. 
In general, nutritional complications, dumping and chronic diarrhea are 
commonly described after LRYGB, but not after LSG. However, micronutrient 











BMI %EWL No. of subject BMI
Al-Sabah[32], 2015 135 135 none 19 (12-21)‡ 48.5 32.0 75.2% 54 (40%) 30.8
Aldaqal [22], 2013 64 32 healthy subjects 15.2 (13-17) 49.6 29.3 78.8% 32 (100%) ---
Alqahtani [4], 2012 108 108 none 13.9 (5-21) 49.6 32.4 61.3% 41 (38.0%) 31.8
Boza [33], 2012 51 51 none <19 38.5 25.2 96.2% 40 (78.4%) 26.3
Cozacov [34], 2014 18 LRYGB
    LRYGB 8 18.1 48.5 28.9 87.9% †* 6 (75%) ---
    LSG 10 17.1 46.2 32.5 64.9% †* 9 (90%) ---
Lennerz [23], 2014 365
    LRYGB 116 19.6 (16-21) 49.7 33.3 69.8% * 50 (43.1%) ---
    LSG 78 18.5 (8-21) 50.8 35.4 61.8% * 37 (47.4%) ---
Nadler [20], 2012 23 23 none 17.3 (14-19) 52.0 39.0 40% 9 (39.1%) ---
Nocca [35], 2014 61 61 none 19.5 (18-20) 46.7 unknown 66.7% 50 (81.9%) unknown
Raziel [19], 2014 32 32 none 16.7 (14-18) 43.2 unknown 81.7% 15 (46.8%) unknown
van Mil, 2014 65 LRYGB
    LRYGB 20 19 (18-20) 45.0 29.7 80.9% 14 (70.0%) 29.7
    LSG 45 19 (18-20) 44.8 28.3 84.5% 30 (66.7%) 25.7
‡ median and range
† no data available on 1 year follow-up. Data shown for median follow-up of 4 years
* calculated using the 85th percentile on the CDC growth charts
LSG; laparoscopic sleeve gastrectomy. LRYGB; laparoscopic Roux en Y gastric bypass. LAGB; laparoscopic adjustable gastric banding. 
GB; gastric balloon. GP; gastric pacemaker. BPD; biliopancreatic diversion.
LRYGB, LAGB, 
GB, GP and 
BPD
Table 4
BMI and excess weight loss changes in adolescents LSG in different studies









No. of subjects at 
maximum follow-up
78.6% 46 (34.1%) --- --- --- 24+ 46 (34.1%)
--- --- --- --- --- 12 32 (100%)
62.3% 8 (7.4%) --- --- --- 24 8 (7.4%)
92.9% 34 (66.7%) --- --- --- 24 34 (66.7%)
--- --- --- --- --- 60 2 (25%)
--- --- --- --- --- 60 1 (10%)
--- --- --- --- --- 30 10 (8.6%)
--- --- --- --- --- 30 8 (10.3%)
--- --- --- --- --- 12 9 (39.1%)
78.4% 32 (52.4%) --- --- --- 48 unknown
71.0% 8 (25.0%) unknown 75.9% 4 (12.5%) 60 2 (6.3%)
81.0% 11 (55.0%) 33.2 57.4% 7 (35.0%) 45 2 (13.3%)
96.8% 23 (51.1%) 29.4 78.7% 11 (24.4%) 72 1 (2.5%)
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P eop rative 
BMI
BMI %EWL No. of subject BMI
Al-Sabah[32], 2015 135 135 none 19 (12-21)‡ 48.5 32.0 75.2% 54 (40%) 30.8
A daqal [22], 2013 64 32 healthy subjects 15.2 (13-17) 49.6 29.3 78.8% 32 (100%) ---
Alqahtani [4], 2012 108 108 none 13.9 (5-21) 49.6 32.4 61.3% 41 (38.0%) 31.8
Boza [33], 2012 51 51 none <19 38.5 25.2 96.2% 40 (78.4%) 26.3
Cozacov [34], 2014 18 LRYGB
    LRYGB 8 18.1 48.5 28.9 87.9% †* 6 (75%) ---
    LSG 10 17.1 46.2 32.5 64.9% †* 9 (90%) ---
Lennerz [23], 2014 365
    LRYGB 116 9.6 (16-21) 49.7 33.3 69.8% * 50 (43.1%) ---
    LSG 78 18.5 (8-21) 50.8 35.4 61.8% * 37 (47.4%) ---
Nadler [20], 201 23 23 none 17.3 (14-19) 52.0 39.0 40% 9 (39.1%) ---
Nocca [35], 2014 61 61 none 9.5 (18-20) 46.7 unknown 66.7% 50 (81.9%) unknown
Raziel [19], 2014 32 32 none 6.7 (14-18) 43.2 unknown 81.7% 15 (46.8%) unknown
van Mil, 2014 65 LRYGB
    LRYGB 20 19 (18-20) 45.0 29.7 80.9% 14 (70.0%) 29.7
    LSG 45 19 (18-20) 44.8 28.3 84.5% 30 (66.7%) 25.7
‡ median and range
† no d t  available on 1 year follow-up. Data shown for median follow-up of 4 years
* calculated using e 85th perce tile on the CDC growth charts
LSG; laparoscopic sleeve gastrectomy. LRYGB; laparosc pic Roux en Y gastric bypass. LAGB; laparoscopic djust ble gastric banding. 
GB; gastric balloon. GP; gastric pacemaker. BPD; biliop n reatic diversion.
LRYGB, LAGB, 
GB, GP and 
BPD
Baseline haracteristics 1 year follow-up
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after LRYGB. These results emphasize the need for long-term follow-up results 
after bariatric surgery and it may be even more important in adolescents than 
adults, since they are dependent on micronutrients for their development and 
growth.
Unfortunately, follow-up in adolescent bariatric patients is poor. In general, 
Stefater et al.30 expressed their concerns in the follow-up of adolescents. In our 
clinic, patients are expected to attend follow-up at 6 months, 1 year and annually 
thereafter. In our cohort, 12.7% of all adolescents never attended any face-to-face 
follow-up after the procedure, compared to 3.6% of all other bariatric patients, aged 
≥ 20 years. An eventual lost-to-follow-up rate of 5.5% in this cohort was reached by 
telephonic consultations. However, data collected by telephone may be less reliable. 
Since bariatric support group attendance can positively influence the long-term 
outcome of bariatric surgery and increase follow-up attendance,31 group counseling 
may be even more effective and important in adolescents.
Obviously, the small sample size and the imbalanced number of subjects 
at baseline are limitations of this study. In the LRYGB group only seven subjects 
attended follow-up three years postoperatively. Furthermore, allocation to a 
specific procedure, based on patient characteristics, can bias the results of this 
study. Approximately 10% of all subjects were allocated to a specific procedure 
based on patient characteristics. Once these subjects were excluded from analyses, 
results of the study did not change. Therefore, it can cautiously be concluded that 
the allocation procedure did not influence the results in these older adolescents. 
Nevertheless, since this study is a non-randomized and retrospective study, this 
selection bias cannot be completely excluded.
In conclusion, bariatric surgery seems to be an effective method for weight 
loss in morbidly obese late adolescents. Considering the weight loss results of 
LSG in our patient cohort as well as in other studies and the additional theoretical 
advantages of LSG (improved quality of life and preservation of an intact 
gastrointestinal tract), LSG may be an appropriate bariatric technique to perform 
in obese adolescents. Unfortunately, since results of LSG in adolescents have only 
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been described in small numbers worldwide, more prospective data are needed on 
long-term effects and safety, resolution of morbidity, improvement in quality of life 
and total costs. When results of LRYGB and LSG in adolescents would be compared 
in a randomized controlled trial and results in terms of weight loss, complications 
and comorbidity resolution would be equal, the theoretical advantages of the LSG 
would make this procedure the procedure of preference in this young age group.
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Abstract 
Background
With the increasing prevalence of morbid obesity and healthcare costs in general, 
interest is shown in safe, efficient and cost-effective bariatric care. This study 
describes an enhanced recovery after bariatric surgery (ERABS) protocol and 
the results of implementing such protocol on procedural times, length of stay 
in hospital (LOS) and the number of complications, such as readmissions and 
reoperations.
Materials and methods
Results of implementing an ERABS protocol were analyzed by comparing a cohort 
treated according to the ERABS protocol (2012–2014) with a cohort treated before 
implementing ERABS (2010–2012). Differences between both cohorts were analyzed 
using independent T-tests and chi-squared tests.
Results
A total of 1,967 patients (mean age 43.3 years, 80% female) underwent a primary 
bariatric procedure between 2010–2014, of which 1,313 procedures were performed 
after implementation of ERABS. A significant decrease of procedural times and 
a significantly decreased LOS, from 3.2 to 2.0 nights (p < 0.001) were seen after 
implementation of ERABS. Significantly more complications were seen post-ERABS 
(16.1% versus 20.7%, p = 0.013), although no significant differences were seen in the 
number of major complications.
Conclusions
Implementation of ERABS can result in shorter procedural times and a decreased 
LOS, which may lead to more efficient and cost-effective bariatric care. The increase 
in complications was possibly due to better registration of complications.
The main goal of an ERABS protocol is efficient, safe and evidence-based bariatric 




Enhanced Recovery After Bariatric Surgery
Introduction
With the rising prevalence of obesity1 and obesity-related diseases,2-3 the 
obesity-related healthcare costs have become a considerable economic 
burden.4 Bariatric surgery is the most effective treatment for morbid 
obesity,5-7 resulting in sustainable weight loss and effective treatment of 
obesity-related diseases.6-8 In search of efficient and cost-effective healthcare, 
enhanced recovery after surgery (ERAS) protocols (or fast-track protocols) 
have been developed for different types of abdominal procedures.9-11 More 
recent interest has been shown in enhanced recovery after bariatric surgery 
(ERABS) protocols, although data in the literature is currently scarce.12-17 The 
combination of the increasing number of bariatric procedures worldwide and 
the specific perioperative difficulties and risks for this particular population13,15 
makes this type of surgery highly eligible for ERAS protocols. Implementation 
of evidenced based interventions and standardization of bariatric care can 
increase efficiency and cost-effectiveness in these procedures,14 without the 
loss of safety.
This study describes the ERABS protocol for both laparoscopic Roux-en-Y 
gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) in a large 
volume teaching hospital in Rotterdam, the Netherlands and the results of 
implementing an ERABS protocol on procedural times, length of stay in hospital 
and number of complication and reoperations.
Materials and methods
The Sint Franciscus Gasthuis in Rotterdam, the Netherlands, has a bariatric clinic, 
which performs mainly LSG and LRYGB procedures and has been a European 
training location for ERABS programs since 2013. The ERABS protocol was 
introduced in this clinic at the beginning of 2012.
Prospectively collected outcome data of all consecutive cases that underwent 
primary LRYGB or LSG from January 2010 to June 2014 in the Sint Franciscus 
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Gasthuis were collected and analyzed. Since the ERABS protocol was introduced in 
2012, all patients treated between January 2010 and December 2011 are considered 
“pre-ERABS”. This pre-ERABS protocol has previously been published by Elte et al.18 
All patients treated from January 2012 until June 2014 are considered “post-ERABS”.
The primary outcome parameter is length of stay in hospital (LOS) and 
secondary outcomes are procedural times, such as surgical time, the number of 
readmissions and reoperations within 30 days and number of complications  
within 30 days. Thirty-day complications were recorded and graded according  
the Clavien–Dindo classification.19,20 
All analyses were performed using SPSS (PASW) 18.0 software (SPSS Inc., 
Chicago, Illinois, USA). Categorical data were described as percentage of the total 
cohort. Continuous variables were presented as mean ± standard deviation (SD). 
Differences between pre-ERABS and post-ERABS in continuous data were analyzed 
using independent T-tests. The differences in categorical data were analyzed using 
the chi-squared test. 95% confidence intervals were calculated of all procedural 
times. All results were evaluated at a significance threshold of p < 0.05.
The Sint Franciscus Gasthuis ERABS protocol
The team
In order to achieve standardization of the treatment process, the ERABS protocol 
has been composed by a multidisciplinary team, that consisted of delegates from  
all involved departments.21 The protocol and possible adjustments to this protocol 
are discussed within this team on a monthly basis. Decisions are made on an 
evidence-based, cost-effective basis and consensus on all aspects needs to be 
reached within the team. All patients are treated according the ERABS protocol; 
there is no preselection.
Workup for bariatric surgery
Eligibility for bariatric surgery is assessed using the European IFSO criteria.22 
When patients meet the criteria and attended the mandatory bariatric information 
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evening, they will be scheduled for one-stop-shop workups. These workups are 
divided into several grouped appointments. The first workup is called intake 
day, on which the patient is screened by the bariatric nurse and the psychologist. 
The second workup is analysis day. This day includes screening by the internist, 
the dietician, the physiotherapist and, when necessary, the pulmonologist. After 
approval for surgery, the patients are scheduled for the third one-stop-shop workup, 
called planning day. During this day, the patient will be screened by the surgeon and 
the anesthesiologist and the operation will be planned by the responsible nurse. 
This structure ensures comprehensive provision of information.
Mandatory weighing is performed one week prior to surgery. Since weight loss 
can decrease perioperative risks, weight gain prior to surgery is prohibited and weight 
loss is stimulated. Surgery will be postponed when patients do not lose any weight.
Type of surgery
LRYGB is recommended to patients, who suffer from severe gastro-esophageal 
reflux disease (GERD) or type 2 diabetes (T2DM) or patients who show extreme 
sweet eating behavior. In patients with a BMI > 60 kg/m2, large incisional hernias, 
expected severe small bowel adhesions, Crohn’s disease or patients listed for kidney 
transplantation the LSG is the recommended procedure. Otherwise, the procedure 
of the patient’s preference will be performed.
Preoperative care
Patients will be trained to self-administer a daily dose of low molecular weight 
heparin (LMWH) subcutaneously (i.e. 5,000 IE dalteparin), starting on the evening 
before surgery and continued to 4 weeks postoperatively. Intake of solid food is 
allowed up to 6 hours prior to surgery and intake of clear fluids up to two hours 
prior to surgery. All patients are admitted to the hospital on the day of surgery.
In case of a history of deep venous thrombosis (DVT) or pulmonary 
embolism (PE), anti-embolism stockings are provided before transportation to the 
OR. Patients are required to urinate before transportation to the OR to abandon 
need for urine catheters. Patients receive an intravenous line on the holding.  
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No sedative premedication is given to allow each patient to make transfers from his 
own bed onto the operation table and vice versa. High-risk patients (i.e. patients 
with obstructive sleep apnea syndrome, DM or superobese patients) are scheduled 
first on the OR to allow longer postoperative monitoring at recovery.
Perioperative management
Fifteen minutes before surgery, the patient receives intravenous antibiotics, 
analgesia and anti-emetics (Figure 1).23 The patient is connected to a blood pressure 
cuff, EKG leads and a pulse oximeter, which remain connected throughout all 
preoperative procedures to assure maximum efficiency.
Positioning on the OR table is done while the patient is awake, in order to 
prevent pressure ulcers or neural injuries.24 The legs are fixed with soft reusable 
leg fixator bands. The patients head is positioned on a special head elevated 
laryngoscopy position cushion25 to maximize sniffing position and facilitate mask 
ventilation and intubation. 
Throughout the procedure, patients are monitored using a Bispectral Index, 
applied to the patient’s forehead.26 Anesthetic induction and surgical preparation 
of the patient are performed simultaneously. After preoxygenation27 for 3 minutes, 
the protocol, depicted in Figure 1, is followed for induction of anesthesia. 
Rocuroniumbromide (30–40 mg) is administered after the patient is sufficiently 
anesthetized, using the wink reflex to confirm the sleeping state. Patients are 
intubated 2–3 minutes after administration and anesthesia is maintained according 
to the flow-chart (Figure 1). Since desflurane and remifentanil are non-lipophil 
anesthetic agents,28 quick washout and awakening after termination can be ensured 
in this particular population.
Both surgical procedures are standardized in detail; the LRYGB procedure 
was previously described by Leiffson et al.29 and the LSG by Gadiot et al.30 
Intraoperative blood loss is managed with clips with a low threshold, since  
intra- and postoperative bleeding prolongs recovery.
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Termination of anesthesia is achieved by discontinuing desflurane and 
remifentanil and administrating sugammadex to reverse residual neuromuscular 
block.31 The tube is removed after opening the eyes and adequate respiration is 
assured. The patient is asked to slide over from the operation table into their bed  
in order to achieve early ambulation.32 
All patients are transferred to the recovery room for postoperative 
monitoring and will be treated for pain and nausea23 according the protocol 
(Figure 1). The patients are discharged to the wards, preferably within 2 hours 
postoperatively. Standardized pain protocol includes four times daily 1,000 mg 
acetaminophen and six times daily 10–15 mg morphine intramuscular, when 
required, for maximally 24 hours.
Figure 1
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Postoperative care at the ward
None of the patients is routinely admitted to the ICU, since it increases the risk 
of DVT/PE, as patient’s mobility is compromised due to extra lines and catheters.33 
When patients return to the ward, they are directly encouraged to drink full liquid 
diet and to ambulate, since early mobilization decreases the incidence of DVT.34,35 
Within 24 hours postoperatively, the standardized postoperative analgesia 
protocol will be changed into four times daily 1,000 mg of acetaminophen and 
three times daily 50 mg of tramadol, if necessary. Caution is advised in prescribing 
NSAIDs, due to the gastrointestinal side effects.36 Adequate analgesia is highly 
important for enhanced recovery, since it supports early mobilization and thereby 
decreases the incidence of DVT/PE and atelectasis.37 Postoperative nausea is 
preferably treated with a single dose of 4 mg ondansetron.
All patients with drug dependent T2DM can decrease the dosage of the 
anti-diabetic medication by 50% immediately after surgery. Blood glucose levels 
are monitored closely. Intravenous fluid administration is calibrated on urine 
production, with an accepted minimum average production of 50 ml per hour.  
An overload of intravenous fluids can delay gut function activation and thereby 
prolong hospital stay.38 
When patients meet all discharge criteria (Table 1), they will be discharged 
one day postoperatively. The bariatric nurse specialist provides the patients with 
information on diet, exercise, medication, vitamin and mineral supplements, 
LMWH, proton pump inhibitors and alarm symptoms, prior to discharge. 
Additionally, the patient will receive written instructions.
129
7
Enhanced Recovery After Bariatric Surgery
Outpatient follow-up
Patients are advised to maintain on a full liquid diet for two weeks, postoperatively. 
Proton pump inhibitors, in a daily dose of 40 mg esomeprazole, are continued for 
6 weeks. One week postoperatively, the bariatric nurse will contact all patients to 
monitor their recovery. Follow-up visits with the surgeon are scheduled 8 weeks  
and 1 year postoperatively. Follow-up visits with the internist are scheduled after  
4 months and then annually. 
Results
Between January 2010 and June 2014, 2,126 consecutive patients received bariatric 
surgery in our bariatric unit. Ten patients were excluded from analysis because 
the bariatric procedure was performed simultaneously with a different major 
procedure. Of the remaining 2,116 patients, 1,967 (93.0%) were primary procedures 
and 149 (7.0%) were revisions. In all primary procedures, 917 (46.6%) LRYGB 
procedures were performed, against 1,050 (53.4%) LSG procedures. The number  
of patients in the pre- and post-ERABS period is specified in Table 2.
Discharge criteria
Anamnesis
    Pain VAS-score < 4
    Nausea No complaints of nausea or vomiting
    Intake > 1 L of fluids within 24 h
    Mobilization Adequate mobilization
    Calf pain No complaints of calf pain
    Well being Patient feels confident about discharge
Physical examination
    Abdomen No abdominal tension
    Fever Body temperature < 38°C
    Heart rate Frequency < 100 bpm
    Oxygen saturation O2Sat > 95%
    Drain production Production < 30 ml/24h
Laboratory results
    Hemoglobine Postoperative decrease < 2mmol/L
    Leucocyte count Leucocytes < 14 x 109/L
    CRP CRP < 100 mg/L
Table 1
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The prevalence of hypertension, age and BMI were significantly higher in the 
pre-ERABS group, while obstructive sleep apnea syndrome and GERD were more 
frequently present in the post-ERABS patients. Other baseline characteristics are 
described in Table 3.
Total Pre-ERABS Post-ERABS
No. Of procedures 2116 721 1395
   Primary procedures 1967 (93.0%)† 654 (90.7%)† 1313 (94.1%)†
     Primary LSG 1050 (53.4%)* 417 (63.8%)* 633 (48.2%)*
     Primary LRYGB 917 (46.6%)* 237 (36.2%)* 680 (51.8%)*
   Revisional procedures 149 (7.0%)† 67 (9.3%)† 82 (5.9%)†
† percentage of total no. of procedures
* percentage of no. of primary procedures
Table 2






Age* 44.2 (±11.0) 42.9 (±10.8) p  = 0.015
Sex†
    Female
524 (80.1%) 1064 (81.0%) p  = 0.628
Height* 1.69 (±0.09) 1.69 (±0.09) p  = 0.212
BMI* 45.6 (±5.89) 44.3 (±5.45) p  < 0.001
Waist circumference* 132 (±14.8) 135 (±13.3) p  < 0.001
Medical History
    Type 2 Diabetes† 163 (24.9%) 307 (23.4%) p  = 0.450
    Hypertension† 226 (34.6%) 366 (27.9%) p  = 0.002
    Hyperlipemia† 124 (19.0%) 220 (16.8%) p  = 0.225
    COPD† 27 (4.1%) 57 (4.3%) p  = 0.826
    OSAS† 34 (5.2%) 115 (8.8%) p  = 0.005
    GERD† 70 (10.7%) 298 (22.7%) p  < 0.001
    Abdominal surgery† 213 (32.6%) 433 (33.0%) p  = 0.856
    Current smoker† 147 (23.0%) 335 (25.8%) p  = 0.186
Table 3
* p-values were measured using independent T-tests
† p-values were measured using Chi-squared tests
Baseline characterictics in mean (±SD) or absolute number (percentage)
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Complications and readmissions
During admission, 93 subjects (4.7%) developed a complication of any kind, of 
which 48 subjects (2.4%) developed major complications, with a Clavien–Dindo 
classification of 3a or higher. Three hundred and two patients (15.4%) revisited 
the outpatient or emergency department within 30 days postoperatively. One 
hundred and forty-seven patients (7.5%) were readmitted due to complications. 
Of all readmissions, 50 patients (2.5%) required reoperation. Detailed information 
on complications, readmissions and reoperations is listed in Tables 4 and 5. The 
number of early readmissions, within 48 hours after surgery, were not statistically 




n = 1313 p -value*
Complication rate
    during hospital stay
32 (4.9%) 65 (5.0%) p  = 0.956
Wound infection 1 (0.2%) 2 (0.2%) p  = 0.998
Abces or hematoma 4 (0.6%) 8 (0.6%) p  = 0.995
Bleeding
    which required transfusion  
    or intervention
14 (2.1%) 24 (1.8%) p  = 0.632
Perforation 1 (0.2%) 6 (0.5%) p  = 0.286
Anastomotic leakage 2 (0.3%) 9 (0.7%) p  = 0.288
Anastomotic stenosis 0 (0%) 1 (0.1%) p  = 0.480
Sepsis 2 (0.3%) 9 (0.7%) p  = 0.288
Cardiac complications 0 (0%) 5 (0.4%) p  = 0.114
Renal dysfunction 4 (0.6%) 3 (0.2%) p  = 0.179
Pneumonia 3 (0.5%) 7 (0.5%) p  = 0.827
Lung embolism 0 (0%) 2 (0.2%) p  = 0.318
Urinary tract infection 1 (0.2%) 2 (0.2%) p  = 0.998
Other 13 (2.0%) 22 (1.7%) p  = 0.622
Table 4
* p-values were measured using Chi-square tests
Complications during admission
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Operation room logistics
All procedural times, such as surgical time, were significantly decreased after 
implementation of ERABS. Procedural times are specified in Table 6. As a result 
the mean (±SD) amount of surgical procedures in one OR increased significantly 
from 5.2 (±1.6) procedures to 6.1 (±1.3) procedures per day when performing LRYGB 
(p < 0.001) and from 7.0 (±1.9) procedures to 8.0 (±1.7) procedures per day when 







    within 30 days
82 (12.5%) 220 (16.8%) p  = 0.015
Readmission
    within 30 days
48 (7.3%) 99 (7.5%) p  = 0.859
Reoperation†
    within 30 days
13 (2.0%) 37 (2.8%) p  = 0.204
Clavien-Dindo classification
    complications within 30 days
105 (16.1%) 272 (20.7%) p  = 0.013
Minor 79 (12.1%) 198 (15.1%) p  = 0.071
    Grade I 45 (6.9%) 160 (12.2%)
    Grade II 34 (5.2%) 38 (2.9%)
Major 26 (4.0%) 74 (5.6%) p  = 0.596
    Grade IIIa 4 (0.6%) 7 (0.5%)
    Grade IIIb 8 (1.2%) 33 (2.5%)
    Grade IVa 13 (2.0%) 30 (2.3%)
    Grade IVb 0 (0%) 4 (0.3%)
    Grade V 1 (0.2%) 0 (0%)
† including reoperations during primary admission
Table 5
* p-values were measured using Chi-square tests
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Induction 17.9 (17.4-18.4) 14.6 (14.4-14.8) p  < 0.05
Surgical time 57.8 (55.7-59.9) 50.5 (49.6-51.5) p  < 0.05
    Bypass 76.6 (72.6-80.6) 59.6 (58.3-60.9) p  < 0.05
    Sleeve 47.1 (45.3-48.8) 40.8 (39.8-41.7) p  < 0.05
Emergence time† 8.9 (8.5-9.3) 7.6 (7.5-7.8) p  < 0.05
Time at recovery 89.6 (86.9-92.3) 79.9 (78.3-81.5) p  < 0.05
Total time in OR 84.6 (82.1-87.0) 72.8 (71.7-73.8) p  < 0.05
    Bypass 103.5 (98.8-108.1) 82.2 (80.8-83.6) p  < 0.05
    Sleeve 73.8 (71.6-76.0) 62.6 (61.6-63.7) p  < 0.05
Table 6
† Time between end of surgery and transport to recovery area
With the implementation of ERABS the mean length of stay reduced from 3.0 to 
2.1 nights (p < 0.001). Before introduction of ERABS, 39.4% of all subjects were 
discharged on the first postoperative day. Since the introduction, this percentage  
is increased to 74.2% of all subjects, with 91.7% of all subjects being discharged 
within two days postoperatively.
Figure 2
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Discussion
ERAS protocols have shown that optimizing and standardizing perioperative 
care results in a significant reduction in hospital stay and postoperative 
morbidity. This resulted in an increased interest in such protocols for bariatric 
surgery (ERABS protocols). In this study, the mean length of stay decreased 
from 3.0 to 2.1 nights after introduction of ERABS care, respectively allowing 
39.4% and 74.2% of the patients to be discharged on the first postoperative 
day. This decrease in length of stay is mainly caused by the clarification of the 
discharge criteria with the introduction of ERABS. Although discharge before 
the ERABS protocol was also determined on clinical parameters, such as 
temperature, pulse and CRP, no clear thresholds for the different parameters 
were defined and patient discharge was probably more conservative. Clear 
thresholds were first introduced with ERABS (Table 1), and patients who met 
all criteria on the first postoperative day were discharged directly on that day.
There was no significant difference in the number of complications during 
admission in both cohorts. However, within 30 days postoperatively, significantly 
more complications occurred in the post-ERABS group (20.7% versus 16.1%,  
p = 0.013). On the other hand, this increase did not result in a significant difference 
in the number of major complications, with a Clavien–Dindo score of 3a or 
higher (4.0% pre-ERABS versus 5.6% post-ERABS, p = 0.596), or the number of 
reoperations (2.0% pre-ERABS versus 2.8% post-ERABS, p = 0.204). Although 
not significant, we have to take a critical view on the percentage increase in 
complications and reoperations. First of all, due to increasing demands on 
health care and perioperative care in the Netherlands, hospitals are increasingly 
encouraged to register the perioperative course of their patients. As a result, the 
registration of complications has been improved in recent years. Furthermore, 
our clinic has made a transition from paper patient charts to digital charts in the 
same period in which ERABS was introduced. In the era of paper charts, hospitals 
were unfortunately confronted with loss of patient information throughout the 
hospital, while patient data is now centrally stored causing a minimized loss of data. 
However, in this cohort, we cannot differentiate between an increased number of 
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complications due to better registration or due to decreased safety caused by  
the introduction of ERABS, for example caused by the pursuit of high numbers  
of procedures and short turnover times. Possibly, there is a maximum efficiency  
in which we can guarantee patient safety and therefore it is of major importance  
to register complications thoroughly and adjust the protocol, when necessary,  
to achieve the most safe and efficient bariatric care. 
In current literature, very low rates of perioperative complications 
after ERABS13,39,40 have been described, but it remains unclear how and which 
complications are scored in these studies. One study16 described their scoring 
system in detail and also used the Clavien–Dindo classification. Results of our 
study are comparable with their results, with an increase in complications after 
implementation of ERABS, although it did not cause an increase in serious adverse 
events. In our cohort, most major complications requiring invasive treatment 
occurred more than 48 hours after the primary procedure. These complications 
were not likely to be prevented by extending the length of stay to 3 nights, as in  
the pre-ERABS group.
After the implementation, patients were more likely to revisit the emergency 
department within 30 days. However, early readmission rates (7.5%) and 
reoperation rates (2.5%) did not change significantly and were similar to rates  
in previous ERABS studies.15,16 This ERABS protocol includes intensive monitoring 
of patients by telephone by the obesity nurse, with a low threshold to reassess 
patients in the emergency department and to readmit the patients for observation. 
This monitoring may explain the higher number of early revisits.
Additionally, ERABS allows the performance of a higher volume of bariatric 
procedures, which, as a result, improves the quality of surgery,42-47 without 
increasing perioperative morbidity.13,32,39,47,48 As a result, ERABS protocols may 
increase cost-effectiveness of bariatric surgery.14,39 In the future, bariatric surgery 
will consume an increasing part of limited health economic and surgical resources 
of our already burdened health care system. In this study, all procedural times were 
significantly reduced after implementation of ERABS. This efficiency enabled us to 
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currently perform seven LRYGB procedures or eight LSG procedures per surgeon 
within 8 hours in one OR. Nonsurgical times within the operation room improved 
by working efficient and parallel to each other and decreased average time in the 
OR from 103 to 82 minutes in LRYGB and from 74 to 63 minutes in LSG. The use 
of dedicated bariatric teams and standardization of the protocol is probably the 
main cause of this reduced procedural duration and it improves teamwork, without 
having an adverse effect on patients’ outcome.49 
In conclusion, implementation of ERABS can result in shorter procedural 
times and a decreased LOS, which may lead to more efficient and cost-effective 
bariatric care. Even though the number of complications increased after 
implementation of ERABS, the number of major complications, readmissions  
and reoperations did not change. Therefore, by implementing an ERABS protocol, 
you can achieve efficient and safe bariatric care, as well as a substantial reduction 
in operation time, LOS and costs. It is of major importance to intensively monitor 
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Postoperative checklist for bariatric surgery
Abstract 
Background
Morbidly obese patients are at higher risk of complications after surgery.  
In bariatric surgery, pre- and intraoperative checklists are commonly used to 
identify high-risk patients preoperatively, to decrease the number of postoperative 
complications. This pilot study evaluates the effect of a postoperative checklist in 
bariatric surgery, addressing regularly measured parameters, on the occurrence and 
early recognition of complications.
Materials and methods
An in-house-developed postoperative checklist was used on the first  
postoperative day after bariatric surgery and included information on nausea,  
pain, temperature, heart rate and laboratory markers. Complications were scored 
using the Clavien–Dindo (CD) classification and three groups were formed: no 
complications (CD0), minor complications (CD1 and 2) and major complications 
(≥CD3a). Differences between groups were analyzed using nonparametric tests.
Results
694 subjects were included (79.5% female, age 42.6 [±10.8] years, BMI 43.8 [±5.8] 
kg/m2). 29 subjects developed major complications within 30 days postoperatively. 
There were no significant differences in baseline characteristics between groups. 
Subjects with major complications were less willing to be discharged due to 
complaints, compared to subjects with no or minor complications (14.8% versus 
3.6% and 4.6%, respectively) and had a higher decrease of hemoglobin level  
(0.8 versus 0.6 and 0.65 mmol/l, respectively).
Conclusions
The patients’ willingness for discharge, in combination with hemoglobin decrease, 
may be the best early predictors of major complications after bariatric surgery. This 
postoperative checklist may be an adequate instrument to identify patients who can 
be safely discharged home on the first postoperative day and thereby play a part in 
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Introduction
Bariatric surgery is the most effective long-term treatment option for patients 
suffering from morbid obesity and its related diseases.1-4 However, patients 
with morbid obesity are at higher risk for intraoperative and short- and  
long-term postoperative complications compared to lean patients,5 which can 
result in prolonged hospital stay, readmission, reoperation and even death.6 
Pre- and intraoperative checklists are becoming increasingly commonplace as a 
safety tool in standardized surgical treatment programs and these checklists are 
increasingly seen as best practice. It is known that proper use of these checklists 
results in a lower rate of postoperative complications.7 In addition, the use of 
postoperative checklists to structurally monitor signs of possible complications  
and subsequent early intervention could contribute to better patient care. However, 
in current literature, information on the use of postoperative checklists, addressing 
generally used postoperative parameters, such as heart rate, C-reactive protein 
(CRP) and hemoglobin values, is scarce. This pilot study presents the results 
of an in-house developed postoperative checklist for bariatric surgery based on 
these parameters and evaluates the different components of this checklist. To our 
knowledge, this is the first study that addresses the use of a postoperative checklist 
and its effect on complication management in bariatric surgery.
Materials and methods
Study population
All patients who underwent laparoscopic sleeve gastrectomy (LSG)8 or laparoscopic 
Roux-en-Y gastric bypass (LRYGB)9 within our bariatric clinic after the introduction 
of the checklist in February 2014 until December 2014 were included in this 
retrospective cohort study. Inclusion criteria for bariatric surgery are in accordance 
to international IFSO criteria.10 All patients were treated according to the enhanced 
recovery after bariatric surgery protocol11 and expected to be discharged on the first 
postoperative day. The choice of operation was made according to the patient’s and 
doctor’s preference based on comorbidity, age, the presence of gastro-esophageal 
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reflux disease (GERD) and dietary pattern. Since this is the first study to describe a 
postoperative bariatric checklist, no formal power calculation was performed.
Baseline characteristics
Baseline characteristics were collected during the initial outpatient preoperative 
screening and included gender, age, medical history and smoking habit. Weight (in kg) 
and BMI (in kg/m2) were the main measurements for anthropometry. Baseline 
laboratory tests were performed approximately two months before surgery. The 
postoperative laboratory measures are performed on the first postoperative day.
Postoperative checklist
An in-house-developed, computerized postoperative checklist was used during the 
ward rounds on the first postoperative day. Cutoff points were determined based on 
clinical experience. Pain was scored using a visual analog scale (VAS).12 Willingness 
for discharge was defined by asking the patient explicitly whether they agree to be 
discharged and was not influenced by the outcome of the other parameters in the 
checklist or the judgment of the clinician. Parameters and their cutoff points are 
shown in Table 1. Based on the outcome of the checklist, using the predetermined 
cutoff points, it was determined whether patients were ready for discharge or had  
to stay for further observation. An experienced bariatric surgeon determined further 
patient management, which could include patient discharge, further evaluation or 
reintervention.
Complications
Any abnormal course within 30 days postoperatively was scored as a complication. 
The severity of this complication was scored using the Clavien–Dindo (CD) 
classification.13,14 For statistical and clinical considerations, patients were divided  
into three groups: no complications, minor complication (CD1 and CD2) and  
major complications (CD3a or higher).
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Statistical analysis
All analyses were performed using SPSS (PASW) 18.0 software (SPSS Inc., 
Chicago, Illinois, USA). Outcomes of the checklist were described as median with 
interquartile range (IQR) or absolute number with percentage. Subjects without 
a completed checklist were excluded from analysis. Differences between the three 
groups, based on the CD classification, were analyzed using nonparametric tests.  
In order to determine the absolute differences in the parameters within the 
checklist, these parameters were considered to be continuous variables. 
Additionally, to determine the appropriateness of the different cutoff points for 
these parameters, all variables were transformed into dichotomous variables 
(“patient meets criterion” versus “patient fails criterion”) using these predefined 
cutoff points. Results were evaluated at a significance threshold of p < 0.05.
Table 1
Parameter Score Cut-off points
History
     VAS for pain 0 – 10 ≥ 4
     Nausea score 1 – 4 ≥ 4
     Ate liquid food? Yes / No No
     Mobilizing? Yes / No No
     Patient consent with going home? Yes / No No
Physical examination
     Abdominal guarding? Yes / No Yes
     Heart rate ≥ 120 bpm
     O2 saturation ≤ 90 %
     Drain production in 24 hours ≥ 30 ml
Lab findings
     Hemoglobin decrease ≥ 1 mmol/l, or
≥ 1.6 g/dl
     White blood cell count post-operative ≥ 14 x10^9/l
     C-reactive protein post-operative ≥ 79 mg/l
VAS visual analogue scale
Parameters presented in the postoperative checklist for bariatric surgery. 
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Results
After implementation of the checklist a high compliance to complete the checklist 
on the first postoperative day was achieved; after 2 months, in more than 95% of all 
bariatric patients the checklist was completed and this percentage remained stable 
over time.
Baseline characteristics
A total of 694 patients were included between February and December 2014. The 
majority of patients were female (79.5%) and the mean age was 42.6 (±10.8) years. The 
mean BMI was 43.8 (±5.81) kg/m2 with a mean waist circumference of 131 (±12.2) cm 
or 51.6 (±4.8) inches. Medical history included earlier abdominal surgery (33.3%), 
hypertension (33.0%), type 2 diabetes mellitus (21.3%), GERD (18.0%) dyslipidemia 
(15.4%), sleep apnea (10.1%) and chronic obstructive pulmonary disease (3.6%). 
Additional baseline characteristics are shown in Table 2.
Surgical techniques
From the total of 694 procedures performed in this period, 630 procedures (90.8%) 
were primary procedures, while 64 procedures were revisional procedures after 
previous bariatric surgery, such as laparoscopic adjusted gastric banding or sleeve 
gastrectomy. Of all primary procedures the most frequently performed surgery was 
the laparoscopic Roux-en-Y gastric bypass (LRYGB), with 350 procedures (55.6%), 
followed by the laparoscopic sleeve gastrectomy (LSG), with 278 procedures 
(44.1%). In only two cases was a primary mini-gastric bypass performed.
Complications
In 147 patients a complication occurred within 30 days postoperatively, of which 
there were 118 minor complications (17%) and 29 major complications (4%). 
Baseline characteristics of patients, who developed a complication within 30 days, 
were not significantly different from the baseline characteristics of patients without 
complications, except for the preoperative occurrence of GERD. Further details  
are shown in Table 3.
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Within the group of minor complications 17 subjects developed a minor 
complication during their initial stay in the hospital and 104 subjects developed a 
minor complication after discharge. Only 16 of the 118 subjects required medical 
treatment of their complication (CD2), the rest were treated conservatively.  
Within this group, the major complaints were abdominal pain, nausea, surgical  




   female
552 (79.5%)
Age
   (years)
42.6 (±10.8)
Height
    (meters)




   (kg/m2)
43.8 (±5.81)
Waist circumference
   (cm)




    Type 2 diabetes 148 (21.3%)
    Hypertension 229 (33.0%)
    Dyslipidemia 107 (15.4%)
    OSAS 70 (10.1%)
    GERD 125 (18.0%)
    Abdominal surgery 231 (33.3%)
Smoking
    Yes 142 (20.5%)
    Quit smoking 182 (26.5%)
Characteristics procedure
    Primary procedure 630 (90.8%)
    Re-do procedure 64 (9.2%)
    Gastric bypass 398 (57.3%)
    Sleeve gastrectomy 290 (41.8%)
    Minibypass 6 (0.9%)
Baseline characteristics in absolute numbers or mean value, with its percentage or 
standard deviation, respectively, presented within brackets
BMI body mass index; OSAS obstructive sleep apnea syndrome; 
GERD gastro esophageal reflux disease
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Within the group of major complications 13 of 29 subjects developed the 
complication after they were discharged. In 7 of these 13 subjects, the initial 
stay in hospital was extended due to a negative checklist outcome. However, 
the complications only occurred 7 or more days after the procedure. The most 
frequently occurring complications within 7 days postoperative were bleeding, 











Sex (female) 437 (79.9%) 92 (78.0%) 23 (79.3%)
Age (years) 44 (36-51) 42 (31-50.8) 46 (40-50.5)
Height
    (meter)







BMI (kg/m2) 42.9 (40.2-46.6) 42.4 (40.6-46.9) 42.3 (39.3-46.3)
Waist circumference
    (cm)







Systolic blood pressure (mmHg) 135 (122-146) 135 (120-149) 133 (124-153)
Diastolic blood pressure (mmHg) 75 (69-83) 76 (70-81) 80 (74-89)
Current smoker 108 (19.7%) 29 (24.6%) 5 (17.2%)
Quited smoker 140 (25.6%) 33 (28.0%) 9 (31.0%)
Medical history
    Type 2 diabetes 112 (20.5%) 26 (22.0%) 10 (34.5%)
    Hypertension 179 (32.7%) 37 (31.4%) 13 (44.8%)
    Hypercholesterolemia 83 (15.2%) 19 (16.1%) 5 (17.2%)
    COPD 20 (3.7%) 4 (3.4%) 1 (3.4%)
    OSAS 51 (9.3%) 15 (12.7%) 4 (13.8%)
    GERD 84 (15.4%) 34 (28.8%) 7 (24.1%)
    Previous bariatric surgery 54 (9.9%) 14 (11.9%) 3 (10.3%)
    Previous abdominal surgery 181 (33.1%) 41 (34.7%) 9 (31.0%)
Completed checklits 512 (93.6%) 109 (92.4%) 26 (89.7%)
† Independent samples Kruskal-Wallis test
◊ Chi squared test
Baseline characteristics in absolute numbers or median value, with its percentage or IQR, respectively, presented 
within brackets
IQR interquartile range; CD Clavien Dindo classification; BMI body mass index; COPD chronic obstructive pulmonary disease; 
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Outcome of checklist
The checklist was completed in 648 subjects within this cohort. On all different 
parameters included in the checklist, only the hemoglobin decreased, and the 
patients’ willingness for discharge were significantly different between the three 
complication groups (Table 4). Within the group of patients who developed a major 
complication the median hemoglobin decrease was 0.8 mmol/l (1.18 g/dl), compared 
to 0.6 mmol/l (0.96 g/dl) in the group without any complications and 0.65 mmol/l 
(1.04 g/dl) in the group with a minor complication (p = 0.009). Within the minor 
complication group and the group without complications, approximately 95% of all 
patients felt confident to be discharged on the first day postoperatively, while 14.8% 










VAS for pain 3 (2 - 4) 3 (2 - 4) 3 (2 - 5.5)
Nausea scale 1 (1 - 2) 1 (1 - 2) 1 (1 - 2)
Oral intake
    Yes 487 (95.1%) 100 (91.7%) 25 (92.6%)
    No, per surgeons order 4 (0.8%) 2 (1.8%) 0 (0.0%)
    No, due to complaints 18 (3.5%) 6 (5.5%) 2 (7.4%)
Ambulation 505 (98.6%) 107 (98.2%) 27 (100.0%)
Willingness for discharge
    Yes 486 (94.9%) 101 (92.7%) 23 (85.2%)
    No, per surgeons order 3 (0.6%) 1 (0.9%) 0 (0.0%)
    No, due to complaints 18 (3.5%) 5 (4.6%) 4 (14.8%)
Body temperature
    degrees Celsius 37.3 (36.9 - 37.6) 37.2 (36.8 - 37.4) 37.5 (37.0 - 37.8)
    degrees Fahrenheit 99 (98 - 100) 99 (98 - 99) 100 (99 - 100)
Heart rate (bpm) 78 (70 - 87) 78 (69 - 86) 79 (72 - 95)
Oxygen saturation (%) 97 (95 - 98) 96 (95 - 98) 96 (94 - 97)
Abdominal distension 504 (98.4%) 106 (97.2%) 26 (96.3%)
Drain
    No drain 408 (79.7%) 85 (78.0%) 20 (74.1%)
    Drain production < 30 ml 72 (14.1%) 14 (12.8%) 6 (22.2%)
    Drain production > 30 ml 23 (4.5%) 6 (5.5%) 1 (3.7%)
Hemoglobin decrease
    (mmol/l) 0.6 (0.3 - 0.9) 0.65 (0.2 - 1.0) 0.8 (0.5 - 1.5)
    (g/dl) 0.96 (0.48 - 1.44) 1.04 (0.32 - 1.60) 1.28 (0.80 - 2.40)
Leukocyte count (x10^9/l) 11.9 (10.1 - 13.6) 12.0 (9.8 - 13.7) 13.0 (11.2 - 15.1)
CRP (mg/l) 18 (12 - 32) 20 (12 - 34) 27 (17 - 45)
* Fisher's exact test
† Independent samples Kruskal-Wallis test
◊ Chi squared test
Baseline characteristics in absolute numbers or median value, with its percentage 
or IQR, respectively, presented within brackets
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Oral intake
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Abdominal distension 504 (98.4%) 106 (97.2%) 26 (96.3%)
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    No drain 408 (79.7%) 85 (78.0%) 20 (74.1%)
    Drain production < 30 ml 72 (14.1%) 14 (12.8%) 6 (22.2%)
    Drain production > 30 ml 23 (4.5%) 6 (5.5%) 1 (3.7%)
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    (mmol/l) 0.6 (0.3 - 0.9) 0.65 (0.2 - 1.0) 0.8 (0.5 - 1.5)
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CRP (mg/l) 18 (12 - 32) 20 (12 - 34) 27 (17 - 45)
* Fisher's exact test
† Independent samples Kruskal-Wallis test
◊ Chi squared test
Baseline characteristics in absolute numbers or median value, with its percentage 
or IQR, respectively, presented within brackets
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Patient discharge is dependent on the outcome of the checklist, using 
predefined cutoff values, as described in Table 1. Independent analysis of the 
different parameters in the checklist, after transformation to dichotomous 
variables, showed a significant difference in the rate of major complications 
between patients who did or did not meet the criterion of VAS for pain, white  
blood cell count and the willingness of the patient for discharge.
There was no significant difference in the occurrence of major complications, 
using the current cutoff values for hemoglobin decrease, heart rate and CRP. 
Further details are shown in Table 5. Using these cutoff points, the positive 
predictive value of this checklist on development of a major complication is 6%, 







    > 4
66 (12.9%) 19 (17.4%)
Nausea scale  
    ≥ 4
28 (5.5%) 5 (4.6%)
Diet
    no intake
22 (4.3%) 8 (7.3%)
Mobilisation
    not mobilized
5 (1.0%) 1 (0.9%)
Willingness for discharge
    not willing
21 (4.1%) 6 (5.5%)
Abdominal distension
    present
1 (0.2%) 0 (0.0%)
Heart frequency 
    ≥ 120 bpm
1 (0.2%) 0 (0.0%)
Oxygen saturation 
    ≤ 90%
2 (0.4%) 0 (0.0%)
Drain production 
    ≥ 30 ml
23 (4.5%) 6 (5.5%)
Hemoglobine decrease 
    ≥ 1 mmol/l or ≥ 1.6 g/dl
109 (21.3%) 25 (22.9%)
Leukocyt count 
    ≥ 14 x10^9/l
108 (21.1%) 23 (21.1%)
C-reactive protein 
    ≥ 79 mg/l
20 (3.9%) 7 (6.4%)
VAS visual analogue scale
Incidence of major complications* based on the predefined cut off point in the computerized checklist
* All parameters were transformed into dichotomous variables based on the predefined cutoff points
Major complications
n=26 p -waarde
8 (30.7%) p =0.025
3 (11.5%) p =0.383
2 (7.7%) p =0.354
0 (0.0%) p =0.874
4 (15.4%) p =0.039
1 (3.8%) p =0.083
0 (0.0%) p =0.873
0 (0.0%) p =0.759
1 (3.8%) p =0.864
10 (38.5%) p =0.126
12 (46.2%) p =0.012
1 (3.8%) p =0.427
I i   j  li i     i    i  i   i  li
 ll    i  i  i l     i   i
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Discussion
With the increasing prevalence of bariatric surgery, in combination with the 
high risk of intra- and postoperative complications, there is an emerging 
demand for bariatric safety tools. The use of pre- and intraoperative checklists 
has been proven to decrease the rate of postoperative complications. Even 
though many clinics will use the same postoperative parameters to evaluate 
the risk of postoperative complications, it has not been investigated which 
parameters are most reliable in predicting the complication risk in bariatric 
patients.
Analyzing the differences in patient characteristics between patients without 
complications, with minor complications and with major complications, patients 
with preoperative complaints of GERD were more likely to develop a complication, 
either minor or major. This effect was not restricted to a specific surgical procedure 
or influenced by smoking habit. The largest effect of GERD on the occurrence of 
complications was seen in the group of minor complications. This may be caused by 
the synergetic effect of GERD on complaints of nausea and abdominal discomfort, 
which leads to an increased frequency of emergency room visits, without a 
requirement of additional treatment.
However, the main focus of this study was to early identify symptoms of 
complications, using a postoperative discharge checklist. Interestingly, the patients 
who developed major complications were less willing to be discharged on the first 
postoperative day, even though these patients expected to be discharged on that 
day. There was no difference in oral intake and ambulation between the three 
groups, which may be explained by the protocol in which patients are required en 
encouraged to start early refeeding and mobilization.11 Additionally, there were 
no significant differences in the experienced pain and nausea between the three 
different groups. Therefore, the VAS and nausea score may not be appropriate 
measures to estimate the possibility of a major complication. However, after 
analysis of the appropriateness of the cutoff point for VAS, it had been found 
that subjects with a VAS score of 4 or higher were more likely to develop a major 
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complication compared to subjects with a lower VAS score. Therefore, a high VAS 
score should alert the clinician, while low VAS scores do not exclude the possibility 
of development of a complication.
There was no difference in the physical exam findings of the two groups. 
While the parameters were measured at an early stage, and therefor fever might not 
be expected to have developed, it is interesting that even in the major complication 
group there was no difference in heart rate or abdominal distension.
Within laboratory evaluation of postoperative subjects, most interest is 
shown in the decrease of hemoglobin, indicating postoperative bleeding, and 
inflammatory markers CRP and leukocyte count. Within this cohort, only the 
level of hemoglobin decrease was different in subjects with major complications 
compared to all other subjects. Therefore, the level of hemoglobin decrease may 
be a predictive factor in the development of complications. Unfortunately, the 
considerable overlap in hemoglobin decrease levels between the three groups 
makes it difficult to differentiate between subjects prone to develop a major 
complication and those who are not, purely based on the hemoglobin decrease. 
It can be concluded that a high hemoglobin decrease should alert for a major 
complication, although major complications cannot be excluded in subjects with 
small hemoglobin decreases. The lack of differences in the inflammatory markers 
can be explained by the fact that inflammatory complications, such as anastomotic 
leakage and abscesses will usually not occur within 24 hours postoperatively. It is 
important to realize, that not all complications occur within this first postoperative 
day and may therefore not be identified in the first 24 hours. However, early 
discharge after bariatric surgery, as applied in enhanced recovery after bariatric 
surgery protocols, does not increase the risk of complications and therefore early 
discharge is considered safe.15-16 
Overall, significant differences were only seen in the level of hemoglobin 
decrease and the patient’s willingness to be discharged. However, the computerized 
checklist uses certain cutoff point for each parameter. In addition to the patient’s 
unwillingness to be discharged, subjects with major complications were more 
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likely to meet the VAS criterion and the leukocyte count criterion, and therefore, 
these two parameters may have an additional value in the early recognition of 
complications. Other cutoff points, such as a heart rate of 120 bpm or higher, 
occurred seldom and appeared to be inadequate. With the current cutoff points 
of the different parameters in the checklist a negative predictive value of 98% 
was reached, which means that most patients who were sent home on the first 
postoperative day based on the outcome of the checklist did not develop major 
complications. However, the positive predictive value was only 6%, which means 
that 94% of all reevaluations and additional investigations during hospital 
admission could have been avoided. It can be concluded from this pilot study 
that the checklist, in its current state, is not a good tool to identify subjects who 
will develop a major complication, but it can identify subjects who can safely be 
discharged on the first postoperative day. The next step in the development of this 
postoperative checklist is to increase the positive predictive value by determining 
better cutoff values and omitting unnecessary parameters. A prospective study 
should demonstrate whether the use of this checklist would eventually promote 
early recognition of complications and decrease the severity of these complications.
In conclusion, the patient’s willingness to be discharged home and the level 
of hemoglobin decrease appear to be the most discriminating parameters within 
this checklist, although the VAS score and leukocyte count may have a role as well. 
Overall, a postoperative checklist may be a useful tool to identify bariatric patients 
that can be safely discharged home on the first postoperative day. The current 
checklist has a very low positive predictive value and should therefore be optimized 
with critical evaluation of the necessary parameters and determination of the best 
cutoff values.
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General discussion and future perspectives
Introduction
Today, obesity is a major health problem that impacts both individual patients 
and public health. With the increasing prevalence of obesity, the number 
of patients suffering from obesity-related diseases, as well as the number 
of patients seeking obesity treatment, continues to rise. Over the past two 
decades, interest in obesity has rapidly increased, as is clearly depicted by 
the number of publications outlined in Figure 1. While the oldest publication 
on PubMed with the term “obesity” in the title dates to 1880 and describes 
an autopsy of a morbidly obese man,1 it was not until 1945 that the annual 
number of publications on obesity entered the dozens and 2001 that the 
number entered the thousands; the ongoing exponential rise of published 
research has continued ever since.2 This thesis reflects the broad range of 
interests in terms of obesity research today, from epidemiology, etiology and 
pathophysiology to treatment modalities involving effectiveness, safety, costs 
and patient satisfaction.
Figure 1
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Part I: 
Cardiovascular consequences of obesity
The relationship of cardiovascular risk and the level of obesity
Even though most people are quite aware of the health hazards of overweight and 
obesity, especially for cardiovascular health,3,4 the relationship between level of 
obesity and severity of cardiovascular derangement remains unclear. It is generally 
accepted that obese individuals have an increased risk for overall mortality in 
general, and cardiovascular mortality in particular.4,5 Moreover, it has been well 
established that these mortality rates rise with increasing BMI. Chapter 2 
investigated the relationship between BMI and cardiovascular risk factors. In 
accordance with previous studies, we found that obese subjects have significantly 
increased levels of certain cardiovascular risk factors, such as blood pressure,  
LDL-cholesterol and glucose. However, the severity of obesity, in terms of BMI, was 
not found to be associated with the levels of these cardiovascular risk factors. For 
example, systolic and diastolic blood pressure, as well as LDL- and HDL-cholesterol, 
gradually worsen up to a BMI of approximately 35–40 kg/m2 and then plateau, as if a 
limit to the effect of progressive weight gain on the deterioration of cardiovascular 
risk factors exists. We have proposed an effect of differences in adipose tissue 
distribution in different levels of obesity, since central adiposity is known to  
be metabolically more unhealthy and is associated with hypertension, insulin  
resistance and dyslipidemia, as well as both cardiovascular and overall mortality.6–8 
We performed CT-volumetry of subcutaneous abdominal and visceral adipose 
tissue in a small subgroup of the obese subjects; the increase in BMI was primarily 
explained by an increase of subcutaneous adipose tissue volumes rather than an 
increase in visceral fat. We believe that a maximal expansion capacity of the visceral 
adipose tissue may exist and that further deterioration of cardiovascular risk factors 
with increasing BMI may be limited. The expansion ability of visceral adipose tissue 
in relation to increasing levels of BMI should be further evaluated to determine the 
role of visceral adipose tissue expansion in the deterioration of cardiovascular risk 
and disease. A more thorough understanding of this process may be useful in the 
development of better treatment modalities.
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Nevertheless, one may question what the specific cause of increased mortality is, 
since cardiovascular risk factors do not further deteriorate with a BMI over 40 kg/m2.  
In contrast to cardiovascular risk factors, a clear relationship exists between BMI 
and markers for systemic inflammation and atherosclerosis, which suggests the 
presence of a chronic low-grade inflammatory disease.9 The expansion of adipose 
tissue may be related to the excessive production and release of pro-inflammatory 
markers, such as interleukin 6 and adipokines, and may contribute to the process of 
atherosclerosis. Another hypothesis lies in the versatility of cardiovascular mortality; 
existing mortality studies do not distinguish between cardiovascular death caused 
by atherosclerotic or non-atherosclerotic heart disease, such as hypertensive heart 
disease, cardiomyopathies or heart failure. The increased cardiovascular mortality 
risk may be caused not by atherosclerotic diseases but by non-atherosclerotic causes 
such as, for example, diastolic and systolic dysfunction leading to heart failure caused 
by mechanical changes in obesity. In addition, obesity is closely associated with an 
increased risk of atrial fibrillation, which by itself impairs left ventricle function.
Gender differences in cardiovascular disease and obesity
Women are known to be relatively protected for cardiovascular disease,10 particularly 
before menopause.11 Despite obesity being associated with the increased risk of 
cardiovascular disease, Chapter 3 has demonstrated that morbidly obese women are 
still relatively protected when compared to their male counterparts. This advantage 
is reflected by both cardiovascular risk factors and cardiovascular outcome measures, 
in terms of carotid intima media thickness and pulse wave velocity. As previously 
described, in lean women, the advantage diminishes post menopause, and the 
prevalence of cardiovascular disease approaches similar rates for women and men in 
the seventh decade of life.10,11 For obese women, a postmenopausal state, compared to 
a premenopausal state, also has negative effects on cardiovascular health, although 
the disadvantage is subtler than in lean women. It has been suggested that hormonal 
imbalances affect the development of cardiovascular disease. In premenopausal 
women, the incidence of ischemic heart disease is low,11 and estrogen is thought 
to have both anti-atherosclerotic and anti-inflammatory properties. While the 
ovaries are the most important source for estrogen in premenopausal years, after 
menopause, the primary source for estrogen is estrone, which can be produced 
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from the conversion of androgens in adipose tissue.11 Even though the levels of 
estrogen decrease after menopause, the excessive amount of adipose tissue may 
cause a subtler decrease in estrogen levels and thereby attenuate the effect of the 
postmenopausal state in women suffering from morbid obesity.
The effect of type 2 diabetes mellitus and inflammation 
on cardiovascular disease
A major health problem associated with obesity is type 2 diabetes mellitus (T2DM), 
which causes micro- and macrovascular complications; subjects suffering from 
T2DM are more likely to develop atherosclerosis12 and cardiovascular disease.13,14 
Additionally, low-grade systemic inflammation is thought to be a major contributor 
to the development of these cardiovascular complications,15 and obesity is 
considered a form of low-grade inflammation.16 Therefore, the increased risk of 
cardiovascular disease and mortality in obese subjects may be partially explained  
by both the increased inflammatory state and the increased occurrence of T2DM.
Chapter 4 demonstrated that the occurrence of T2DM in obese patients 
negatively affects vascular health in terms of carotid intima media thickness and 
pulse wave velocity. However, these two parameters are primarily influenced by age, 
gender, blood pressure and lipid profile, and not by the occurrence of T2DM itself. 
This result suggests that not T2DM, but other cardiovascular risk factors linked to 
T2DM, have the greatest impact on vascular health in obese subjects.
Additionally, it has been suggested that increased cardiovascular risk 
and disease in obese diabetes patients, when compared to their non-diabetic 
counterparts, may be explained by differing levels of systemic inflammation.  
Despite obese patients suffering from T2DM having increased inflammatory 
markers when compared to non-diabetics, this did not result in differences  
in cardiovascular outcomes, as described in Chapter 5.
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Part II: 
Treatment strategies for obesity
Bariatric surgery in adolescents
Obesity is a major health problem not only in adults but also in children and 
adolescents, with an increasing prevalence in these age groups in recent decades.19–21 
Unfortunately, the health risks of obesity also exist for these young patients.22–24 
Even if they achieve normal weight in adulthood, their cardiovascular risk will 
remain increased when compared to children with normal weight.25 Bariatric 
surgery is thought to be the only long-term effective treatment for morbid obesity 
and morbid obesity-related diseases, with substantial and long-term weight loss. 
However, much discussion is ongoing regarding the ethics of bariatric surgery in 
children and adolescents. Can young patients make informed decisions on such 
chronic interventions? Can they estimate the consequences, both in the short and 
long term, of such operations? On the other hand, are we allowed to withhold from 
them the best effective treatment, knowing the risks they will encounter in both 
their current and future lives when untreated? A high need for information remains 
on the most effective and safest bariatric procedure in children and adolescents, 
including information on long-term results and patient satisfaction. Chapter 6 
has reported the encouraging results of both the laparoscopic Roux-en-Y gastric 
bypass (LRYGB) and the laparoscopic sleeve gastrectomy (LSG) in a group of 
young adults. We recommend the LSG for young adults and adolescents due to its 
theoretical advantages, including the lack of dumping, with improved quality of life, 
less malnutrition and vitamin disturbances, the possibility of normal endoscopy 
after surgery and options for revisional surgery. A primary concern in these young 
patients is the lack of long-term follow-up; a special follow-up program may need to 
be implemented to increase follow-up attendance and thus increase patient safety.
Increasing efficiency and monitoring safety of bariatric surgery
With the increasing number of morbidly obese subjects, the number of bariatric 
procedures performed worldwide is also increasing. In the search for safe and 
efficient treatment, enhanced recovery after bariatric surgery (ERABS) protocols 
have been developed,26–30 as described in Chapter 7. Implementation of this protocol 
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has significantly decreased the length of stays in the hospital. Furthermore, 
operation times have become significantly shorter after implementation, from 
which the patient benefits in term of risk of thrombosis, infection and other 
postoperative complications. The implementation of an ERABS protocol does not 
result in an increase of major complications and is therefore considered safe. The 
majority of minor complications in the post-ERABS group were complaints of 
nausea in patients who did not stick to the prescribed diet. With more extensive 
education, particularly postoperatively, the number of minor complications can 
likely be reduced. Overall, ERABS is thought to be a safe method to perform 
bariatric surgery in high volumes, and it may actually lead to a reduction in 
healthcare costs.
Even though the length of stay in the hospital has significantly decreased 
after the implementation of ERABS, it is essential to differentiate patients who 
can be discharged early from those who may develop complications. Although 
pre- and intraoperative checklists are becoming a standard safety tool in many 
surgical treatment programs, a postoperative checklist to identify patients prone 
to complications was first described in Chapter 8. The checklist in its current form 
had a very high negative predictive value, and patients who met the criteria of the 
checklist could be sent home safely. However, the positive predictive value was very 
low, indicating a high percentage of unnecessary reevaluation and investigation in 
this group. The current checklist is being reevaluated annually to adjust its cutoff 
points and increase its positive and negative predictive values.
Future perspectives
A new insight emerging from this thesis relates to the finding that the extent of 
obesity, in terms of BMI, does not appear to influence the risk of cardiovascular 
disease. We assume that the distribution of adipose tissue may be influential in this 
finding. Data from a small subgroup analysis described in Chapter 2 suggests that 
the expansion capacity of visceral adipose tissue in morbid obesity may be limited. 
Importantly, visceral adipose tissue is known to be more metabolically unhealthy 
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than the other adipose tissue compartments. Body composition analysis should be 
performed using DEXA scans, which are low in radiation exposure to the patient 
and relatively inexpensive. In a large group of subjects with a wide BMI range, from 
normal weight to morbidly obese, the differences in volumes of adipose tissue 
depots will be measured and correlated to the cardiovascular risk and disease to test 
our hypothesis. Furthermore, in collaboration with the department of cardiology in 
our hospital, a clinical study is being conducted to investigate the pathophysiology 
of subclinical cardiac dysfunction in morbid obesity; first results are currently being 
analyzed, and first publications are to be expected in 2020.
A primary task in the field of bariatric surgery is to define which patients 
have the highest profit of bariatric surgery. Can we, preoperatively, identify the 
patient who will have the best results of bariatric surgery in terms of weight loss 
and resolution of comorbidity? Based on the current thesis, BMI should likely not 
be the primary criterion for performing bariatric surgery. As previously described 
in the SOS study,31 bariatric surgery leads to a clear decrease in the number of 
cardiovascular events and cardiovascular mortality. However, no relationship was 
observed between preoperative BMI and the extent of decrease in cardiovascular 
events and mortality postoperatively. This thesis further shows that BMI is not a 
good predictor of metabolic or cardiovascular health in obese subjects. Therefore, 
we believe that international guidelines for bariatric surgery should be adjusted. 
They should not only focus on BMI; the primary focus should be on the metabolic 
and cardiovascular characteristics of the individual patient. Previous studies31–32 
showed that preoperative BMI did not influence the resolution or new development 
of metabolic and cardiovascular disease after bariatric surgery. However, subjects 
with high fasting glucose or insulin levels show more resolution of metabolic and 
cardiovascular disease and a higher decrease in mortality after bariatric surgery. 
Furthermore, subjects suffering from obstructive sleep apnea syndrome (OSAS) 
have a higher risk of developing cardiovascular disease, and bariatric surgery gives 
a clear resolution of OSAS.31 Additionally, in the majority of bariatric studies, 
the study population consists primarily of female subjects, while premenopausal 
women are relatively protected against cardiovascular disease when compared to 
men. The effects of bariatric surgery may be more relevant for men in terms of the 
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resolution of comorbidity and prevention of cardiovascular disease and mortality.
Currently, no clear profile exists of the obese subjects with the highest risk of 
cardiovascular disease or the greatest presumed benefit from bariatric surgery.  
We believe that new international guidelines should focus more on the already 
known factors that can predict an increased risk of cardiovascular disease or 
increased benefit of bariatric surgery. Within the obese population, treatment 
should be more aggressive in men, people with increased fasting glucose or insulin 
levels and people suffering from OSAS, since the greatest gains in both personal and 
public health can be achieved in these specific groups. These factors may also be 
crucial in decision-making on the type of surgical procedure. The LRYGB is known 
to have better results in terms of the resolution and prevention of cardiovascular 
and metabolic disease when compared to the LSG33 and may therefore be the most 
appropriate bariatric procedure in these specific adult subgroups.
Bariatric treatment should provide not only significant and long-lasting 
effects on both weight loss and comorbidity resolution and prevention but also 
a low level of maintenance in which intensive and long-lasting follow-ups are 
unnecessary. Unfortunately, this is still a future perspective. Some patients 
experience weight regain after bariatric surgery. More importantly, metabolic 
deterioration is also regularly described in long-term follow-ups. For example,  
even though glycated hemoglobin (HbA1c) levels significantly decrease after weight 
loss, in the long term, they may slowly increase again, even though weight is not 
regained.34 In the long term, up to 50% of all bariatric patients experience a relapse 
of T2DM or cardiovascular disease, and therefore, their risk of cardiovascular events 
and death is still increased, when compared to non-obese people.31,35 These results 
can be compared with the long-term follow-up results of so-called “metabolically 
healthy” obese subjects. For now, we cannot completely eliminate the increased  
risk of metabolic and cardiovascular disease in obese subjects, but bariatric surgery 
may decrease their occurrence and subsequently slow the progression of these 
diseases. Current bariatric procedures should be adjusted or combined with,  
for example, medical treatment to achieve lifelong effects on metabolic  
and cardiovascular risk factors and disease. Until such treatments have been 
developed, lifelong follow-up is strictly recommended for all bariatric patients.  
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These follow-ups can be transferred to the general practitioner after the 
stabilization of weight and comorbidity. At least an annual follow-up of blood 
pressure, lipid profile and glucose metabolism should be performed to identify  
early changes. Even though revisional bariatric surgery is not extremely effective 
in terms of weight loss, it does have significant effects on comorbidity36 and may 
therefore be considered in these patients.
Based on the results described in Chapter 6, first steps have been taken to 
develop a randomized controlled trial on the LSG and the LRYGB in adolescents 
aged 16–18 years. However, due to low compliance among these young patients, our 
primary concerns are the safety of such procedures and of participation in a surgical 
trial. We believe that intensive support by all involved specialties is an obligation, 
including not only the surgeon, internist and pediatrician but also the dietician, 
psychologist and physiotherapist. Even though bariatric surgery is an effective 
method to achieve substantial weight loss in both adults and adolescents, the 
treatment of obesity must comprise more modalities than surgery alone. Programs 
focusing on the prevention of obesity and weight regain after bariatric surgery 
should be improved and intensified, particularly for these young subjects, who are 
known to show low compliance and short follow-up.
Based on the results of the postoperative checklist in bariatric surgery, as 
described in Chapter 8, the current checklist should be optimized and finetuned. 
An annual reevaluation of the checklist, its cutoff points and the occurrence of 
complications is required to optimize the current checklist. The goal will be to 
increase the positive predictive value of the checklist, without loss of the negative 
predictive value.
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Het woord ‘obesitas’ is afkomstig uit het Latijn en betekent ‘gezet’ of ‘dik’.  
Het is een samenvoeging van het voltooid deelwoord van eten ‘ēsus’ en 
het woord ‘ob’, dat ‘te veel’ betekent. Obesitas is de medische term die 
overgewicht of zwaarlijvigheid beschrijft. 
Obesitas is wereldwijd een groot probleem en het aantal mensen met  
obesitas neemt steeds verder toe. Er zijn verschillende gradaties van overgewicht  
en obesitas, die worden beschreven aan de hand van de Body Mass Index (BMI).  
De BMI wordt berekend aan de hand van de volgende formule:
BMI (kg/m2) = gewicht / lengte2
Een BMI tussen de 18,5 en 25 kg/m2 wordt gezien als een gezond gewicht. Zodra 
de BMI boven de 25 kg/m2 komt, wordt gesproken van overgewicht. Er is sprake 
van obesitas bij een BMI van 30 kg/m2 of hoger. In dit proefschrift komt de term 
‘morbide obesitas’ veelvuldig voor: dit is obesitas met een BMI van 40 kg/m2 
of hoger. De term ‘morbide’ impliceert ernstige gevolgen van deze mate van 
overgewicht op de gezondheid en de levensverwachting van de patiënten. Vanwege 
deze gezondheidsgevolgen wordt obesitas sinds enkele jaren niet enkel gezien als 
een persoonskenmerk, maar ook als een ziekte. De erkenning van obesitas als  
een ziekte heeft ervoor gezorgd dat er steeds meer aandacht is voor het ontstaan,  
de preventie en de behandeling van obesitas.
Inmiddels zijn de uitgebreide gevolgen van obesitas steeds beter bekend. 
Patiënten met obesitas hebben een groter risico op onder andere een hoge 
bloeddruk, een verhoogd cholesterol, hart- en vaatziekten, suikerziekte (diabetes 
mellitus), leververvetting, astma, slaapapneu, (invaliderende) gewrichtsklachten, 
verschillende vormen van kanker en psychische problemen. Dit zorgt ervoor  
dat personen met obesitas gemiddeld minder lang leven dan personen met een 
gezond gewicht.
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Vanwege deze uitgebreide gevolgen van obesitas op de gezondheid wordt 
al lange tijd gezocht naar de beste behandeling voor obesitas. Helaas blijkt een 
levensstijlaanpassing, zoals diëten of sporten, of een behandeling met medicijnen, 
onvoldoende effectief in de behandeling van obesitas en het verbeteren van de 
gezondheid van de patiënt met obesitas. Al sinds de jaren 50 van de 20e eeuw wordt 
nagedacht over de operatieve behandeling van obesitas. Heden ten dage worden 
obesitas-operaties, zogenaamde ‘bariatrische chirurgie’, gezien als de enige effectieve 
behandeling met goede resultaten op de lange termijn. Daarbij treedt niet alleen een 
substantieel gewichtsverlies op, maar ook een verbetering van de aandoeningen die 
met de obesitas verband houden, zoals hoge bloeddruk en diabetes mellitus.
Deel I: 
De gevolgen van obesitas op hart- en vaatziekten
Hart- en vaatziekten en obesitas
Wereldwijd zijn hart- en vaatziekten nog steeds een van de belangrijkste oorzaken 
van overlijden. Er zijn verschillende entiteiten van hart- en vaatziekten, zoals 
aderverkalking (atherosclerose) die kan leiden tot een hartinfarct, een herseninfarct 
of een verstopping van de bloedvaten van armen of benen, en aneurysmatisch 
vaatlijden, wat betekent dat een bloedvat een potentieel gevaarlijke verwijding van 
zijn diameter heeft. De vijf belangrijkste risicofactoren voor hart- en vaatziekten 
zijn roken, verhoogd cholesterol, een hoge bloeddruk, diabetes mellitus en obesitas. 
De relatie tussen hart- en vaatziekten en obesitas is complex; obesitas geeft niet 
alleen op zichzelf een verhoogd risico op hart- en vaatziekten, maar geeft ook een 
verhoogd risico op de andere risicofactoren voor hart- en vaatziekten. Het is bekend 
dat het risico op hart- en vaatziekten en op vroegtijdig overlijden groter wordt op 
het moment dat de BMI hoger is. Dit betekent dat hoe ernstiger de obesitas is, des 
te ernstiger de gevolgen voor de algehele gezondheid zijn. Soms wordt gesuggereerd 
dat dit toenemende risico op hart- en vaatziekten bij een hoger BMI komt, doordat 
deze patiënten ook een hogere bloeddruk hebben of een hoger cholesterol dan 
patiënten met een lager BMI. Deze relatie tussen de BMI en de ernst van de 




In Hoofdstuk 2 wordt het verband beschreven tussen de BMI en de ernst 
van de risicofactoren op hart- en vaatziekten in een groep patiënten met een 
BMI variërend van een gezond gewicht tot zeer ernstige morbide obesitas. Zoals 
verwacht, blijkt dat mensen met obesitas meer risicofactoren hebben om hart- en 
vaatziekten te ontwikkelen dan personen met een gezond gewicht. Zo hebben zij 
gemiddeld een hogere bloeddruk, een hoger cholesterol en meer aanwijzingen voor 
diabetes mellitus. Echter, wat opvalt is dat de mate van obesitas, uitgedrukt in BMI, 
weinig invloed lijkt te hebben op de ernst van de risicofactoren. Een voorbeeld 
hiervan is: de bloeddruk neemt steeds verder toe bij een oplopend BMI tot een 
BMI van 35-40 kg/m2. Boven deze waarde neemt de bloeddruk niet verder toe. Een 
patiënt met een BMI van 55 kg/m2 heeft gemiddeld genomen een vergelijkbare 
bloeddruk als een patiënt met een BMI van 40 kg/m2. In de zoektocht naar een 
verklaring voor deze bevinding is het huidige onderzoek gericht op de vetverdeling 
in de verschillende gradaties van obesitas. Het is algemeen bekend dat de 
zogenaamde ‘vrouwelijke vetverdeling’ met voornamelijk vetophoping op de billen 
en de heupen gezonder is dan de ‘mannelijke ververdeling’ met vet ter plaatse van 
de buik. In een kleine subgroep van de obese patiënten is met behulp van CT-scans 
gemeten hoe de vetverdeling is in relatie tot de hoogte van de BMI. Hierbij is te 
zien dat de hoeveelheid orgaanvet (in de buik) bij mensen met obesitas niet per se 
groter wordt bij een oplopend BMI, maar dat het met name het onderhuids gelegen 
vetweefsel is dat verder toeneemt naarmate de BMI hoger is. De mogelijkheid 
bestaat dat de mate waarin het orgaanvet kan toenemen, beperkt is en dat mensen 
daarna vet gaan stapelen op andere plekken, zoals onderhuids. Aangezien juist de 
hoeveelheid orgaanvet samenhangt met het risico op hart- en vaatziekten, is voor te 
stellen dat de genoemde risicofactoren voor hart- en vaatziekten niet erger worden 
als dit orgaanvet niet verder kan toenemen. Het blijft dan wel de vraag waarom een 
hoger BMI, ondanks gelijke waarden van de risicofactoren van hart- en vaatziekten, 
toch leidt tot een hoger risico om vroegtijdig te overlijden. Wellicht dat deze 
vroegtijdige sterfte niet zozeer verklaard wordt door atherosclerotisch vaatlijden, 
maar bijvoorbeeld door een overbelasting van het hart, hartritmestoornissen en 
hartfalen.
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Geslachtsverschillen in hart- en vaatziekten en obesitas
Het is bekend dat vrouwen relatief beschermd zijn tegen het ontwikkelen van 
hart- en vaatziekten in vergelijking met mannen. Dit is met name het geval bij 
vrouwen voor de overgang. Pas vanaf het zeventigste levensjaar wordt het risico 
op hart- en vaatziekten bij mannen en vrouwen ongeveer gelijk. In Hoofdstuk 3 is 
beschreven dat bij een groep patiënten met morbide obesitas, vrouwen nog steeds 
relatief beschermd zijn tegen hart- en vaatziekten en dat dit voordeel ten opzichte 
van mannen verdwijnt na de overgang. Daarbij is wel te zien dat de gevolgen van 
de overgang op vroege tekenen van aderverkalking minder uitgesproken zijn bij 
vrouwen met obesitas, in vergelijking met vrouwen met een gezond gewicht. 
Waarschijnlijk speelt de hormoonhuishouding een belangrijke rol in het ontstaan 
van hart- en vaatziekten bij vrouwen. Oestrogenen zouden zowel beschermend 
kunnen zijn voor aderverkalking als voor chronische ontstekingsprocessen in het 
lichaam die weer kunnen bijdragen aan aderverkalking. Terwijl de eierstokken 
de belangrijkste bron van oestrogenen zijn bij vrouwen in de vruchtbare 
leeftijd, worden oestrogenen na de overgang met name gevormd vanuit het 
vetweefsel. Bij een overmaat aan vetweefsel, zoals bij morbide obesitas, daalt het 
oestrogeengehalte mogelijk minder hevig na de overgang dan bij vrouwen met een 
gezond gewicht. Op die manier kan obesitas bij vrouwen na de overgang mogelijk 
bescherming bieden tegen de negatieve gevolgen van een lage oestrogeenspiegel  
op het ontstaan van hart- en vaatziekten.
De gevolgen van diabetes mellitus en 
chronische ontsteking op hart- en vaatziekten
Diabetes mellitus is een van de belangrijke risicofactoren voor hart- en vaatziekten. 
Diabetes mellitus zorgt voor schade aan de bloedvaten en kan hierdoor problemen 
veroorzaken in verschillende orgaansystemen, waaronder hart- en vaatziekten. Het 
is algemeen bekend dat personen met obesitas een groot risico hebben om diabetes 
mellitus te ontwikkelen. In Hoofdstuk 4 is aangetoond dat obese patiënten die 
lijden aan diabetes mellitus, meer tekenen hebben van beginnende aderverkalking 
dan obese patiënten zonder diabetes. De mate van deze beginnende aderverkalking 
wordt echter vooral bepaald door de leeftijd, het geslacht, de bloeddruk en het 




mellitus zelf. Het lijkt dus niet specifiek de diabetes mellitus te zijn die het verschil 
in aderverkalking veroorzaakt, maar juist andere risicofactoren die frequenter lijken 
voor te komen bij patiënten met diabetes mellitus. 
In de afgelopen decennia is gebleken dat ontstekingsprocessen in het lichaam 
een belangrijke rol spelen bij het ontstaan van aderverkalking. Het gaat hierbij 
om een laaggradige ontsteking die in het bloed gemeten kan worden. Mensen 
voelen zich hier in principe niet ziek bij, zoals bij een hevige longontsteking of een 
blindedarmontsteking. Gedacht wordt dat een belangrijke rol is weggelegd voor 
het afweersysteem in het ontstaan van aderverkalking; het afweersysteem zorgt 
ervoor dat witte bloedcellen zich kunnen ophopen in de vaatwand en daar plaques 
vormen die de basis zijn van de aderverkalking. Ook bij mensen met obesitas is 
sprake van een laaggradige ontsteking in het bloed. Waarschijnlijk worden vanuit 
het vetweefsel hormonen en eiwitten geproduceerd die betrokken zijn bij het 
afweersysteem. Gedacht wordt dat juist in deze ontsteking de verklaring ligt voor 
het hogere risico op hart- en vaatziekten bij morbide obesitas. In Hoofdstuk 5 is 
naar voren gekomen dat de mate van ontsteking bij obese patiënten met diabetes 
mellitus hoger is dan bij patiënten zonder diabetes, al leidt dit uiteindelijk niet tot 




Gewichtsverlies bij personen met obesitas leidt tot een kleiner risico op het 
ontwikkelen van hart- en vaatziekten en een verbetering van reeds aanwezige  
hart- en vaatziekten. Bij een gewichtsverlies van 5 tot 10% is reeds een sterke 
verbetering zichtbaar van de bloeddruk, het cholesterol en de glucosehuishouding 
bij patiënten met diabetes mellitus type 2. Gewichtsverlies is daarom een van de 
belangrijkste behandeldoelen voor patiënten met obesitas. 
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De eerste stap van de behandeling van overgewicht en obesitas is een 
levensstijlverandering, met gezondere voeding en meer lichaamsbeweging. Met 
dergelijke levensstijlaanpassingen kunnen mensen gemiddeld 5 tot 7% van hun 
initiële lichaamsgewicht verliezen. Helaas is het resultaat vaak maar van korte duur. 
Ook is veel onderzoek verricht naar medicijnen die gewichtsverlies kunnen geven, 
zoals orlistat, liraglutide en lorcarserine. Hiermee kunnen mensen gemiddeld 
4 tot 8% van hun lichaamsgewicht verliezen. Toch worden deze middelen niet 
veel voorgeschreven, omdat er veel discussie is over de effectiviteit, het risico 
op misbruik, het risico op bijwerkingen en de kosten. Na het staken van deze 
medicijnen, komen de meeste patiënten weer aan in gewicht. 
Voor personen met obesitas en morbide obesitas worden bariatrische 
operaties tegenwoordig gezien als de beste behandeling. Deze geven een 
substantieel gewichtsverlies van wel 60 tot 70% van het overgewicht, wat al 
snel kan neerkomen op circa 30 tot 35% van het initiële gewicht, met ook goede 
langetermijnresultaten. Daarbij is een sterke verbetering te zien van de bloeddruk, 
het cholesterol en de diabetes mellitus, waarbij een deel van patiënten zelfs volledig 
kan stoppen met de medicamenteuze behandeling. De meest uitgevoerde operaties 
zijn op dit moment de gastric bypass en de gastric sleeve. De maagband wordt 
tegenwoordig niet meer veel toegepast vanwege teleurstellende resultaten.
Bariatrische chirurgie in adolescenten
Obesitas wordt wereldwijd een steeds groter probleem. Ook bij kinderen en 
adolescenten komt obesitas steeds vaker voor. In de Verenigde Staten lijdt op dit 
moment 17% van alle kinderen aan obesitas. Daarmee hebben de kinderen een 
verhoogd risico om hart- en vaatziekten te ontwikkelen op latere leeftijd, zelfs als zij 
op volwassen leeftijd weer een relatief gezond gewicht hebben. Vroege behandeling 
lijkt het risico op de complicaties van obesitas te verlagen en er wordt steeds 
meer gedacht dat ook voor adolescenten bariatrische chirurgie overwogen moet 
worden als behandelstrategie. Op dit moment worden bariatrische operaties bij 
kinderen in Nederland enkel in studieverband uitgevoerd. Er is veel discussie over 
het verrichten van dergelijke operaties bij kinderen en adolescenten. De vraag is of 




dergelijke ingrijpende behandeling en of  zij kunnen inschatten wat de korte- en  
langetermijngevolgen zijn van deze operaties en daarmee de impact op hun 
dagelijkse leven. Aan de andere kant is het de vraag of het ethisch verantwoord is 
om kinderen en adolescenten niet de best beschikbare behandeling te bieden en 
ze daarbij bloot te stellen aan een verhoogd risico om chronische aandoeningen 
te ontwikkelen, zoals diabetes mellitus en hart- en vaatziekten, en een verhoogd 
risico op vroegtijdige sterfte. In de zoektocht naar de beste chirurgische 
behandeling van obesitas voor adolescenten, inclusief langetermijnresultaten en 
patiëntentevredenheid, worden in Hoofdstuk 6 de resultaten vergeleken van de 
gastric sleeve en de gastric bypass in jonge volwassenen. Beide operaties tonen 
goede resultaten ten aanzien van de mate van gewichtsverlies. Wel is het opvallend 
dat de compliantie van deze jonge patiënten teleurstellend is; zij verschijnen minder 
vaak op de vervolgafspraken, verdwijnen sneller uit de controle en een aanzienlijk 
deel komt direct na de operatie nooit meer terug voor controle. 
Aangezien patiënten na een gastric sleeve minder risico hebben op 
langetermijn-complicaties, zoals ondervoeding of vitaminetekorten, zou de  
gastric sleeve als eventuele eerste-keus-operatie bij adolescenten de voorkeur 
hebben. Daarbij is het van essentieel belang dat een programma wordt opgezet  
om de therapietrouw van deze specifieke patiëntengroep te verbeteren.
Efficiëntie en veiligheid van bariatrische chirurgie
Aangezien het aantal patiënten met obesitas en obesitas-gerelateerde ziekten nog 
altijd toeneemt, lopen de gezondheidskosten ten gevolge van obesitas steeds verder 
op. Ook het aantal bariatrische operaties dat wereldwijd wordt uitgevoerd, neemt 
steeds verder toe met ruim 600.000 bariatrische operaties in 2014. Het is van belang 
om in de chirurgie te blijven zoeken naar methodes om de effectiviteit, de veiligheid 
en de kosteneffectiviteit van bepaalde operaties steeds verder te verbeteren. Zo 
worden bijvoorbeeld eisen gesteld aan het aantal keren dat een chirurg een bepaalde 
operatie uitvoert in een jaar; hoe vaker hij een operatie uitvoert, des te kleiner 
zou het risico op complicaties zijn. Ook in de medische industrie worden continu 
nieuwe hulpmiddelen en instrumenten ontwikkeld om operaties zo efficiënt en 
veilig mogelijk te laten verlopen. Voor verschillende soorten buikoperaties zijn in 
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de afgelopen decennia protocollen ontwikkeld onder de naam ‘Enhanced Recovery 
After Surgery’ (ERAS). Met behulp van dergelijke protocollen wordt de zorg 
rondom een specifieke operatie zoveel mogelijk gestandaardiseerd. De interventies 
bij deze protocollen zijn wetenschappelijk bewezen effectief om een spoedig 
herstel te bereiken met een laag risico op complicaties. Hoofdstuk 7 beschrijft 
een dergelijk protocol specifiek voor bariatrische chirurgie, namelijk het protocol 
Enhanced Recovery After Bariatric Surgery (ERABS). Het implementeren van dit 
protocol heeft geleid tot een kortere opnameduur in het ziekenhuis en een kortere 
operatieduur, wat leidt tot een lager risico op wondinfecties, trombose en andere 
postoperatieve complicaties. Bij het gebruik van het ERABS-protocol werd ook geen 
toename gezien van het aantal ernstige complicaties dat zich voordeed en het lijkt 
derhalve een veilige manier om de efficiëntie en de kosteneffectiviteit te verbeteren. 
Om patiënten veilig vroegtijdig te kunnen ontslaan uit het ziekenhuis na 
bariatrische chirurgie, is het van belang om eventuele signalen van complicaties 
vroegtijdig te kunnen herkennen. Hoofdstuk 8 beschrijft een checklist 
die ontwikkeld is, waarin gebruikgemaakt is van standaard postoperatieve 
klinische parameters, zoals de lichaamstemperatuur, de hartfrequentie en de 
ontstekingswaarden in het bloed. Met behulp van een algoritme bepaalt de checklist 
of patiënten veilig kunnen worden ontslagen op de eerste dag na de operatie. De 
huidige checklist heeft een hoge negatief voorspellende waarde. Dat betekent 
dat als patiënten naar aanleiding van de checklist ontslagen konden worden uit 
het ziekenhuis, dat de kans klein was dat zij later alsnog een complicatie zouden 
ontwikkelen. Daarmee was het ontslag veilig. Helaas was de positief voorspellende 
waarde van de checklist nog zwak. Van alle patiënten die naar aanleiding van de 
checklist nog niet klaar waren voor ontslag, ontwikkelde slechts een klein deel een 
complicatie. Het overige deel moest ten onrechte langer opgenomen blijven in het 
ziekenhuis of aanvullende onderzoeken ondergaan. Door een jaarlijkse herevaluatie 
van de checklist met aanpassing van het algoritme, kan de checklist verder 
geoptimaliseerd worden, met een toename van de positief voorspellende waarde, 





Een opmerkelijke bevinding in dit proefschrift is dat de mate van obesitas geen 
invloed lijkt te hebben op de ernst van de risicofactoren van hart- en vaatziekten. 
Gezien de vele factoren die een rol spelen bij het ontstaan van morbiditeit bij sterk 
overgewicht, is het mogelijk dat relaties pas kunnen worden aangetoond wanneer de 
onderzoeksgroepen voldoende aantallen patiënten bevatten. Het kan zijn dat deze 
studies daar niet aan voldoen. Derhalve lijkt uitbreiding naar studies met grotere 
aantallen patiënten noodzakelijk en kan intensivering van de samenwerking van 
Nederlandse bariatrische klinieken hierbij een unieke mogelijkheid bieden.
Een van de vragen die in dit kader beantwoord kan worden, heeft betrekking 
op de rol van de vetverdeling in verschillende stadia van obesitas. Bij toenemende 
obesitas lijkt met name het onderhuidse vetweefsel zich verder uit te breiden.  
Door de relatie tussen de vetverdelingspatronen en hart- en vaatziekten in kaart  
te brengen, kunnen wellicht op relatief eenvoudige wijze personen met een 
verhoogd risico op cardiovasculaire morbiditeit vroegtijdig geïdentificeerd worden. 
De vetverdeling kan bijvoorbeeld met behulp van DEXA-scans worden vastgesteld 
en vervolgens kunnen worden gecorreleerd met cardiovasculaire risicofactoren.  
Het gebruik van een DEXA-scan kent een aantal voordelen boven het gebruik van 
CT- of MRI-scans, zoals weinig stralingsbelasting voor de patiënt, de snelheid van 
het onderzoek en de kosten. Derhalve lijkt het een voor de hand liggende keuze  
om in onderzoek onder grote aantallen patiënten DEXA-scans te gebruiken.
Naast onderzoek naar de anatomische relatie tussen de vetverdeling en het 
risico op hart- en vaatziekten, is onderzoek naar de mechanismen van het ontstaan 
van comorbiditeit essentieel om in de toekomst patiënten beter en gerichter te 
kunnen behandelen. Dergelijk onderzoek dient gericht te zijn op de biologische 
activiteit van vetweefsel in de verschillende compartimenten en het effect op 
het metabolisme en het immuunsysteem. Het geeft inzicht in of vetweefsel het 
metabolisme en het immuunsysteem kan beïnvloeden en op welke wijze dit tot 
uiting komt bij verschillende vetverdelingen. Samenwerking tussen verschillende 
disciplines is noodzakelijk om de complexiteit van deze patronen te ontrafelen. 
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Voor de huidige studie is een samenwerking aangegaan met cardiologen om de 
kennis van hart- en vaatziekten en veranderingen bij obesitas, waaronder de cardiale 
functie, te integreren in de analyse van de comorbiditeit van obese patiënten. 
Onderzoek naar de pathofysiologie van de hartdysfunctie van patiënten met 
obesitas kan op deze wijze worden uitgebreid door een relatie te leggen met de 
karakteristieken van obese patiënten in de huidige studies. De eerste resultaten 
van deze gezamenlijke aanpak worden in 2020 verwacht. Ook hier zal validatie in 
grotere cohorten waarschijnlijk nodig zijn, hetgeen ook in dit opzicht het belang van 
een multidisciplinaire samenwerking op nationaal niveau onderstreept.
Een belangrijk vraagstuk in de bariatrische chirurgie is gericht op de 
identificatie van patiënten die het meeste profijt hebben van bariatrische chirurgie. 
De vraag is of het mogelijk is om voorafgaand aan de operatie die patiënten te 
identificeren die uiteindelijk het beste resultaat zullen bereiken, zowel op het gebied 
van gewichtsverlies als op het gebied van het verbeteren van obesitasgerelateerde 
ziekte. Aan de hand van het huidige proefschrift wordt gedacht dat de BMI 
van patiënten niet de belangrijkste leidraad moet zijn om de behandelkeuze te 
bepalen. Eerdere studies laten immers zien dat er geen relatie bestaat tussen de 
preoperatieve BMI en de kans op vermindering van hart- en vaatziekten na de 
operatie. Ook is aangetoond dat de BMI geen voorspellende waarde heeft voor de 
cardiovasculaire gezondheid van morbide obese patiënten. Verder onderzoek dient 
gericht te zijn op een nadere analyse van verschillende patiëntenkarakteristieken 
en het risico op hart- en vaatziekten om voorspellende markers te kunnen 
definiëren. Zo is bijvoorbeeld aangetoond dat patiënten met een hoog nuchter 
bloedsuikergehalte of hoge insulinespiegels een beter resultaat behalen na 
bariatrische chirurgie en dan met name een vermindering van het overlijdensrisico 
ten gevolge van hart- en vaatziekten. Ook is aangetoond dat obese patiënten met 
slaapapneu meer risico hebben op hart- en vaatziekten en dat bariatrische chirurgie 
dit risico kan beïnvloeden door het gunstige effect van de ingreep op de ernst van 
de slaapapneu. Ook de invloed van het geslacht op de uitkomsten van bariatrische 
chirurgie verdient meer aandacht. Het merendeel van de patiënten in de huidige 
studies is vrouw, terwijl juist mannen een hoger risico lijken te hebben op hart- en 




op gelijke wijze profiteren van bariatrische chirurgie. Tot op heden ontbreekt 
een voorspellend profiel van patiënten die duidelijk baat hebben bij bariatrische 
chirurgie. Dergelijke voorspellende karakteristieken dienen uiteindelijk opgenomen 
te worden in richtlijnen om zowel de patiënten als de artsen juist te informeren. Op 
dit moment is aan te bevelen om mannen met morbide obesitas, patiënten met hoge 
bloedsuiker- of insulinespiegels en patiënten met slaapapneu eerder te behandelen. 
Ten aanzien van het type operatie geeft de gastric bypass een betere afname van 
hart- en vaatziekten dan de sleeve-resectie en zou derhalve de voorkeur genieten 
voor deze patiëntengroep. 
Bariatrische chirurgie kan leiden tot significant gewichtsverlies en een 
verbetering van hart- en vaatziekten. Echter, vervolgonderzoek na bariatrische 
chirurgie toont aan dat tot 50% van de geopereerde patiënten uiteindelijk alsnog 
diabetes mellitus of hart- en vaatziekten ontwikkelt of terugkrijgt, ook zonder 
opnieuw aan te komen in gewicht. Behandelde morbide obese patiënten lijken 
op deze wijze dus nog steeds een verhoogd risico op vroegtijdig overlijden te 
houden in vergelijking met controlepersonen.  Derhalve blijft de noodzaak bestaan 
om patiënten na succesvolle bariatrische chirurgie te blijven controleren om 
langetermijnrisico’s vroegtijdig op te sporen en te behandelen. In het geval van 
nieuwe gewichtstoename kan eventueel een tweede bariatrische operatie worden 
overwogen. De effecten hiervan op het gebied van gewichtsverlies lijken vooralsnog 
beperkt, maar er worden zeker effecten op het gebied van de reductie van de 
comorbiditeit gezien. Het effect hiervan dient nader te worden onderzocht voor 
verschillende subgroepen, zoals mannen en vrouwen en verschillende leeftijden. 
Met deze huidige studies zijn de eerste stappen gezet voor een 
gerandomiseerd onderzoek naar verschillende operatietechnieken voor 
morbide obese adolescenten in de leeftijd van 16 tot 18 jaar. Een intensief 
begeleidingsprogramma met betrokkenheid van de chirurg, de internist, de 
kinderarts, de fysiotherapeut, de diëtist en de psycholoog is noodzakelijk om een 
bariatrisch programma onder adolescenten te laten slagen. Met name bij deze 
jongeren is het essentieel dat de behandeling meer omvat dan de operatie alleen. 
Onder andere uitgebreide educatie over de preventie van obesitas en de preventie 
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van gewichtstoename na bariatrische chirurgie dient onderdeel te zijn van het 
programma om jongeren te helpen om een gezonde levensstijl te ontwikkelen en te 
behouden. Bariatrische chirurgie zal uiteindelijk met name een plaats krijgen voor 
de behandeling van patiënten met een hoog risico op complicaties van morbide 
obesitas. Verder onderzoek, ook in verschillende subgroepen van patiënten met 
ernstig overgewicht, zal zich uiteindelijk niet alleen richten op het effect van de 
operatie op het gewichtsverlies en de verbetering van de comorbiditeit, maar ook op 
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